These are representative sample records from Science.gov related to your search topic.
For comprehensive and current results, perform a real-time search at Science.gov.
1

Histology of Breast Cancer Metastasis Theresa Reno  

E-print Network

Histology of Breast Cancer Metastasis Theresa Reno 11/18/08 #12;Hanahan and Weinberg, Cell 2000 Cancer: 6 Hallmarks #12;Breast Anatomy and Histology Normal Breast Histology - H&E Stain Ross and Pawlina, Histology: A Text and Atlas Ducts - Simple columnar epithelium Normal ductules with basement membrane #12

Gleeson, Joseph G.

2

Abstract--Breast cancers can be histologically categorized (graded) based upon their architectural patterns and cellular  

E-print Network

Abstract-- Breast cancers can be histologically categorized (graded) based upon their architectural patterns and cellular types. Inaccurate histologic grading can result in inappropriate treatment for histologic grading that should enhance grading reliability. We present the initial efforts to develop

Breen, David E.

3

Histological evaluation of AMPK signalling in primary breast cancer  

PubMed Central

Background AMP-activated protein kinase (AMPK) acts as a cellular fuel gauge that responds to energy stress by suppressing cell growth and biosynthetic processes, thus ensuring that energy-consuming processes proceed only if there are sufficient metabolic resources. Malfunction of the AMPK pathway may allow cancer cells to undergo uncontrolled proliferation irrespective of their molecular energy levels. The aim of this study was to examine the state of AMPK phosphorylation histologically in primary breast cancer in relation to clinical and pathological parameters. Methods Immunohistochemistry was performed using antibodies to phospho-AMPK (pAMPK), phospho-Acetyl Co-A Carboxylase (pACC) an established target for AMPK, HER2, ER?, and Ki67 on Tissue Micro-Array (TMA) slides of two cohorts of 117 and 237 primary breast cancers. The quick score method was used for scoring and patterns of protein expression were compared with clinical and pathological data, including a minimum 5 years follow up. Results Reduced signal, compared with the strong expression in normal breast epithelium, using a pAMPK antibody was demonstrated in 101/113 (89.4%) and 217/236 (91.9%) of two cohorts of patients. pACC was significantly associated with pAMPK expression (p = 0.007 & p = 0.014 respectively). For both cohorts, reduced pAMPK signal was significantly associated with higher histological grade (p = 0.010 & p = 0.021 respectively) and axillary node metastasis (p = 0.061 & p = 0.039 respectively). No significant association was found between pAMPK and any of HER2, ER?, or Ki67 expression, disease-free survival or overall survival. Conclusion This study extends in vitro evidence through immunohistochemistry to confirm that AMPK is dysfunctional in primary breast cancer. Reduced signalling via the AMPK pathway, and the inverse relationship with histological grade and axillary node metastasis, suggests that AMPK re-activation could have therapeutic potential in breast cancer. PMID:19723334

2009-01-01

4

Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies  

PubMed Central

Metaplastic breast cancer (MBC) is a rare subtype of invasive breast cancer that tends to have an aggressive clinical presentation as well as a variety of distinct histologic designations. Few systemic treatment options are available for MBC, as it has consistently shown a suboptimal response to standard chemotherapy regimens. These characteristics result in a worse overall prognosis for patients with MBC compared to those with standard invasive breast cancer. Due to its rarity, data focusing on MBC is limited. This review will discuss the clinical presentation, breast imaging findings, histologic and molecular characteristics of MBC as well as potential future research directions. PMID:24499560

2013-01-01

5

Histologic review of breast cancer cases in survivors of atomic bombs in Hiroshima and Nagasaki, Japan  

Microsoft Academic Search

A panel of Japanese and American pathologists reviewed existing histologic material used to study breast cancer risk among the A-bomb survivors in Hiroshima and Nagasaki, a population in which incidence studies have found a strong relationship between breast cancer risk and radiation dose. The primary charge to the panel was to define a body of confirmed cases in the Life

Shoji Tokuoka; Masahide Asano; Tsutomu Yamamoto; Masayoshi Tokunaga; Goi Sakamoto; William H. Hartmann; Robert V. P. Hutter; Charles E. Land; Donald E. Henson

1984-01-01

6

Endobronchial metastatic breast cancer with pagetoid histology mimicking bronchial pagetoid squamous cell carcinoma in situ.  

PubMed

We report a case of a 56-year-old woman with endobronchial breast cancer metastasis of unusual histology. The patient presented with persistent cough, and a lesion was noted in the left mainstem bronchus on bronchoscopic examination. Biopsy revealed extensive squamous metaplasia of bronchial epithelium along with large, atypical cells exhibiting pagetoid intraepithelial spread within squamous mucosa. Immunohistochemical stains were compatible with a diagnosis of metastatic breast adenocarcinoma with pagetoid spread. To our knowledge, this is the first reported case of endobronchial breast cancer metastasis with this histologic presentation. In this report, we describe the clinical, radiographic, bronchoscopic, histologic, and immunohistochemical characteristics of this case. We provide a brief review of existing literature on endobronchial breast cancer metastasis. In addition, we discuss the principal differential diagnosis of bronchial pagetoid lesions. This report raises awareness of this uncommon manifestation of metastatic breast cancer. PMID:21663936

West, Dava; Geradts, Joseph; Wahidi, Momen; Roggli, Victor

2011-11-01

7

Gene expression abnormalities in histologically normal breast epithelium from patients with luminal type of breast cancer.  

PubMed

The gene expression profile of breast cancer has been described as a great breakthrough on the way to comprehend differences in cancer origin, behavior and therapy. However, gene expression profile in histologically normal epithelium (HNEpi) which could harbor genetic abnormalities predisposing breast tissue to develop malignancy was minor scope for scientists in the past. Thus, we aimed to analyze gene expressions in HNEpi and breast cancer tissue (BCTis) in order to establish its value as potential diagnostic marker for cancer development. We evaluated a panel of disease-specific genes in luminal type (A/B) of breast cancer and tumor surrounding HNEpi by qRT-PCR Array in 32 microdissected samples. There was 20.2 and 2.4 % deregulation rate in genes with at least 2-fold or 5-fold over-expression between luminal (A/B) type breast carcinomas and tumor surrounding HNEpi, respectively. The high-grade luminal carcinomas showed higher number of deregulated genes compared to low-grade cases (50.6 vs. 23.8 % with at least 2-fold deregulation rate). The main overexpressed genes in HNEpi were KLK5, SCGB1D2, GSN, EGFR and NGFR. The significant differences in gene expression between BCTis and HNEpi samples were revealed for BAG1, C3, CCNA2, CD44, FGF1, FOSL1, ID2, IL6R, NGFB, NGFR, PAPPA, PLAU, SERPINB5, THBS1 and TP53 gene (p < 0.05) and BCL2L2, CTSB, ITGB4, JUN, KIT, KLF5, SCGB1D2, SCGB2A1, SERPINE1 (p < 0.01), and EGFR, GABRP, GSN, MAP2K7 and THBS2 (p < 0.001), and GSN, KLK5 (p < 0.0001). The ontological gene analyses revealed high deregulations in gene group directly associated with breast cancer prognosis and origin. PMID:25407308

Zubor, Pavol; Hatok, Jozef; Moricova, Petra; Kajo, Karol; Kapustova, Ivana; Mendelova, Andrea; Racay, Peter; Danko, Jan

2014-11-19

8

Gene Expression Profi ling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis  

Microsoft Academic Search

Background: Histologic grade in breast cancer provides clini- cally important prognostic information. However, 30% - 60% of tumors are classifi ed as histologic grade 2. This grade is associated with an intermediate risk of recurrence and is thus not informative for clinical decision making. We examined whether histologic grade was associated with gene expression profi les of breast cancers and

Christos Sotiriou; Pratyaksha Wirapati; Sherene Loi; Adrian Harris; Steve Fox; Johanna Smeds; Hans Nordgren; Pierre Farmer; Viviane Praz; Benjamin Haibe-Kains; Christine Desmedt; Denis Larsimont; Fatima Cardoso; Hans Peterse; Dimitry Nuyten; Marc Buyse; Marc J. Van de Vijver; Jonas Bergh; Martine Piccart; Mauro Delorenzi

2006-01-01

9

Genetic Reclassification of Histologic Grade Delineates New Clinical Subtypes of Breast Cancer  

Microsoft Academic Search

Histologic grading of breast cancer defines morphologic subtypes informative of metastatic potential, although not without considerable interobserver disagreement and clinical heterogeneity particularly among the moderately differen- tiated grade 2 (G2) tumors. We posited that a gene expression signature capable of discerning tumors of grade 1(G1 ) and grade 3 (G3) histology might provide a more objective measure of grade with

Anna V. Ivshina; Joshy George; Oleg Senko; Benjamin Mow; Thomas C. Putti; Johanna Smeds; Thomas Lindahl; Yudi Pawitan; John E. L. Wong; Edison T. Liu; Jonas Bergh; Vladimir A. Kuznetsov; Lance D. Miller

10

Breast pathology after cryotherapy. Histological regression of breast cancer after cryotherapy.  

PubMed

A breast saving treatment is contemporary the preferred method of treatment with comparable results in comparing with mastectomy. In this study were evaluated the effects of cryotherapy by histological verification of changes in post treatment resection specimens. Fifty-three patients in age of 38-81 year with histologically confirmed breast cancer in needle biopsies were managed by cryotherapy between 1999 and 2007. The patients were operated between day 1 and 35 after cryotherapy. The histologic examination of operation materials showed in all cases at least partial tumor destruction. In general in 54.7% of all handled cases (29 patient) there was no residual tumor. In 6 cases (22.2%) from group 1 and in 23 cases (88.5%) of group 2 no tumor rest was found. Cryotherapy can lead to complete destruction of tumoral tissue. In our study all 29 (54.7%) of tumor-free cases after cryotherapy were those with cT1 stage. The experience of operator and the correct selection of appropriate patients (primarily taking the tumor size into account) play the most important role for achieving the best results. PMID:25119005

Gajda, Mieczyslaw R; Mireskandari, Masoud; Baltzer, Pascal A; Pfleiderer, Stefan O; Camara, Oumar; Runnebaum, Ingo B; Kaiser, Werner A; Petersen, Iver

2014-03-01

11

Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors  

Microsoft Academic Search

BackgroundWhen sentinel node dissection reveals breast cancer metastasis, completion axillary lymph node dissection is ideally performed during the same operation. Intraoperative histologic techniques have low and variable sensitivity. A new intraoperative molecular assay (GeneSearch BLN Assay; Veridex, LLC, Warren, NJ) was evaluated to determine its efficiency in identifying significant sentinel lymph node metastases (>.2 mm).

Peter Blumencranz; Pat W. Whitworth; Kenneth Deck; Anne Rosenberg; Douglas Reintgen; Peter Beitsch; Anees Chagpar; Thomas Julian; Sukamal Saha; Eleftherios Mamounas; Armando Giuliano; Rache Simmons

2007-01-01

12

Gene expression profiles of estrogen receptor positive and estrogen receptor negative breast cancers are detectable in histologically normal breast epithelium  

PubMed Central

Purpose Previously, we found that gene expression in histologically normal breast epithelium (NlEpi) from women at high breast cancer risk can resemble gene expression in NlEpi from cancer-containing breasts. Therefore, we hypothesized that gene expression characteristic of a cancer subtype might be seen in NlEpi of breasts containing that subtype. Experimental Design We examined gene expression in 46 cases of microdissected NlEpi from untreated women undergoing breast cancer surgery. From 30 age-matched cases (15 estrogen receptor (ER)+, 15 ER-) we used Affymetryix U133A arrays. From 16 independent cases (9 ER+, 7 ER-), we validated selected genes using qPCR. We then compared gene expression between NlEpi and invasive breast cancer using 4 publicly available datasets. Results We identified 198 genes that are differentially expressed between NlEpi from breasts with ER+ (NlEpiER+) compared to ER- cancers (NlEpiER-). These include genes characteristic of ER+ and ER- cancers (e.g., ESR1, GATA3, and CX3CL1, FABP7). QPCR validated the microarray results in both the 30 original cases and the 16 independent cases. Gene expression in NlEpiER+ and NlEpiER- resembled gene expression in ER+ and ER- cancers, respectively: 25-53% of the genes or probes examined in 4 external datasets overlapped between NlEpi and the corresponding cancer subtype. Conclusions Gene expression differs in NlEpi of breasts containing ER+ compared to ER- breast cancers. These differences echo differences in ER+ and ER- invasive cancers. NlEpi gene expression may help elucidate subtype-specific risk signatures, identify early genomic events in cancer development and locate targets for prevention and therapy. PMID:21059815

Graham, Kelly; Ge, Xijin; de las Morenas, Antonio; Tripathi, Anusri; Rosenberg, Carol L.

2010-01-01

13

Breast Cancer  

MedlinePLUS

... version of this page please turn Javascript on. Breast Cancer What is Breast Cancer? How Tumors Form The body is made up ... tumors form in the breast tissue. Who Gets Breast Cancer? Breast cancer is one of the most common ...

14

Breast cancer prognostic classification in the molecular era: the role of histological grade  

Microsoft Academic Search

Breast cancer is a heterogeneous disease with varied morphological appearances, molecular features, behavior, and response to therapy. Current routine clinical management of breast cancer relies on the availability of robust clinical and pathological prognostic and predictive factors to support clinical and patient decision making in which potentially suitable treatment options are increasingly available. One of the best-established prognostic factors in

Emad A Rakha; Jorge S Reis-Filho; Frederick Baehner; David J Dabbs; Thomas Decker; Vincenzo Eusebi; Stephen B Fox; Shu Ichihara; Jocelyne Jacquemier; Sunil R Lakhani; José Palacios; Andrea L Richardson; Stuart J Schnitt; Fernando C Schmitt; Puay-Hoon Tan; Gary M Tse; Sunil Badve; Ian O Ellis

2010-01-01

15

Gene expression profiling of histologically normal breast tissue in females with human epidermal growth factor receptor 2?positive breast cancer.  

PubMed

Gene expression profile?based taxonomy of breast cancer (BC) has been described as a significant breakthrough in comprehending the differences in the origin and behavior of cancer to allow individually tailored therapeutic approaches. In line with this, we hypothesized that the gene expression profile of histologically normal epithelium (HNEpi) could harbor certain genetic abnormalities predisposing breast tissue cells to develop human epidermal growth factor receptor 2 (HER2)?positive BC. Thus, the aim of the present study was to assess gene expression in normal and BC tissue (BCTis) from patients with BC in order to establish its value as a potential diagnostic marker for cancer development. An array study evaluating a panel of 84 pathway? and disease?specific genes in HER2?positive BC and tumor?adjacent HNEpi was performed using quantitative polymerase chain reaction in 12 patients using microdissected samples from frozen tissue. Common prognostic and predictive parameters of BC were assessed by immunohistochemistry and in situ hybridization. In the BCTis and HNEpi samples of 12 HER2?positive subjects with BC, the expression of 2,016 genes was assessed. A total of 39.3% of genes were deregulated at a minimal two?fold deregulation rate and 10.7% at a five?fold deregulation rate in samples of HNEpi or BCTis. Significant differences in gene expression between BCTis and HNEpi samples were revealed for BCL2L2, CD44, CTSD, EGFR, ERBB2, ITGA6, NGFB, RPL27, SCBG2A1 and SCGB1D2 genes (P<0.05), as well as GSN, KIT, KLK5, SERPINB5 and STC2 genes (P<0.01). Insignificant differences (P<0.07) were observed for CCNA1, CLU, DLC1, GABRP and IL6 genes. The ontological gene analyses revealed that the majority of the deregulated genes in the HNEpi samples were part of the functional gene group directly associated with BC origin and prognosis. Functional analysis showed that the most frequent gene deregulations occurred in genes associated with apoptosis and cell cycle regulation in BCTis samples, and with angiogenesis, regulation of the cell cycle and transcriptional activity in HNEpi samples. The molecular profiling of HNEpi breast tissue revealed gene expression abnormalities that may represent potential markers of increased risk for HER2?positive malignant transformation of breast tissue, and may be able to be employed as predictors of prognosis. PMID:25373323

Zubor, Pavol; Hatok, Jozef; Moricova, Petra; Kapustova, Ivana; Kajo, Karol; Mendelova, Andrea; Sivonova, Monika Kmetova; Danko, Jan

2015-02-01

16

The routine histological investigation of axillary lymph nodes for metastatic breast cancer.  

PubMed

A simple method of preparing axillary nodes from breast cancer patients for routine histology is presented. It is based on appreciation of nodal anatomy and the pathophysiology of tumour growth in them. Current methods assume that the latter is a random process, but this is not so. It has long been known that tumour cells enter via the afferent lymphatics. They may also exit by the efferent. It has not been generally realized that these vessels enter/leave the node in the same plane of section, or that a section in this plane, a hilar section, is theoretically the one of choice for the identification of tumour cells in the node. It is shown here that use of hilar sections alone allows the identification of tumour-free and tumour-bearing nodes, as well as the tumour status of the efferent vessels, with considerable certainty. The use of random sections, in contrast, carries a high risk of false negative reporting. PMID:6379134

Hartveit, F

1984-07-01

17

Breast Cancer  

MedlinePLUS

Breast cancer affects one in eight women during their lives. Breast cancer kills more women in the United States than ... cancer. No one knows why some women get breast cancer, but there are a number of risk factors. ...

18

Correlation of Ki-67 and MCM-2 proliferative marker expression with grade of histological malignancy (G) in ductal breast cancers.  

PubMed

The study aimed at examining a relationship between expression of Ki-67 antigen and minichromosome maintenance 2 protein (MCM-2) and a grade of histological malignancy G in ductal breast cancers. The function of widely used marker of proliferation Ki-67 is still not clear. In contrast, the MCM-2 protein is well known to play an important role in controlling the cell cycle. Both proteins represent small protein molecules, which manifest nuclear expression only during cell division of normal and neoplastic cells. Their expression is noted in several malignant tumours. These studies were conducted on 56 archival paraffin blocks of ductal breast cancers. Immunohistochemical reactions were performed using monoclonal Ki-67- and MCM-2-specific antibodies. Statistical analysis demonstrated a positive correlation between expressions of two proteins (r=0.6; p<0.05). The most intense expression of these two markers was demonstrated in G3 grade cancers. Statistical analysis showed more pronounced expression of Ki-67 antigen in G3 grade cancers as compared to cancers of G1 and G2 grades (p<0.001) and, in the case of MCM-2 protein, a more pronounced expression in G3 grade cancers, as compared to those of G1 (p<0.05) or G2 grade (p<0.01). The results obtained in our study suggest that MCM-2 could be used as a marker of proliferation in breast carcinomas. PMID:21097442

Wojnar, Andrzej; Kobierzycki, Christopher; Krolicka, Anna; Pula, Bartosz; Podhorska-Okolow, Marzena; Dziegiel, Piotr

2010-09-30

19

Breast Cancer  

MedlinePLUS

... for it when they are older. What Is Breast Cancer? The human body is made of tiny building ... liver, or elsewhere. Continue Why Do People Get Breast Cancer? Any woman can get breast cancer, but doctors ...

20

Large-scale computations on histology images reveal grade-differentiating parameters for breast cancer  

Microsoft Academic Search

BACKGROUND: Tumor classification is inexact and largely dependent on the qualitative pathological examination of the images of the tumor tissue slides. In this study, our aim was to develop an automated computational method to classify Hematoxylin and Eosin (H&E) stained tissue sections based on cancer tissue texture features. METHODS: Image processing of histology slide images was used to detect and

Sokol Petushi; Fernando U Garcia; Marian M Haber; Constantine Katsinis; Aydin Tozeren

2006-01-01

21

Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.  

PubMed

Invasive lobular carcinoma (ILC) has been reported to be less responsive to neoadjuvant chemotherapy (NAC) than invasive ductal carcinoma (IDC). We sought to determine whether ILC histology indeed predicts poor response to NAC by analyzing tumor characteristics such as protein expression, gene expression, and imaging features, and by comparing NAC response rates to those seen in IDC after adjustment for these factors. We combined datasets from two large prospective NAC trials, including in total 676 patients, of which 75 were of lobular histology. Eligible patients had tumors ?3 cm in diameter or pathologic documentation of positive nodes, and underwent serial biopsies, expression microarray analysis, and MRI imaging. We compared pathologic complete response (pCR) rates and breast conservation surgery (BCS) rates between ILC and IDC, adjusted for clinicopathologic factors. On univariate analysis, ILCs were significantly less likely to have a pCR after NAC than IDCs (11 vs. 25 %, p = 0.01). However, the known differences in tumor characteristics between the two histologic types, including hormone receptor (HR) status, HER2 status, histological grade, and p53 expression, accounted for this difference with the lowest pCR rates among HR+/HER2- tumors in both ILC and IDC (7 and 5 %, respectively). ILC which were HR- and/or HER2+ had a pCR rate of 25 %. Expression subtyping, particularly the NKI 70-gene signature, was correlated with pCR, although the small numbers of ILC in each group precluded significant associations. BCS rate did not differ between IDC and ILC after adjusting for molecular characteristics. We conclude that ILC represents a heterogeneous group of tumors which are less responsive to NAC than IDC. However, this difference is explained by differences in molecular characteristics, particularly HR and HER2, and independent of lobular histology. PMID:22961065

Lips, Esther H; Mukhtar, Rita A; Yau, Christina; de Ronde, Jorma J; Livasy, Chad; Carey, Lisa A; Loo, Claudette E; Vrancken-Peeters, Marie-Jeanne T F D; Sonke, Gabe S; Berry, Donald A; Van't Veer, Laura J; Esserman, Laura J; Wesseling, Jelle; Rodenhuis, Sjoerd; Shelley Hwang, E

2012-11-01

22

Use of Different Postmenopausal Hormone Therapies and Risk of Histology-and Hormone ReceptorDefined Invasive Breast Cancer  

E-print Network

­Defined Invasive Breast Cancer Agnès Fournier1 , Alban Fabre1 , Sylvie Mesrine1 , Marie-Christine Boutron-Ruault1. Abstract Purpose We previously found that the risk of invasive breast cancer varied according- and hormone receptor- defined breast cancer. Patients and Methods We used data from the French E3N cohort

Boyer, Edmond

23

Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer.  

PubMed Central

The value of various prognostic factors in breast cancer patients has been determined in a number of studies. Few reports have been published on the dependence of treatment outcome on histological and immunohistochemical characteristics in the primary tumour in patients with metastatic disease. We studied the incidence and prognostic value of histological and molecular abnormalities in the primary tumour of patients who had developed metastatic breast cancer. Eligible patients received a fluorouracil, epirubicin and cyclophosphamide (FEC) regimen either once a week or once every 4 weeks. Adequate specimens for various analyses were available from 127 patients. Median follow-up time of the patients ranged from 15 to 101 months. In this study, the histological grade of the malignancy best predicted response to chemotherapy (P < 0.0005). Most of the responses were observed in patients with grade 1 tumours; in this group, time to progression was delayed. C-erb B-2 gene amplification and oncoprotein expression had no predictive value. Neither p53 nor cathepsin-D predicted treatment outcome after chemotherapy. None of the factors had an effect on overall survival. Among breast cancer patients who received anthracycline-containing chemotherapy, response to treatment correlated with histological grade. In patients with histological grade 1 breast cancer, the time to progression was longest. However, overall survival was not affected by histological grade nor the other parameters tested. In addition to histological grade, other prognostic factors that are not included in this study need to be identified to determine which patients with metastatic breast cancer would benefit from cytotoxic treatment. PMID:9328152

Niskanen, E.; Blomqvist, C.; Franssila, K.; Hietanen, P.; Wasenius, V. M.

1997-01-01

24

Breast Cancer Prevention  

MedlinePLUS

... to keep cancer from starting. General Information About Breast Cancer Breast cancer is a disease in which malignant (cancer) cells ... Cancer Treatment Genetics of Breast and Ovarian Cancer Breast cancer is the second most common type of cancer ...

25

Biomarkers in breast cancer  

Microsoft Academic Search

Breast cancer is one of the most frequently diagnosed cancers among women in the western world. Due to the aggressive behaviour\\u000a of some specific types and the possibility of an early diagnosis, breast cancer has been constantly studied. Tumour size,\\u000a histological type, cellular and nuclear characteristics, mitotic index, vascular invasion, hormonal receptors and axillary\\u000a lymph node status are biomarkers routinely

Graciela Laguens; Silvia Coronato; Wanda Di Girolamo

2006-01-01

26

What Is Breast Cancer?  

MedlinePLUS

... Next Topic Types of breast cancers What is breast cancer? Breast cancer is a malignant tumor that starts ... The remainder of this document refers only to breast cancer in women. For information on breast cancer in ...

27

Breast Multiple Primary and Histology Rules Matrix  

Cancer.gov

Breast Multiple Primary Rules – Matrix C500 – C509 (Excludes lymphoma and leukemia M9590 – 9989 and Kaposi sarcoma M9140) * Prepare one abstract. Use the histology coding rules to assign the appropriate histology code. ** Prepare two or more abstracts.

28

6 Common Cancers - Breast Cancer  

MedlinePLUS

... Bar Home Current Issue Past Issues 6 Common Cancers - Breast Cancer Past Issues / Spring 2007 Table of Contents For ... her down. Photo: AP Photo/Brett Flashnick Breast Cancer Breast cancer is a malignant (cancerous) growth that ...

29

Learning about Breast Cancer  

MedlinePLUS

... genetic terms used on this page Learning About Breast Cancer What do we know about heredity and breast ... Cancer What do we know about heredity and breast cancer? Breast cancer is a common disease. Each year, ...

30

Risks of Breast Cancer Screening  

MedlinePLUS

... cancer screening: Cancer Screening Overview General Information About Breast Cancer Breast cancer is a disease in which malignant (cancer) cells ... Cancer Treatment Genetics of Breast and Gynecologic Cancers Breast cancer is the second leading cause of death from ...

31

Breast Cancer -- Male  

MedlinePLUS

... Home > Types of Cancer > Breast Cancer in Men Breast Cancer in Men This is Cancer.Net’s Guide to Breast Cancer in Men. Use the menu below to choose ... social workers, and patient advocates. Cancer.Net Guide Breast Cancer in Men Overview Statistics Risk Factors and Prevention ...

32

Male Breast Cancer  

MedlinePLUS

Although breast cancer is much more common in women, men can get it too. It happens most often to men between ... 60 and 70. Breast lumps usually aren't cancer. However, most men with breast cancer have lumps. ...

33

aallll IIrreell aanndd ccaanncceerr ssttaattiissttiiccss sseeccoonndd rreeppoorrtt 11999988--22000000 Breast cancer (female) Breast cancer (female)  

E-print Network

--22000000 22 Breast cancer (female) Breast cancer (female) Breast cancer (female) Breast cancer (female) Breast cancer (female) Breast cancer (female) Breast cancer (female) Breast cancer (female) Breast cancer (female) Breast cancer (female) Breast cancer (female) Breast cancer (female) Breast cancer (female

Paxton, Anthony T.

34

Breast Cancer Knowledge  

MedlinePLUS

... right-hand corner of the player. Breast Cancer Knowledge HealthDay January 26, 2015 Related MedlinePlus Pages Breast ... finds many women battling breast cancer may lack knowledge about their specific illness. Researchers surveyed 500 women ...

35

Breast Cancer and Bone Loss  

MedlinePLUS

... Breast Cancer and Bone Loss Share: Fact Sheet Breast Cancer and Bone Loss July, 2010 Download PDFs English ... JoAnn Pinkerton, MD What is the link between breast cancer and bone loss? Certain treatments for breast cancer ...

36

Drugs Approved for Breast Cancer  

MedlinePLUS

... Cancer Terms NCI Drug Dictionary Drugs Approved for Breast Cancer This page lists cancer drugs approved by the ... Used in Breast Cancer Drugs Used to Prevent Breast Cancer Evista (Raloxifene Hydrochloride) Keoxifene (Raloxifene Hydrochloride) Nolvadex (Tamoxifen ...

37

Breast Cancer Information Clearinghouse  

NSDL National Science Digital Library

NYSERNet's Breast Cancer Information Clearinghouse: an Internet accessible resource for breast cancer patients and their families. Current partners represent government health agencies, hospitals, libraries, hospice and non-profit agencies.

38

Breast Cancer: Early Detection  

MedlinePLUS

... saved articles window. My Saved Articles » My ACS » Breast Cancer Prevention and Early Detection Download Printable Version [PDF] » ( ... the factors that may affect your risk for breast cancer, and find out what you can do to ...

39

Breast Cancer and Depression  

MedlinePLUS Videos and Cool Tools

... the lower right-hand corner of the player. Breast Cancer and Depression HealthDay October 28, 2014 Related MedlinePlus Pages Breast Cancer Depression Women's Health Transcript Depression is a disabling ...

40

Breast Cancer Screening  

MedlinePLUS Videos and Cool Tools

... the lower right-hand corner of the player. Breast Cancer Screening HealthDay December 3, 2014 Related MedlinePlus Pages Breast Cancer Mammography Women's Health Transcript Mammography screening strategies based ...

41

Nutrition and breast cancer  

Microsoft Academic Search

The major risk factors for breast cancer are hormone-related, and the only well-established diet-related risk factors for breast cancer are obesity and alcohol consumption. Obesity increases breast cancer risk in postmenopausal women by around 30%, probably by increasing serum concentrations of bioavailable oestradiol. Moderate alcohol intakes increase breast cancer risk by about 7% per alcoholic drink per day, perhaps also

Timothy J Key; Naomi E Allen; Elizabeth A Spencer; Ruth C Travis

2003-01-01

42

Mayo Clinic researchers report that a new breast cancer risk prediction model may be more accurate than current model  

Cancer.gov

A new breast cancer risk prediction model combining histologic features of biopsied breast tissue from women with benign breast disease and individual patient demographic information more accurately classified breast cancer risk than the current screening standard.

43

Differences in fluorescence profiles from breast cancer tissues due to changes in relative tryptophan content via energy transfer: tryptophan content correlates with histologic grade and tumor size but not with lymph node metastases  

NASA Astrophysics Data System (ADS)

The correlation between histologic grade, an increasingly important measure of prognosis for patients with breast cancer, and tryptophan levels from tissues of 15 breast carcinoma patients was investigated. Changes in the relative content of key native organic biomolecule tryptophan were seen from the fluorescence spectra of cancerous and paired normal tissues with excitation wavelengths of 280 and 300 nm. Due to a large spectral overlap and matching excitation-emission spectra, fluorescence resonance energy transfer from tryptophan-donor to reduced nicotinamide adenine dinucleotides-acceptor was noted. We used the ratios of fluorescence intensities at their spectral emission peaks, or spectral fingerprint peaks, at 340, 440, and 460 nm. Higher ratios correlated strongly with high histologic grade, while lower-grade tumors had low ratios. Large tumor size also correlated with high ratios, while the number of lymph node metastases, a major factor in staging, was not correlated with tryptophan levels. High histologic grade correlates strongly with increased content of tryptophan in breast cancer tissues and suggests that measurement of tryptophan content may be useful as a part of the evaluation of these patients.

Sordillo, Laura A.; Sordillo, Peter P.; Budansky, Yury; Pu, Yang; Alfano, Robert R.

2014-12-01

44

Nutrition and breast cancer  

Microsoft Academic Search

Epidemiologic evidence on the relation between nutrition and breast cancer is reviewed. After several decades of study, many aspects of the role of diet in breast cancer etiology are still unclear. Results from large prospective studies do not support the concept developed from animal and ecologic evidence that dietary fat intake in mid-life is associated with breast cancer risk. Thus,

David J. Hunter; Walter C. Willett

1996-01-01

45

Benign lesions and cancer of the breast.  

PubMed

The retroprospective study of breast cancer in relation to benign breast lesions (BBL) involved an analysis of the breast cancer incidence in a cohort of women with a history of BBL. This cohort was formed on the basis of histological and cytological investigations performed during 1982-1991. A total of 10,776 cases with BBI were recorded, followed-up and analyzed. The total person-years of follow-up was 60,872. A total of 35 women with breast cancer were detected during the study. Cohort members with a BBL history were stratified into six subcohorts with respect to morphological and cytological patterns. Comparison of the observed breast cancer incidence with the expected breast cancer incidence calculated on the basis of the age-adjusted breast cancer incidence in the general population showed no significant rise in breast cancer incidence in the whole BBL cohort. The ratio of observed to expected incidence rates was 1.16. The analysis of subcohorts with diverse BBL patterns demonstrated a marked increase in breast cancer incidence only in the intraductal papilloma and cyst subcohorts. The ratios of observed and expected rates were 5.4 and 1.6, respectively. There was no significant difference from population levies of breast cancer risk in subcohorts with history of fibroadenoma, fibrocystic disease, breast nipple discharge and other lesions. Similar results were obtained in the prospective part of the study. PMID:10866034

Levshin, V; Pikhut, P; Yakovleva, I; Lazarev, I

1998-02-01

46

Breast cancer screening.  

PubMed

Mammography remains the primary technique for breast cancer screening. Women with dense breast tissue may benefit from digital mammography and tomosynthesis, and women at high risk may benefit from magnetic resonance imaging. However, false-positive results are problematic. The North Carolina breast density law necessitates education about screening options for women with dense breasts. PMID:24663133

Freimanis, Rita I; Yacobozzi, Margaret

2014-01-01

47

Rehabilitation of breast cancer  

Microsoft Academic Search

\\u000a During 1996, 184,300 women were diagnosed with breast cancer. Although 44,300 women died of breast cancer [1], three fourths\\u000a of those women diagnosed will be cancer survivors. Breast cancer at presentation is a unique disease due to its insidious\\u000a onset. It often presents without warning, on a mammogram, on self-examination, or on physician examination. The disease affects\\u000a more young women

Krystina Kiel; Paula Kopp

48

Genetics Home Reference: Breast cancer  

MedlinePLUS

... PubMed Recent literature OMIM Genetic disorder catalog Conditions > Breast cancer On this page: Description Genetic changes Inheritance Diagnosis ... names Glossary definitions Reviewed August 2007 What is breast cancer? Breast cancer is a disease in which certain ...

49

Breast Cancer in Young Women  

MedlinePLUS

... Podcasts Health-e-Cards Web Badges Infographics Twitter Breast Cancer in Young Women Share Compartir Most breast cancers ... lower your risk. What Is CDC Doing about Breast Cancer in Young Women? CDC works with public, non- ...

50

Clinicopathological characters of triple negative breast cancer  

Microsoft Academic Search

Objective  To study the clinicopathological characters of triple negative breast cancer (TNBC).\\u000a \\u000a \\u000a \\u000a Methods  A total of 629 patients with breast cancer were reviewed, who were treated from 2003 to 2007 in Chongqing Cancer Institute.\\u000a The comparison of clinicopathological features including TNM classification, histological type, tumor location, axillary lymphonodes\\u000a status and neoadjuvant chemotherapy between TNBC and nontriple negative breast cancer (NTNBC) was performed.

Xin Zhou; Qian Liu

2010-01-01

51

Triple-negative breast cancer  

Microsoft Academic Search

ABSTRACT: Perou's molecular classification defines tumors that neither express hormone receptors nor overexpress HER2 as triple-negative (TN) tumors. These tumors account for approximately 15% of breast cancers. The so-called basaloid tumors are not always synonymous with TN tumors; they differ in the fact that they express different molecular markers, have a higher histologic grade, and have a worse prognosis. Clinically

Reinaldo D Chacón; María V Costanzo

2010-01-01

52

Clinical management of women at increased risk for breast cancer  

Microsoft Academic Search

A large number of women in the population are at risk for the development of breast cancer. Methods now exist to accurately assess risk and to provide quantitative estimates of the chance of a woman developing breast cancer in her lifetime. Histologic assessment of premalignant breast pathology aids in the evaluation of risk. The availability of primary chemoprevention clinical trials

Victor G. Vogel; Anita Yeomans; Eric Higginbotham

1993-01-01

53

[Brachytherapy of breast cancer].  

PubMed

For breast cancer, interstitial brachytherapy remains an accurate irradiation technique for delivering a high dose (increasing the local control) in a small volume (decreasing the toxicity). In this article, we present the technical data related to the breast brachytherapy proceeding, from the implantation of the vectors to the treatment itself, including the planning. The different indications of breast brachytherapy include all the breast irradiations focusing on the initial tumour bed (partial irradiation of the breast), such as boost, accelerated and partial breast irradiation (APBI) and second conservative radiosurgical treatment in case of ipsilateral in-breast recurrence. The results in terms of efficacy and toxicity are presented for each indication. Interstitial breast brachytherapy, performed according with the standard rules, remains a major technique for breast cancer treatment. PMID:23453755

Chand, M-È; Rivera, S; Hennequin, C; Hannoun-Lévi, J-M; Quero, L

2013-04-01

54

Breast cancer in China.  

PubMed

The health burden of cancer is increasing in China, with more than 1·6 million people being diagnosed and 1·2 million people dying of the disease each year. As in most other countries, breast cancer is now the most common cancer in Chinese women; cases in China account for 12·2% of all newly diagnosed breast cancers and 9·6% of all deaths from breast cancer worldwide. China's proportional contribution to global rates is increasing rapidly because of the population's rising socioeconomic status and unique reproductive patterns. In this Review we present an overview of present control measures for breast cancer across China, and emphasise epidemiological and socioeconomic diversities and disparities in access to care for various subpopulations. We describe demographic differences between China and high-income countries, and also within geographical and socioeconomic regions of China. These disparities between China and high-income countries include younger age at onset of breast cancer; the unique one-child policy; lower rates of provision and uptake for screening for breast cancer; delays in diagnosis that result in more advanced stage of disease at presentation; inadequate resources; and a lack of awareness about breast cancer in the Chinese population. Finally, we recommend key measures that could contribute to improved health outcomes for patients with breast cancer in China. PMID:24872111

Fan, Lei; Strasser-Weippl, Kathrin; Li, Jun-Jie; St Louis, Jessica; Finkelstein, Dianne M; Yu, Ke-Da; Chen, Wan-Qing; Shao, Zhi-Ming; Goss, Paul E

2014-06-01

55

Breast Lumps: A 21-Year Single-Center Clinical and Histological Analysis  

PubMed Central

Objective: To review the presentation and histological diagnosis of breast lumps of patients seen in Trans Ekulu Hospital Enugu Southeastern Nigeria from 1993 to 2013 in a period of 21 years. Materials and Methods: This is a retrospective study covering a period of 21 years. Case notes of patients containing clinical information and their histology reports were studied. Results: Only 38% of the patients came within 3 months of finding lumps in their breast. One hundred and thirty-seven patients (83%) had benign disease, i.e., fibroadenoma, mammary dysplasia, cysts, adenomas, tuberculosis, phyllodes tumor, mastitis, and lipoma. Only 16.9% i.e., 28 patients had breast cancer, out of which two females were in their 20s, and three were males. Conclusions: Benign breast diseases, i.e., fibroadenoma, fibroadenosis, cysts, adenomas, tuberculosis, phyllodes, mastitis, and lipoma are the commoner breast diseases in our locality. PMID:24665202

Njeze, Gabriel E

2014-01-01

56

International Breast Cancer & Nutrition (IBCN) Project Breast cancer is  

E-print Network

International Breast Cancer & Nutrition (IBCN) Project NEED Breast cancer is emerging as a uniquely on molecularly- driven research and to design models that adequately serve the study of breast cancer risk scientists and public health experts is dedicated to research on the primary prevention of breast cancer

Ginzel, Matthew

57

BREAST CANCER AND EXERCISE  

ClinicalTrials.gov

Prevent Osteoporosis and Osteoporotic Fractures; Improve Quality of Life; Improve Weight Control, and Muscular and Cardiovascular Fitness; Help the Patients to Return to Working Life; Reduce the Risk of Breast Cancer Recurrence; Prevent Other Diseases and Reduce All-Cause Mortality in Patients With Primary Breast Cancer.

2008-03-19

58

Triple negative breast cancers: Clinical and prognostic implications  

Microsoft Academic Search

Triple negative breast cancers are defined by the absence of oestrogen, progesterone and HER2 expression. Most triple negative cancers display distinct clinical and pathological characteristics with a high proportion of these tumours occurring at a younger age of onset and in African–American women. Triple negative tumours typically demonstrate high histological grade and are the most common breast cancer subtype in

S. J. Dawson; E. Provenzano; C. Caldas

2009-01-01

59

Dietary factors and breast cancer risk in Vaud, Switzerland  

Microsoft Academic Search

The relationship between dietary factors and the risk of breast cancer was investigated in a case?control study conducted in the Canton of Vaud, Switzerland as a pilot phase for a larger cooperative study within the SEARCH Programme of the International Agency for Research on Cancer (Lyon, France). A total of 107 incident, histologically confirmed cases of breast cancer and 318

Fabio Levi; Carlo La Vecchia; Cristina Gulie; Eva Negri

1993-01-01

60

Breast Cancer and the Environment  

MedlinePLUS

Breast Cancer and the Environment ?QUESTIONS aNd aNSwErS What does it mean to say 1 in 8 women will get breast cancer? Researchers have been ... to breast cancer. Many people are concerned that environmental factors are increasing the risk of breast cancer. ...

61

Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer Or Other Cancers  

ClinicalTrials.gov

HER2-negative Breast Cancer; HER2-positive Breast Cancer; Male Breast Cancer; Malignant Neoplasm; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer

2014-07-01

62

Protect Yourself from Breast Cancer  

MedlinePLUS

... for professional printing [PDF-1.1MB] Cancer Home Breast Cancer: Know the Risks Infographic Language: English Español (Spanish) Share Compartir Breast Cancer: Know the Risks Many things can increase the ...

63

Hormones, Women and Breast Cancer  

MedlinePLUS

... Edition hoW is Breast cancer treated? Treatment for breast cancer depends on the type and the stage of the cancer. Typical treatments include surgery, radiation therapy, chemotherapy, anti-estrogen hormone therapy, or a combination ...

64

Breast Cancer Risk in American Women  

MedlinePLUS

Breast Cancer Risk in American Women Key Points Based on current breast cancer incidence rates, experts estimate that ... risk of developing the disease. Personal history of breast cancer : Women who have had breast cancer are more ...

65

Breast cancer screening  

Microsoft Academic Search

Radiographic imaging of the breast began in the early years of the twentieth century. Continuous advances in film quality, energy sources, targets, grids, and filters have all contributed to superior image resolution. Federal quality standards now regulate screening mammography, and mass screening for breast cancer has become widely accepted in the United States. Wider application of screening has resulted in

Kathleen M. Harris; Victor G. Vogel

1997-01-01

66

Breast and Gynecologic Cancer  

Cancer.gov

This group conducts and supports research on the prevention and early detection of breast, cervix, endometrial, and ovarian cancers. Clinical trials and the evaluation of new agents, surrogate biomarkers, and new technologies to identify premalignant lesions are developed and supported.

67

Diet and breast cancer  

Microsoft Academic Search

Clarification of the role of diet in breast cancer pathogenesis is important in order to identify modifiable risk factors\\u000a on which to focus prevention efforts. Excess weight and weight gain in adult life are related to higher risk of postmenopausal\\u000a breast cancer, and weight loss after menopause is associated with substantially reduced risk. Even moderate alcohol consumption\\u000a contributes considerably to

Eleni Linos; Michelle D. Holmes; Walter C. Willett

2007-01-01

68

Alcoholic beverage consumption and risk of breast cancer in Spain  

Microsoft Academic Search

The relation between alcoholic beverage consumption and risk of breast cancer was examined. We used data from a population-based, case-control study that included almost all incident cases occurring in five Spanish regions from February 1990 to July 1991. A total of 762 women between 18 and 75 years of age, with a histologically confirmed, first diagnosis of breast cancer, were

Jose M. Martin-Moreno; Peter Boyle; Lydia Gorgojo; Walter C. Willett; Jesus Gonzalez; Fernando Viliar; Patrick Maisonneuve

1993-01-01

69

Digital Tomosynthesis: Advanced Breast Cancer  

E-print Network

Digital Tomosynthesis: Advanced Breast Cancer Imaging Technique Max Wiedmann #12;Digital in CT. #12;Breast Cancer · The leading Cause of death for women ages 40-55. · Is only behind lung and bronchus cancer in terms of number of deaths in US. · Early detection of breast cancer is believed to save

Fygenson, Deborah Kuchnir

70

Your Body After Breast Cancer  

MedlinePLUS

... Breast Cancer , Coping with Cancer Your Body After Breast Cancer Article date: September 28, 2012 By Melissa Weber Newlywed Sarah Lien didn’t ... age 24, she was diagnosed with stage 3 breast cancer in 2010. “I had no control over what ...

71

Stereotactic Image-Guided Navigation During Breast Reconstruction in Patients With Breast Cancer  

ClinicalTrials.gov

Ductal Breast Carcinoma in Situ; Lobular Breast Carcinoma in Situ; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer

2012-11-14

72

Lymphovascular Invasion and Lobular Histology are Associated with Increased Incidence of Isolated Tumor Cells in Sentinel Lymph Nodes from Early-Stage Breast Cancer Patients  

PubMed Central

Background Isolated tumor cells (ITC) are more likely to be identified when serial sectioning and immunohistochemical staining are used to evaluate sentinel lymph nodes (SLN). Our goal was to identify clinicopathologic features associated with ITC in patients undergoing sentinel lymph node dissection (SLND). Methods We reviewed clinicopathologic data for 3557 patients with no clinical evidence of lymph node metastases undergoing SLND between November 1993 and March 2007. Patients were staged according to the 6th edition of the American Joint Committee on Cancer staging system, with metastasis ?.2 mm classified as ITC. Results A SLN was identified in 3475 patients (97.7%), including 2518 (72.4%) with negative nodes and 169 (4.9%) with ITC. A statistically significant association existed between lobular histology and the identification of ITC; 13.6% of patients with ITC had lobular histology versus 7.3% of patients with a negative SLN (P = .003). The presence of lymphovascular invasion (LVI) was also associated with ITC; 18.3% of patients with ITC had LVI in the primary tumor versus 8.5% of patients with a negative SLN (P < .001). No difference existed between patients with and without ITC with respect to T stage, grade, estrogen receptor, progesterone receptor, HER2/neu status, or biopsy method. Conclusion The association between ITC and LVI, a known predictor of poor outcome, suggests ITC may have clinical relevance. The relationship between lobular histology and ITC is consistent with the known pattern of lobular metastases, which frequently present as small foci requiring immunohistochemistry for detection. Longer follow-up is needed to determine whether ITC have prognostic significance. PMID:18815841

Mittendorf, Elizabeth A.; Sahin, Aysegul A.; Tucker, Susan L.; Meric-Bernstam, Funda; Yi, Min; Nayeemuddin, Khazi M.; Babiera, Gildy V.; Ross, Merrick I.; Feig, Barry W.; Kuerer, Henry M.; Hunt, Kelly K.

2015-01-01

73

Breast Cancer Detection  

NASA Technical Reports Server (NTRS)

The BioScan System was developed by OmniCorder Technologies, Inc. at the Jet Propulsion Laboratory. The system is able to locate cancerous lesions by detecting the cancer's ability to recruit a new blood supply. A digital sensor detects infrared energy emitted from the body and identifies the minute differences accompanying the blood flow changes associated with cancerous cells. It also has potential use as a monitoring device during cancer treatment. This technology will reduce the time taken to detect cancerous cells and allow for earlier intervention, therefore increasing the overall survival rates of breast cancer patients.

2000-01-01

74

Histological and biological evolution of human premalignant breast disease  

Microsoft Academic Search

Most human invasive breast cancers (IBCs) appear to develop over long periods of time from certain pre-existing benign lesions. Of the many types of benign lesions in the human breast, only a few appear to have significant premalignant potential. The best characterized of these include atypical hyperplasias and in situ carcinomas and both categories are probably well on along the

D C Allred; S K Mohsin; SAW Fuqua

2001-01-01

75

Gastric Metastasis of Ectopic Breast Cancer Mimicking Axillary Metastasis of Primary Gastric Cancer  

PubMed Central

Ectopic breast tissue has the ability to undergo all the pathological changes of the normal breast, including breast cancer. Gastrointestinal metastasis of breast cancer is rarely observed and it is very difficult to differentiate gastric metastases from primary gastric cancer. We present a case of 52-year-old female, who suffered from abdominal pain. Physical examination showed a palpable mass in the left anterior axilla and computerized tomography revealed gastric wall thickening with linitis plastica. When gastroscopic biopsy showed no signs of malignancy, excisional biopsy was performed in the left axilla. Histological examination revealed invasive lobular carcinoma of the breast, consistent with ectopic breast cancer. Further gastroscopic submucosal biopsies and immunohistochemical studies revealed gastric metastases of invasive lobular carcinoma. Axillary ectopic breast tissue carcinomas can mimic axillary lymphadenopathies. Additionally, gastric metastasis of breast cancer is an uncommon but possible condition. To the best of our knowledge, this is the first report of ectopic breast cancer with gastric metastasis.

Kay?l?o?lu, Selami Ilgaz; Akyol, Cihangir; Esen, Ebru; Cans?z-Ersöz, Cevriye; Kocaay, Ak?n F?rat; Genç, Volkan; Kepenekçi, ?lknur; Demirer, Seher

2014-01-01

76

Effect of organ-specific fibroblasts on proliferation and differentiation of breast cancer cells  

Microsoft Academic Search

Summary Breast carcinomas contain both tumor cells and stromal cells, including fibroblasts, endothelial cells, and lymphocytes. Proliferation of breast cancer cells may be controlled partly by mesenchymal cells, especially fibroblasts. We studied effects of fibroblasts on tumorigenicity and histologic features of breast cancer cells vivo, and analyzed fibroblast-produced growth-promoting factors in vitro. Breast carcinoma cells from four lines, and fibroblasts

Masakazu Yashiro; Katsumi Ikeda; Masashige Tendo; Tetsuro Ishikawa; Kosei Hirakawa

2005-01-01

77

Preventing Breast Cancer: Making Progress  

MedlinePLUS

... Navigation Bar Home Current Issue Past Issues Preventing Breast Cancer: Making Progress Past Issues / Fall 2006 Table of ... 000 women will have been diagnosed with invasive breast cancer, and nearly 41,000 women will die from ...

78

Breast Cancer, Exercise and Acupuncture  

MedlinePLUS Videos and Cool Tools

... the lower right-hand corner of the player. Breast Cancer, Exercise and Acupuncture HealthDay November 12, 2014 Related MedlinePlus Pages Acupuncture Breast Cancer Exercise and Physical Fitness Transcript Exercise therapy and ...

79

Breast Cancer Prevention Clinical Trials  

Cancer.gov

Programs and Projects Breast Cancer Prevention Clinical Trials Ongoing Phase I/II Prevention Trials Funded and Monitored by the Breast and Gynecologic Cancer Research Group (BGCRG) Principal Investigator Funding Mechanism Title of Award

80

Combined magnetic resonance, fluorescence, and histology imaging strategy in a human breast tumor xenograft model  

PubMed Central

Applications of molecular imaging in cancer and other diseases frequently require combining in vivo imaging modalities, such as magnetic resonance and optical imaging, with ex vivo optical, fluorescence, histology, and immunohistochemical (IHC) imaging, to investigate and relate molecular and biological processes to imaging parameters within the same region of interest. We have developed a multimodal image reconstruction and fusion framework that accurately combines in vivo magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI), ex vivo brightfield and fluorescence microscopic imaging, and ex vivo histology imaging. Ex vivo brightfield microscopic imaging was used as an intermediate modality to facilitate the ultimate link between ex vivo histology and in vivo MRI/MRSI. Tissue sectioning necessary for optical and histology imaging required generation of a three-dimensional (3D) reconstruction module for 2D ex vivo optical and histology imaging data. We developed an external fiducial marker based 3D reconstruction method, which was able to fuse optical brightfield and fluorescence with histology imaging data. Registration of 3D tumor shape was pursued to combine in vivo MRI/MRSI and ex vivo optical brightfield and fluorescence imaging data. This registration strategy was applied to in vivo MRI/MRSI, ex vivo optical brightfield/fluorescence, as well as histology imaging data sets obtained from human breast tumor models. 3D human breast tumor data sets were successfully reconstructed and fused with this platform. PMID:22945331

Jiang, Lu; Greenwood, Tiffany R.; Amstalden van Hove, Erika R.; Chughtai, Kamila; Raman, Venu; Winnard, Paul T.; Heeren, Ron; Artemov, Dmitri; Glunde, Kristine

2014-01-01

81

Adiponectin and breast cancer  

Microsoft Academic Search

Adiponectin, an adipose tissue-derived hormone, has been studied intensively for the past decade because of its anti-inflammatory,\\u000a anti-atherogenic, and anti-diabetic properties. Recent advances suggest that adiponectin also plays an important role in the\\u000a development and progression of various cancers, especially obesity-related cancers. In this review, the authors focus on the\\u000a potential role of adiponectin in breast cancer, an obesity- and

Xiuping Chen; Yitao Wang

82

Radiation Therapy for Breast Cancer  

MedlinePLUS

RADIATION THERAPY FOR BREAST CANCER © ASTRO 2011 Printed on Recycled Paper CARING FOR YOURSELF NOTES/QUESTIONS FOR YOUR DOCTOR Facts to Help Patients Make ... Oncology Group www.rtog.org HELPFUL WEBSITES ON BREAST CANCER Breast Cancer Network of Strength www.networkofstrength.org ...

83

Columnar cell lesions, mammographic density and breast cancer risk  

Microsoft Academic Search

Background Mammographic density is the third largest risk factor for ductal carcinoma in-situ (DCIS) and invasive breast cancer. However,\\u000a the question of whether risk-mediating precursor histological changes, such as columnar cell lesions (CCLs), can be found\\u000a in dense but non-malignant breast tissues has not been systematically addressed. We hypothesized that CCLs may be related\\u000a to breast composition, in particular breast

Gulisa Turashvili; Steven McKinney; Lisa Martin; Karen A. Gelmon; Peter Watson; Norman Boyd; Samuel Aparicio

2009-01-01

84

Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors  

ClinicalTrials.gov

Ductal Breast Carcinoma In Situ; Lobular Breast Carcinoma In Situ; Paget Disease of the Breast; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer

2015-01-27

85

Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer  

ClinicalTrials.gov

Ductal Breast Carcinoma in Situ; Lobular Breast Carcinoma in Situ; Male Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer

2014-11-19

86

Genetic factors and breast cancer laterality  

PubMed Central

Background Women are more likely to develop cancer in the left breast than the right. Such laterality may influence subsequent management, especially in elderly patients with heart disease who may require radiation therapy. The purpose of this study was to explore possible factors for such cancer laterality. Methods In this work, clinical data for consecutive patients with histologically confirmed breast cancer were reviewed, with emphasis on clinical presentation and family history. Results Between 2005 and 2012, 687 patients with breast cancer were seen. Two women with incomplete data and eleven men were excluded. In total, 343 (50.9%) patients presented with left breast cancer, 311 (46.1%) with right breast cancer, and 20 (3.0%) with simultaneous bilateral malignancy. There were no significant differences between the three groups, especially in regards to clinical presentation and tumor characteristics. A total of 622 (92.3%) patients had unilateral primary, 20 (3.0%) had simultaneous bilateral, and 32 (4.7%) had metachronous primary breast cancer with subsequent contralateral breast cancer after 7.5–236 months. The worst 10-year survival was for bilateral simultaneous (18%) compared with unilateral (28%) and metachronous primaries (90%). There were no differences in survival in relation to breast cancer laterality, handedness, and presence or absence of a family history of cancer. There were significant similarities between patients and first-degree relatives in regards to breast cancer laterality, namely same breast (30/66, 45.5%), opposite breast (9/66, 13.6%), and bilateral cancer (27/66, 40.9, P=0.01163). This was more evident among patients and their sisters (17/32, 53.1%) or mothers (11/27, 40.7%, P=0.0689). There were also close similarities in relation to age at initial diagnosis of cancer for patients and their first-degree relatives for age differences of ?5 years (48/166, 28.9%), 6–10 years (34/166, 20.5%), and >11 years (84/166, 50.6%, P=0.12065). Conclusion High similarities between patients and their first-degree relatives in regards to cancer laterality and possibly age at initial diagnosis of cancer may suggest an underlying inherited genetic predisposition. PMID:24790468

Amer, Magid H

2014-01-01

87

Screening of Breast Cancer  

Microsoft Academic Search

\\u000a In the randomized controlled trials carried out in the late 1970s and the 1980s, mammographic screening was demonstrated to\\u000a have an impact in decreasing mortality from breast cancer. The evaluation of mammographic service screening programmes implemented\\u000a in several Western European countries in the late 1980s and the 1990s demonstrated that these programmes may have an even\\u000a higher effect on breast

Per Skaane

88

Cryosurgery of breast cancer  

PubMed Central

With recent improvements in breast imaging, the ability to identify small breast tumors is markedly improved, prompting significant interest in the use of cryoablation without surgical excision to treat early-stage breast cancer. The cryoablation is often performed using ultrasound-guided tabletop argon-gas-based cryoablation system with a double freeze/thaw cycle. Recent studies have demonstrated that, as a primary therapy for small breast cancer, cryoablation is safe and effective with durable results, and can successfully destroy all cancers <1.0 cm and tumors between 1.0 and 1.5 cm without a significant ductal carcinoma-in-situ (DCIS) component. Presence of noncalcified DCIS is the cause of most cryoablation failures. At this time, cryoablation should be limited to patients with invasive ductal carcinoma <1.5 cm and with <25% DCIS in the core biopsy. For unresectable advanced breast cancer, cryoablation is a palliation modality and may be used as complementary for subsequent resection or other therapies. PMID:25083433

Zhou, Liang; Xu, Kecheng

2012-01-01

89

Cryosurgery of breast cancer.  

PubMed

With recent improvements in breast imaging, the ability to identify small breast tumors is markedly improved, prompting significant interest in the use of cryoablation without surgical excision to treat early-stage breast cancer. The cryoablation is often performed using ultrasound-guided tabletop argon-gas-based cryoablation system with a double freeze/thaw cycle. Recent studies have demonstrated that, as a primary therapy for small breast cancer, cryoablation is safe and effective with durable results, and can successfully destroy all cancers <1.0 cm and tumors between 1.0 and 1.5 cm without a significant ductal carcinoma-in-situ (DCIS) component. Presence of noncalcified DCIS is the cause of most cryoablation failures. At this time, cryoablation should be limited to patients with invasive ductal carcinoma <1.5 cm and with <25% DCIS in the core biopsy. For unresectable advanced breast cancer, cryoablation is a palliation modality and may be used as complementary for subsequent resection or other therapies. PMID:25083433

Niu, Lizhi; Zhou, Liang; Xu, Kecheng

2012-08-01

90

MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer  

ClinicalTrials.gov

Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; HER2-positive Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Triple-negative Breast Cancer

2014-10-16

91

Vitamin D and Breast Cancer  

PubMed Central

In addition to its role in calcium homeostasis and bone health, vitamin D has also been reported to have anticancer activities against many cancer types, including breast cancer. The discovery that breast epithelial cells possess the same enzymatic system as the kidney, allowing local manufacture of active vitamin D from circulating precursors, makes the effect of vitamin D in breast cancer biologically plausible. Preclinical and ecologic studies have suggested a role for vitamin D in breast cancer prevention. Inverse associations have also been shown between serum 25-hydroxyvitamin D level (25(OH)D) and breast cancer development, risk for breast cancer recurrence, and mortality in women with early-stage breast cancer. Clinical trials of vitamin D supplementation, however, have yielded inconsistent results. Regardless of whether or not vitamin D helps prevent breast cancer or its recurrence, vitamin D deficiency in the U.S. population is very common, and the adverse impact on bone health, a particular concern for breast cancer survivors, makes it important to understand vitamin D physiology and to recognize and treat vitamin D deficiency. In this review, we discuss vitamin D metabolism and its mechanism of action. We summarize the current evidence of the relationship between vitamin D and breast cancer, highlight ongoing research in this area, and discuss optimal dosing of vitamin D for breast cancer prevention. PMID:22234628

Klein, Paula; Grossbard, Michael L.

2012-01-01

92

Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer  

ClinicalTrials.gov

Inflammatory Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Mucinous Ductal Breast Carcinoma; Papillary Ductal Breast Carcinoma; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Tubular Ductal Breast Carcinoma

2014-12-09

93

human breast cancer cells  

E-print Network

Background: Colloidal silver has been used as an antimicrobial and disinfectant agent. However, there is scarce information on its antitumor potential. The aim of this study was to determine if colloidal silver had cytotoxic effects on MCF-7 breast cancer cells and its mechanism of cell death. Methods: MCF-7 breast cancer cells were treated with colloidal silver (ranged from 1.75 to 17.5 ng/mL) for 5 h at 37°C and 5 % CO2 atmosphere. Cell Viability was evaluated by trypan blue exclusion method and the mechanism of cell death through detection of mono-oligonucleosomes using an ELISA kit and TUNEL assay. The production of NO, LDH, and Gpx, SOD, CAT, and Total antioxidant activities were evaluated by colorimetric assays. Results: Colloidal silver had dose-dependent cytotoxic effect in MCF-7 breast cancer cells through induction of apoptosis, shown an LD50 (3.5 ng/mL) and LD100 (14 ng/mL) (*P colloidal silver. Conclusions: The present results showed that colloidal silver might be a potential alternative agent for human breast cancer therapy. Background

Moisés A Franco-molina; Edgar Mendoza-gamboa; Crystel A Sierra-rivera; Ricardo A Gómez-flores; Pablo Zapata-benavides; Paloma Castillo-tello; Juan Manuel Alcocer-gonzález; Diana F Mir; Reyes S Tamez-guerra; Cristina Rodríguez-padilla

94

Breast Cancer Statistics  

Cancer.gov

The maps show a pattern of elevated mortality rates for female breast cancer extending from the Mid-Atlantic through the Northeastern states has persisted for many years. Established risk factors are believed to be largely responsible, but the remaining reasons are unknown.

95

Better breast cancer detection  

Microsoft Academic Search

X-rays go digital, computers read film, and chemicals mark tumors, but will these new technologies make it in the clinic? The imaging technologies considered for breast cancer include film-screen mammography, full field digital mammography, ultrasound, magnetic resonance imaging, scintimammography, thermography, electrical impedance imaging, optical imaging, electric potential measurement, positron emission tomography, novel ultrasound techniques, elastography, magnetic resonance spectroscopy, thermoacoustic computed

S. K. Moore

2001-01-01

96

Breast Cancer Screening  

MedlinePLUS

... ongoing clinical trials is available from the NCI Web site . Three tests are used by health care providers to screen ... ongoing clinical trials is available from the NCI Web site . Risks of Breast Cancer Screening Screening tests have risks. Decisions about screening tests can be ...

97

Breast-conserving surgery in breast cancer.  

PubMed

The breast cancer treatment is based nowadays on new surgical options: breast-conserving surgery, which applies at least for the first and second stage cancer, with radical intention. We have been practicing breast-conserving surgery for the last 16 years and we have performed 303 breast conserving operations from a total of 673. We recorded 12 local recurrences (3,96%) and 2 deaths due to cancer progression. Our protocol includes removal of the primary tumor with enough surrounding tissue to ensure negative margins of the resectable specimen, associated with axillary lymph-node dissection and postoperative breast irradiation. Our oncologist indicated chemotherapy on different postoperative conditions: tumor size, axillary lymph node involvement, patient's age, etc. The purpose of this paper is to emphasize our modest experience, nevertheless to draw the attention on important results, obtained by long-term monitoring of the patients who underwent breast-conserving surgery, in a two prospective protocols, and demonstrate the importance and applicability of breast conserving therapy. The conclusion of this study is that breast-conserving surgery followed by breast irradiation is reliable, as the results are similar with radical mastectomies; the main objective is to obtain a good cosmetic result, which depends on tumor size / breast size. PMID:23116836

Tenea Cojan, T S; Vidrighin, C D; Ciobanu, M; Paun, I; Teodorescu, M; Mogos, G; Tenovici, M; Florescu, M; Mogos, D

2012-01-01

98

Breast Cancer Among Asian Women  

Cancer.gov

A study of breast cancer among Asian populations, including mainland China, Hong Kong, and Malaysia, with the aim of identifying distinct molecular alterations in tumors and adjacent normal tissues, and examining the associations of these molecular changes with risk factors (genetic and environmental), breast tissue composition and density, and breast cancer subtypes.

99

Thermographic detection of breast cancer  

Microsoft Academic Search

The author outlines the historical attempts made to use infrared thermography for breast cancer detection. He concludes that the technique was a great idea that failed. One can produce good thermal images of the breast, and these images often show features that reflect disease. But the association between skin temperature and breast cancer is too weak to be useful, given

K. R. Foster

1998-01-01

100

Breast Cancer Research at NASA  

NASA Technical Reports Server (NTRS)

Dr. Harry Mahtani analyzes the gas content of nutrient media from Bioreactor used in research on human breast cancer. NASA's Marshall Space Flight Center (MSFC) is sponsoring research with Bioreactors, rotating wall vessels designed to grow tissue samples in space, to understand how breast cancer works. This ground-based work studies the growth and assembly of human mammary epithelial cells (HMEC) from breast cancer susceptible tissue. Radiation can make the cells cancerous, thus allowing better comparisons of healthy vs. tunourous tissues.

1998-01-01

101

Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery  

ClinicalTrials.gov

Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer

2014-02-05

102

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer  

ClinicalTrials.gov

Estrogen Receptor-positive Breast Cancer; Gastrinoma; Glucagonoma; HER2-negative Breast Cancer; Insulinoma; Mucositis; Oral Complications; Pancreatic Polypeptide Tumor; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Recurrent Islet Cell Carcinoma; Recurrent Renal Cell Cancer; Somatostatinoma; Stage III Renal Cell Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Stage IV Renal Cell Cancer

2014-11-04

103

Silicone Breast Implants Are Not Linked to Breast Cancer Risk  

Cancer.gov

In one of the largest studies on the long-term health effects of silicone breast implants, researchers from the National Cancer Institute (NCI) in Bethesda, Md., found no association between breast implants and the subsequent risk of breast cancer.

104

FastStats: Mammography/Breast Cancer  

MedlinePLUS

... Submit What's this? Submit Button NCHS Home Mammography/Breast Cancer Share Compartir Data are for the U.S. Mammography ... Department Summary Tables, table 15 [PDF - 330 KB] Breast cancer mortality Number of breast cancer deaths for females: ...

105

Male Breast Cancer: One Man's Story  

MedlinePLUS Videos and Cool Tools

... a Researcher Lab Websites Health Library Blog Home Health Library Male Breast Cancer: One Man's Story Male Breast Cancer: One Man's Story Posted in: Risk and Prevention , Treatments and Procedures Cancer types: Breast ...

106

Do We Know What Causes Breast Cancer?  

MedlinePLUS

... cause normal breast cells to become cancerous. Inherited gene mutations Certain inherited DNA mutations can dramatically increase ... of breast cancer that runs in families. Acquired gene mutations Most DNA mutations related to breast cancer ...

107

Breast cancer stem cells: implications for therapy of breast cancer  

PubMed Central

The concept of cancer stem cells responsible for tumour origin, maintenance, and resistance to treatment has gained prominence in the field of breast cancer research. The therapeutic targeting of these cells has the potential to eliminate residual disease and may become an important component of a multimodality treatment. Recent improvements in immunotherapy targeting of tumour-associated antigens have advanced the prospect of targeting breast cancer stem cells, an approach that might lead to more meaningful clinical remissions. Here, we review the role of stem cells in the healthy breast, the role of breast cancer stem cells in disease, and the potential to target these cells. PMID:18671830

Morrison, Brian J; Schmidt, Chris W; Lakhani, Sunil R; Reynolds, Brent A; Lopez, J Alejandro

2008-01-01

108

Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer  

ClinicalTrials.gov

Ductal Breast Carcinoma in Situ; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; HER2-positive Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Male Breast Cancer; Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate; Mucinous Ductal Breast Carcinoma; Papillary Ductal Breast Carcinoma; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Tubular Ductal Breast Carcinoma

2011-12-07

109

BREAST CANCER PROGRAM A team of breast cancer experts from multiple specialties work together under  

E-print Network

BREAST CANCER PROGRAM A team of breast cancer experts from multiple specialties work together under advanced and inflammatory breast cancer, breast cancer in the elderly and patients at high risk for breast cancer · A Weekly Breast Tumor Board where patient care is discussed and coordinated Provide surgical

Arizona, University of

110

Spinal intramedullary metastasis of breast cancer.  

PubMed

Objective. Breast cancer accounts for approximately one-third of all cancers in females. Approximately 8.5 % of all central nervous system metastases are located in the spinal cord. These patients have rapidly progressing neurological deficits and require immediate examination. The aim of surgery is decompression of neural tissue and histological evaluation of the tumor. In this paper, we present a case of breast cancer metastasis in thoracic spinal intramedullary area which had been partially excised and then given adjuvant radiotherapy. Case. A 43-year-old female patient with breast cancer for 8 years was admitted to our hospital with complaints of weakness in both legs. Eight years ago, she received chemotherapy and radiotherapy. On her neurological examination, she had paraparesis (left lower extremity: 2/5, right lower extremity: 3/5) and urinary incontinence. Spinal MRI revealed a gadolinium enhancing intramedullary lesion. Pathologic examination of the lesion was consistent with breast carcinoma metastasis. The patient has been taken into radiotherapy. Conclusion. Spinal intramedullary metastasis of breast cancer is an extremely rare situation, but it has a high morbidity and mortality rate. Microsurgical resection is necessary for preservation or amelioration of neurological state and also for increased life expectancy and quality. PMID:25477971

Basaran, Recep; Tiryaki, Mehmet; Yavuzer, Dilek; Efendioglu, Mustafa; Balkuv, Ece; Sav, Aydin

2014-01-01

111

Breast Cancer Metastasis  

PubMed Central

Despite important progress in adjuvant and neoadjuvant therapies, metastatic disease often develops in breast cancer patients and remains the leading cause of their deaths. For patients with established metastatic disease, therapy is palliative, with few breaks and with mounting adverse effects. Many have hypothesized that a personalized or precision approach (the terms are used interchangeably) to cancer therapy, in which treatment is based on the individual characteristics of each patient, will provide better outcomes. Here, we discuss the molecular basis of breast cancer metastasis and the challenges in personalization of treatment. The instability of metastatic tumors remains a leading obstacle to personalization, because information from a patient’s primary tumor may not accurately reflect the metastasis, and one metastasis may vary from another. Furthermore, the variable presence of tumor subpopulations, such as stem cells and dormant cells, may increase the complexity of the targeted treatments needed. Although molecular signatures and circulating biomarkers have been identified in breast cancer, there is lack of validated predictive molecular markers to optimize treatment choices for either prevention or treatment of metastatic disease. Finally, to maximize the information that can be obtained, increased attention to clinical trial design in the metastasis preventive setting is needed. PMID:23895915

Marino, Natascia; Woditschka, Stephan; Reed, L. Tiffany; Nakayama, Joji; Mayer, Musa; Wetzel, Maria; Steeg, Patricia S.

2014-01-01

112

Screening for breast cancer with MRI  

Microsoft Academic Search

Breast MRI has emerged as an extremely powerful tool in breast imaging. The use of breast MRI for cancer detection has the potential to change our current algorithms in the detection of breast cancer. By being able to detect cancer that is occult on conventional imaging, such as mammography and sonography, MRI can detect early breast cancer that was previously

Elizabeth A Morris

2003-01-01

113

Breast Cancer Research at NASA  

NASA Technical Reports Server (NTRS)

Dr. Robert Richmond extracts breast cell tissue from one of two liquid nitrogen dewars. NASA's Marshall Space Flight Center (MSFC) is sponsoring research with Bioreactors, rotating wall vessels designed to grow tissue samples in space, to understand how breast cancer works. This ground-based work studies the growth and assembly of human mammary epithelial cells (HMEC) from breast cancer susceptible tissue. Radiation can make the cells cancerous, thus allowing better comparisons of healthy vs. tunourous tissues.

1998-01-01

114

Breast Cancer Research at NASA  

NASA Technical Reports Server (NTRS)

Breast tissue specimens in traditional sample dishes. NASA's Marshall Space Flight Center (MSFC) is sponsoring research with Bioreactors, rotating wall vessels designed to grow tissue samples in space, to understand how breast cancer works. This ground-based work studies the growth and assembly of human mammary epithelial cells (HMEC) from breast cancer susceptible tissue. Radiation can make the cells cancerous, thus allowing better comparisons of healthy vs. tunourous tissues.

1998-01-01

115

Pathology of hereditary breast cancer  

Microsoft Academic Search

Background  Hereditary breast cancer runs in families where several members in different generations are affected. Most of these breast\\u000a cancers are caused by mutations in the high penetrance genes BRCA1 and BRCA2 accounting for about 5% of all breast cancers. Other genes that include CHEK2, PTEN, TP53, ATM, STK11\\/LKB1, CDH1, NBS1, RAD50, BRIP1 and PALB2 have been described to be high

Petra van der Groep; Elsken van der Wall; Paul J. van Diest

2011-01-01

116

Breast cancer — one term, many entities?  

PubMed Central

Breast cancer, rather than constituting a monolithic entity, comprises heterogeneous tumors with different clinical characteristics, disease courses, and responses to specific treatments. Tumor-intrinsic features, including classical histological and immunopathological classifications as well as more recently described molecular subtypes, separate breast tumors into multiple groups. Tumor-extrinsic features, including microenvironmental configuration, also have prognostic significance and further expand the list of tumor-defining variables. A better understanding of the features underlying heterogeneity, as well as of the mechanisms and consequences of their interactions, is essential to improve targeting of existing therapies and to develop novel agents addressing specific combinations of features. PMID:21965335

Bertos, Nicholas R.; Park, Morag

2011-01-01

117

Correlation between Duffy blood group phenotype and breast cancer incidence  

PubMed Central

Background Different ethnicities have different distribution of Duffy blood group (DBG) phenotypes and different breast cancer morbidity. A study in our lab demonstrated that Duffy antigen/receptor for chemokines (DARC, also known as DBGP, the Duffy protein phenotype), led to the inhibition of tumorigenesis. Therefore, we tested the hypothesis that DBGP is correlated with breast cancer occurrence. Methods DBGP proteins were examined by indirect antiglobulin testing with anti-FYa and anti-FYb antibodies. The phenotypes were classified into four groups according to the agglutination reactions: FYa + FYb+, FYa + FYb-, FYa-FYb + and FYa-FYb-. The phenotypes and pathological diagnosis of consecutively hospitalized female patients (n = 5,022) suffering from breast cancer at the Shanghai Cancer Hospital and Henan Province Cancer Hospital were investigated. The relationships between DBGP expression with breast cancer occurrence, axillary lymph status, histological subtype, tumor size pathological grade and overall survival were analyzed. Results The incidence of breast cancer was significantly different between FYa + FYb + (29.8%), FYa + FYb- (33.2%), FYa-FYb + (45.6%) and FYa-FYb- (59.1%; P = 0.001). Significant different numbers of breast cancer patients had metastases to the axillary lymph nodes in the FYa + FYb + group (25.1%), FYa + FYb- (36.9%), FYa-FYb + (41.0%) and FYa-FYb- (50.0%, (P = 0.005). There was a statistical significance (p = 0.022) of the overall survival difference between patients with difference phenotypes. No significant difference was observed in cancer size (t-test, p > 0.05), histological cancer type (Fisher's exact test, p > 0.05) or histological grade (Fisher's exact test, p > 0.05) between every each DBGP group. Conclusions DBGP is correlated with breast cancer incidence and axillary lymph node metastasis and overall survival. Further investigations are required to determine the underlying mechanism of Duffy blood group phenotype on breast cancer risk. PMID:22928984

2012-01-01

118

Breast Cancer Research at NASA  

NASA Technical Reports Server (NTRS)

High magnification view of human primary breast tumor cells after 56 days of culture in a NASA Bioreactor. The arrow points to bead surface indicating breast cancer cells (as noted by the staining of tumor cell intermediate filaments). NASA's Marshall Space Flight Center (MSFC) is sponsoring research with Bioreactors, rotating wall vessels designed to grow tissue samples in space, to understand how breast cancer works. This ground-based work studies the growth and assembly of human mammary epithelial cell (HMEC) from breast cancer susceptible tissue. Radiation can make the cells cancerous, thus allowing better comparisons of healthy vs. tunorous tissue. Credit: Dr. Jearne Becker, University of South Florida

1998-01-01

119

Rosuvastatin in Treating Women With Cardiovascular Complications Who Are Undergoing Chemotherapy For Breast Cancer  

ClinicalTrials.gov

Cardiovascular Complications; Recurrent Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer

2014-02-17

120

CANCER GENETICS & PREVENTION HEREDITARY BREAST AND OVARIAN CANCER  

E-print Network

(called "triple negative") breast cancers. Below are the estimated lifetime risks of cancer in peopleCANCER GENETICS & PREVENTION HEREDITARY BREAST AND OVARIAN CANCER SYNDROME (HBOC) ­ BRCA1 PATIENT INFORMATION What is Hereditary Breast and Ovarian Cancer syndrome? Hereditary Breast and Ovarian Cancer

Liu, Xiaole Shirley

121

Genetics of Hereditary Breast Cancer  

Microsoft Academic Search

\\u000a The identification and clinical management of patients at inherited risk for breast cancer has become an integral part of\\u000a the practice of preventative medicine and oncology. Although only about 5–10% of all cases of breast cancer are attributable\\u000a to a highly penetrant cancer predisposition gene, individuals who carry a cancer susceptibility gene mutation have a significantly\\u000a higher risk of developing

Paula D. Ryan

122

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery  

ClinicalTrials.gov

Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer

2014-03-05

123

Adjuvant Bisphosphonates for Breast Cancer  

Cancer.gov

Drugs called bisphosphonates may be able to prevent bone metastases in women with early breast cancer. With this trial, researchers are comparing a bisphosphonate called clodronate with two newer, more-potent bisphosphonates--zoledronate and ibandronate--in women with stage I-III breast cancer.

124

Male Breast Cancer Is Different  

MedlinePLUS

... features on this page, please enable JavaScript. Male Breast Cancer Is Different Men's tumor types differ; survival is ... Tuesday, December 9, 2014 Related MedlinePlus Pages Male Breast Cancer Men's Health TUESDAY, Dec. 9, 2014 (HealthDay News) -- ...

125

Hormonal Contraceptive Use and Breast Cancer in Thai Women  

PubMed Central

Background Breast cancer is the most common cancer in women worldwide. We investigated the association of hormonal contraceptive use and breast cancer in Thai women. Methods A cohort study was conducted in Khon Kaen, Thailand. There were 70 cases of histologically confirmed breast cancer among 11 414 women aged 30 to 69 years who were recruited as participants in the cohort study during the period from 1990 through 2001. The study population was followed-up until December 31, 2011. To identify factors associated with incidence of breast cancer, hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using a Cox proportional hazards model. Results The 11 414 women provided a total observation time of 157 200 person-years. Breast cancer risk among women with a history of hormonal contraceptive use was 1.31 times that of women without such a history, but the difference was not statistically significant (95% CI, 0.65–2.65). No type of hormonal contraceptive was associated with a significant increase in breast cancer risk as compared with women who had never used hormonal contraceptives (oral contraception: HR = 1.35, 95% CI, 0.65–2.78; injection contraception: HR = 1.25, 95% CI, 0.56–2.80), and there was no relationship between duration of hormonal contraceptive use and breast cancer. Conclusions There was no association between hormonal contraceptive use and breast cancer; however, this finding should be viewed with caution due to the small number of cases. PMID:24614914

Poosari, Arisara; Promthet, Supannee; Kamsa-ard, Siriporn; Suwanrungruang, Krittika; Longkul, Jirapat; Wiangnon, Surapon

2014-01-01

126

Secondhand smoke exposure in early life and the risk of breast cancer among never smokers (United States)  

Microsoft Academic Search

Evidence is increasing that some early life exposures affect breast cancer risk. Exposure to secondhand smoke (SHS) during childhood may be one such exposure. As part of the WEB Study (Western New York Exposures and Breast Cancer Study), we conducted a population-based, case-control study with 1166 women aged 35 to 79 diagnosed with histologically confirmed, primary, incident breast cancer. Controls

Matthew R. Bonner; Jing Nie; Daikwon Han; John E. Vena; Peter Rogerson; Paola Muti; Maurizio Trevisan; Stephen B. Edge; Jo L. Freudenheim

2005-01-01

127

BREAST CANCER DETECTION USING GENETIC PROGRAMMING  

E-print Network

BREAST CANCER DETECTION USING GENETIC PROGRAMMING Hong Guo, Qing Zhang and Asoke K. Nandi, Feature Extraction, Classification, Breast Cancer Diagnosis. Abstract: Breast cancer diagnosis have been investigated by different machine learning methods. This paper proposes a new method for breast cancer

Fernandez, Thomas

128

BREAST CANCER GROUP WOMEN'S HEALTH INTERDISCIPLINARY  

E-print Network

BREAST CANCER GROUP May 2009 WOMEN'S HEALTH INTERDISCIPLINARY RESEARCH CENTER [WHIRC] #12;2 Table: Breast Cancer Research and Treatment 4 Basic/Translational Research Carcinogenesis and Signaling Group 5R) Signaling in Breast Cancer 6 NF-B Family of Transcription Factors in Breast Cancer 7 Transgenic Mouse

Spence, Harlan Ernest

129

Breast Cancer Steering Committee Roster  

Cancer.gov

Breast Cancer Steering Committee Roster Co-chairs Thomas Buchholz, M.D.MD Anderson Cancer CenterUniversity of TexasHouston, TX Nancy Davidson, M.D.University of Pittsburgh Cancer InstituteUniversity of Pittsburgh Cancer CentersPittsburgh, PA Members William

130

Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Metastatic Breast Cancer  

ClinicalTrials.gov

HER2-positive Breast Cancer; Recurrent Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer

2014-10-29

131

Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer  

ClinicalTrials.gov

Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer

2013-11-21

132

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer  

ClinicalTrials.gov

Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer

2014-10-06

133

RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery  

ClinicalTrials.gov

Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Recurrent Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer

2014-06-30

134

Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid  

ClinicalTrials.gov

Estrogen Receptor-positive Breast Cancer; Invasive Ductal Breast Carcinoma; Progesterone Receptor-positive Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer

2015-01-09

135

Breast Cancer Research at NASA  

NASA Technical Reports Server (NTRS)

Time-lapse exposure depicts Bioreactor rotation. NASA's Marshall Space Flight Center (MSFC) is sponsoring research with Bioreactors, rotating wall vessels designed to grow tissue samples in space, to understand how breast cancer works. This ground-based work studies the growth and assembly of human mammary epithelial cells (HMEC) from breast cancer susceptible tissue. Radiation can make the cells cancerous, thus allowing better comparisons of healthy vs. tunourous tissues.

1998-01-01

136

Pathology of hereditary breast cancer  

Microsoft Academic Search

Patients with germline mutations in BRCA1 or BRCA2 genes are predisposed to breast cancer. The BRCA1-associated breast cancers have distinct morphology, being more often medullary-like, triple negative and showing a ‘basal’ phenotype. On the other hand, BRCA2 and BRCAX cancers are a heterogeneous group without a specific phenotype. When incorporated into risk assessment models, pathology data improves prediction of carrier

Leonard Da Silva; Sunil R Lakhani

2010-01-01

137

International nursing and breast cancer.  

PubMed

Breast cancer is the most common cancer in women worldwide and its incidence is increasing in most countries. Nurses involved in breast cancer care have an impact on early detection of breast cancer, treatment, and symptom management, and they serve as advocates for women with the disease. In many countries nurses are far more numerous than physicians, and nurses are in an ideal position to influence breast cancer care. The International Society of Nurses in Cancer Care (ISNCC) is an organization representing more than 50,000 oncology nurses in 25 countries. The society provides a communication network for national and regional cancer nursing societies and communication on developments in cancer nursing to nurses working in countries where a national cancer nursing group does not exist. The society also acts as a resource for nurses in practice, education, research, and management, and it serves as a link for other international, regional, national, and local organizations in promoting collaboration to achieve ISNCC's goals. In collaboration with the Susan G. Komen Breast Cancer Foundation, the society developed a 2-day "train-the-trainer" workshop for a selected group of cancer nurses from around the world. The workshop includes didactic presentations, skills instruction, and demonstrations that cover the continuum of breast cancer care. Participants have represented the countries of Brazil, Colombia, China, Italy, Spain, Portugal, Turkey, Pakistan, Australia, Germany, South Africa, Greece, and India. They have subsequently developed educational programs for nurses and the public in their countries, started support groups, published educational materials on breast cancer, and participated in political activities. These advances indicate that despite challenges such as nursing shortages and a lack of resources, cancer nurses are making a difference internationally. PMID:12713505

Yarbro, Connie Henke

2003-01-01

138

The many faces of triple negative breast cancer.  

PubMed

Triple negative breast tumors are described by the lack of immunohistochemical expression for hormone receptors (ER and PgR) and Her2 neu. The immunophenotype is, in general,associated with young age and high biological aggressiveness,its frequency in the literature ranging from 10 to 20%. In our study we performed a retrospective classification of triple negative breast cancers in order to show the large spectrum of lesions that can embrace this very special phenotype.Clinicopathological parameters evaluated included age, tumorsize and macroscopic appearance, histological subtype and association with in situ component, the degree of tumor differentiation (nuclear pleomorphism, mitosis count, the formation of tubules), presence of lymph nodes or distant metastases. Triple negative breast cancers represent a particular subtype of tumors but their, now famous, aggressiveness applies only to some histological subtypes. It is very important to correlate the histological features and the phenotypical expression. PMID:25149609

Com?nescu, M; Potec?, A; Cocosila, C; Potec?, T

2014-01-01

139

Breast Cancer Research at NASA  

NASA Technical Reports Server (NTRS)

Human primary breast tumor cells after 56 days of culture in a NASA Bioreactor. A cross-section of a construct, grown from surgical specimens of brease cancer, stained for microscopic examination, reveals areas of tumor cells dispersed throughout the non-epithelial cell background. The arrow denotes the foci of breast cancer cells. NASA's Marshall Space Flight Center (MSFC) is sponsoring research with Bioreactors, rotating wall vessels designed to grow tissue samples in space, to understand how breast cancer works. This ground-based work studies the growth and assembly of human mammary epithelial cell (HMEC) from breast cancer susceptible tissue. Radiation can make the cells cancerous, thus allowing better comparisons of healthy vs. tunorous tissue. Credit: Dr. Jearne Becker, University of South Florida

1998-01-01

140

Breast Cancer Research at NASA  

NASA Technical Reports Server (NTRS)

High magnification of view of tumor cells aggregate on microcarrier beads, illustrting breast cells with intercellular boundaires on bead surface and aggregates of cells achieving 3-deminstional growth outward from bead after 56 days of culture in a NASA Bioreactor. NASA's Marshall Space Flight Center (MSFC) is sponsoring research with Bioreactors, rotating wall vessels designed to grow tissue samples in space, to understand how breast cancer works. This ground-based work studies the growth and assembly of human mammary epithelial cell (HMEC) from breast cancer susceptible tissue. Radiation can make the cells cancerous, thus allowing better comparisons of healthy vs. tunorous tissue. Credit: Dr. Jearne Becker, University of South Florida.

1998-01-01

141

Breast Cancer Research at NASA  

NASA Technical Reports Server (NTRS)

Human primary breast tumor cells after 49 days of growth in a NASA Bioreactor. Tumor cells aggregate on microcarrier beads (indicated by arrow). NASA's Marshall Space Flight Center (MSFC) is sponsoring research with Bioreactors, rotating wall vessels designed to grow tissue samples in space, to understand how breast cancer works. This ground-based work studies the growth and assembly of human mammary epithelial cell (HMEC) from breast cancer susceptible tissue. Radiation can make the cells cancerous, thus allowing better comparisons of healthy vs. tunorous tissue. Credit: Dr. Jearne Becker, University of South Florida

1998-01-01

142

Lifestyle Changes After Breast Cancer Treatment  

MedlinePLUS

... breast cancer stops working Lifestyle changes after breast cancer treatment You can't change the fact that you ... the long term. Some people even start during cancer treatment. Making healthier choices For many people, a diagnosis ...

143

Breast Cancer Chemotherapy and Your Heart  

MedlinePLUS

Breast Cancer Chemotherapy and Your Heart Christine Unitt , BS ; Kamaneh Montazeri , MD ; Sara Tolaney , MD ; Javid Moslehi , MD ... javid.moslehi{at}vanderbilt.edu Next Section Introduction Breast cancer is the most commonly diagnosed cancer in women. ...

144

Breast Cancer and Women with Disabilities  

MedlinePLUS

... this? Submit What's this? Submit Button CDC Features Breast Cancer and Women with Disabilities Language: English Español (Spanish) ... years old, get a mammogram every two years. Breast cancer is the most common cancer in women. And ...

145

Internet Use and Breast Cancer Survivors  

ERIC Educational Resources Information Center

A survey was administered to 400 breast cancer survivors at hospitals and support group meetings in Peninsular Malaysia to explore their level of Internet use and factors related to the Internet use by breast cancer survivors. Findings of this study indicated that about 22.5% of breast cancer survivors used Internet to get information about breast

Muhamad, Mazanah; Afshari, Mojgan; Mohamed, Nor Aini

2011-01-01

146

Antiangiogenic therapy for breast cancer  

Microsoft Academic Search

ABSTRACT: Angiogenesis is an important component of cancer growth, invasion and metastasis. Therefore, inhibition of angiogenesis is an attractive strategy for treatment of cancer. We describe existing clinical trials of antiangiogenic agents and the challenges facing the clinical development and optimal use of these agents for the treatment of breast cancer. Currently, the most promising approach has been the use

Dorte Lisbet Nielsen; Michael Andersson; Jon Lykkegaard Andersen; Claus Kamby

2010-01-01

147

Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery  

ClinicalTrials.gov

Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer

2013-05-07

148

FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer  

ClinicalTrials.gov

Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Male Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer

2014-08-04

149

Can Breast Cancer in Men Be Found Early?  

MedlinePLUS

... and symptoms of breast cancer in men Can breast cancer in men be found early? Early detection improves ... Differences affecting early detection of male and female breast cancers There are many similarities between breast cancer in ...

150

Predicting features of breast cancer with gene expression patterns  

Microsoft Academic Search

Data from gene expression arrays hold an enormous amount of biological information. We sought to determine if global gene\\u000a expression in primary breast cancers contained information about biologic, histologic, and anatomic features of the disease\\u000a in individual patients. Microarray data from the tumors of 129 patients were analyzed for the ability to predict biomarkers\\u000a [estrogen receptor (ER) and HER2], histologic

Xuesong Lu; Zhigang C. Wang; J. Dirk Iglehart; Xuegong Zhang; Andrea L. Richardson

2008-01-01

151

Significance of the tritiated thymidine labeling index in breast cancers  

Microsoft Academic Search

We carried out studiesto determine whether the Tritiated Thymidine Labeling Index (TLI) would correlate with hormone receptors\\u000a as well as with clinical and histological data. Sixty-four patients with breast cancer were the subjects studied. TLI showed\\u000a no relationship to age, menopausal status, T-factor, n-factor, stage, or histological type. However, compared to tubule formation,\\u000a nuclear pleomorphism, and mitotic activity, TLI showed

Keisuke Araki; Masaharu Kimura; Kiyoshi Sakamoto; Reiki Nishimura; Masanobu Akagi

1985-01-01

152

Consumer Health Education. Breast Cancer.  

ERIC Educational Resources Information Center

This short booklet is designed to be used by health educators when teaching women about breast cancer and its early detection and the procedure for breast self-examination. It includes the following: (1) A one-page teaching plan consisting of objectives, subject matter, methods (including titles of films and printed materials), target audience,…

Arkansas Univ., Fayetteville, Cooperative Extension Service.

153

Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer  

ClinicalTrials.gov

BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Ductal Breast Carcinoma in Situ; Lobular Breast Carcinoma in Situ; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer

2015-01-08

154

Gene expression profiling predicts clinical outcome of breast cancer  

Microsoft Academic Search

Breast cancer patients with the same stage of disease can have\\u000amarkedly different treatment responses and overall outcome. The\\u000astrongest predictors for metastases (for example, lymph node\\u000astatus and histological grade) fail to classify accurately breast\\u000atumours according to their clinical behaviour. Chemotherapy\\u000aor hormonal therapy reduces the risk of distant metastases by\\u000aapproximately one-third; however, 70 — 80% of

Laura J. van't Veer; Hongyue Dai; Marc J. van de Vijver; Yudong D. He; Augustinus A. M. Hart; Mao Mao; Hans L. Peterse; Karin van der Kooy; Matthew J. Marton; Anke T. Witteveen; George J. Schreiber; Ron M. Kerkhoven; Chris Roberts; Peter S. Linsley; René Bernards; Stephen H. Friend

2002-01-01

155

Life After Breast Cancer Treatment  

MedlinePLUS

... Support You Need • Hormone Therapy for Breast Cancer • Lymphedema • Radiation Therapy and Side Effects Physical effects of ... your arm you may be at risk of lymphedema [lim-fa-DEE-ma]. With lymphedema, lymphatic fluid ...

156

Non-Cancerous Breast Conditions  

MedlinePLUS

... Push escape to close share window. Print Share Save Saved this Article Close Push escape to close ... Intraductal papillomas Granular cell tumors Fat necrosis and oil cysts Mastitis Duct ectasia Other non-cancerous breast ...

157

Hormone Therapy for Breast Cancer  

Cancer.gov

A fact sheet that describes hormone therapy (including antiestrogens, LH-RH agonists, aromatase inhibitors, and SERMs) and its role in preventing and treating breast cancer. Includes information about possible side effects.

158

Hormones, Women and Breast Cancer  

MedlinePLUS

... used therapy is a female hormone blocker called tamoxifen. A newer therapy uses a pill (anastrozole, letrozole, ... are at high risk for developing breast cancer, tamoxifen or raloxifene can also be taken to prevent ...

159

Surgery for Breast Cancer  

MedlinePLUS

... side effects of breast surgery Aside from pain after the surgery and the change in the shape of the breast(s), the possible side effects of mastectomy and breast-conserving surgery include wound infection, build-up of blood in the wound, and ...

160

Fusion genes in breast cancer  

E-print Network

Fusion genes in breast cancer Elizabeth M. Batty Clare College, University of Cambridge A dissertation submitted to the University of Cambridge in candidature for the degree of Doctor of Philosophy November 2010 ii... is the outcome of work done in collaboration except where specifically indicated in the text. It has not been submitted whole or in part for any other qualification at any other University. iii Summary Fusion genes in breast cancer Elizabeth Batty...

Batty, Elizabeth

2012-02-07

161

NUCKS overexpression in breast cancer  

Microsoft Academic Search

BACKGROUND: NUCKS (Nuclear, Casein Kinase and Cyclin-dependent Kinase Substrate) is a nuclear, DNA-binding and highly phosphorylated protein. A number of reports show that NUCKS is highly expressed on the level of mRNA in several human cancers, including breast cancer. In this work, NUCKS expression on both RNA and protein levels was studied in breast tissue biopsies consisted of invasive carcinomas,

Yiannis Drosos; Mirsini Kouloukoussa; Anne Carine Østvold; Kirsten Grundt; Nikos Goutas; Dimitrios Vlachodimitropoulos; Sophia Havaki; Panagoula Kollia; Christos Kittas; Evangelos Marinos; Vassiliki Aleporou-Marinou

2009-01-01

162

Brain Metastases in Breast Cancer.  

PubMed

Brain metastases are less common than bone or visceral metastases in patients with breast cancer. The overall prognosis of breast cancer patients with brain metastases remains poor, and these metastases are less responsive to systemic therapies. Brain metastasis is associated with a reduced quality of life due to progressive neurologic impairments. Recently, a trend of increased incidence of brain metastases in breast cancer has been noted. Reasons for this increased incidence include the more frequent use of sensitive detection methods such as contrast-enhanced magnetic resonance imaging and increased awareness of brain metastasis among patients and clinicians. Adjuvant and systemic therapy with drugs that have a low blood-brain barrier penetrance can lead to an increased risk of brain metastases in breast cancer patients. Molecular subtype is a predictive factor for overall survival after developing brain metastases. Patients who do not have a poor prognosis based on previously identified prognostic factors should be treated with radiation therapy to control symptoms. Whole-brain radiation therapy, stereotactic irradiation and surgery are tools for the local treatment of brain metastases. Novel molecular target therapy, including HER2-targeted therapy, has demonstrated an antitumor effect on brain metastases. In this review, we provide a practical algorithm for the treatment of breast cancer brain metastases. This review provides an overview of the incidence, risk factors, diagnosis, prognostic factors and current and potential future management strategies of breast cancer brain metastases. PMID:25320339

Niikura, Naoki; Saji, Shigehira; Tokuda, Yutaka; Iwata, Hiroji

2014-12-01

163

Personalized therapy for breast cancer.  

PubMed

Breast cancer is a complex disease characterized by many morphological, clinical and molecular features. For many years, this disease has been classified according to histopathologic criteria, known as the tumor, node and metastasis (TNM) staging system. Clinical criteria that include immunohistochemical markers, such as the estrogen receptor (ER), the progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2), provide a classification of breast cancer and dictates the optimal therapeutic approach for treatment. With genomic techniques, such as real-time reverse transcriptase PCR (RT-PCR), microarrays, next-generation sequencing, and whole-exome sequencing, breast cancer diagnostics is going through a significant evolution. Genomic and transcriptomic technologies make the analysis of gene expression signatures and mutation status possible so that tumors may now be classified more accurately with respect to diagnosis and prognosis. The -omic era has also made the possible identification of new biomarkers involved in breast cancer development, survival and invasion that can be gradually incorporated either into clinical testing or clinical trials. Together, clinical and molecular criteria can contribute to a more personalized management of the breast cancer patient. This article will present the progress made in the diagnosis and management of breast cancer using molecular information provided by genomic and transcriptomic technologies. PMID:24635704

De Abreu, F B; Schwartz, G N; Wells, W A; Tsongalis, G J

2014-07-01

164

Breast and Colon Cancer Family Registries  

Cancer.gov

The Breast Cancer Family Registry (Breast CFR) and the Colon Cancer Family Registry (Colon CFR) were established by the National Cancer Institute (NCI) as a unique resource for investigators to use in conducting studies on the genetics and molecular epidemiology of breast and colon cancer.

165

Microarray Profiling in Breast Cancer Patients  

Microsoft Academic Search

\\u000a Breast cancer is the most common cancer among women. It arises from a variety of genetic, epigenetic, and chromosomal alterations.\\u000a The traditional prognostic and predictive factors in breast cancer mainly focus on the clinical–pathological parameters, which\\u000a are unable to reveal the diverse molecular alterations of breast cancer and are imprecise in predicting breast cancer progression\\u000a and clinical outcomes. In recent

Yong Qian; Xianglin Shi; Vincent Castranova; Nancy L. Guo

166

Environmental pollutants and breast cancer.  

PubMed Central

Breast cancer is the most common cancer in women and the leading cause of cancer death among women 35-54 years of age. Rising incidence, increased risk among migrants to higher risk regions, and poor prediction of individual risk have prompted a search for additional modifiable factors. Risk factors for breast cancer include reproductive characteristics associated with estrogen and other hormones, pharmaceutical hormones, and activities such as alcohol use and lack of exercise that affect hormone levels. As a result, investigation of hormonally active compounds in commercial products and pollution is a priority. Compounds that cause mammary tumors in animals are additional priorities. Animal models provide insight into possible mechanisms for effects of environmental pollutants on breast cancer and identify chemical exposures to target in epidemiologic studies. Although few epidemiologic studies have been conducted for chemical exposures, occupational studies show associations between breast cancer and exposure to certain organic solvents and polycyclic aromatic hydrocarbons (PAHs). Population-based studies have been limited to a few organochlorine compounds and PAHs and have been mostly negative. A variety of challenges in studies of breast cancer and the environment may have contributed to negative findings. Lack of exposure assessment tools and few hypothesis-generating toxicologic studies limit the scope of epidemiologic studies. Issues of timing with respect to latency and periods of breast vulnerability, and individual differences in susceptibility pose other challenges. Substantial work is needed in exposure assessment, toxicology, and susceptibility before we can expect a pay-off from large epidemiologic studies of breast cancer and environment. PMID:12826474

Brody, Julia Green; Rudel, Ruthann A

2003-01-01

167

What Breast Cancer Survivors Need to Know about Osteoporosis  

MedlinePLUS

... browser. Home Osteoporosis Osteoporosis and Other Conditions What Breast Cancer Survivors Need to Know About Osteoporosis Publication available ... Imperfecta Prostate Cancer Rheumatoid Arthritis Smoking Partner Resources Breast Cancer (NIH Senior Health) Breast Cancer FAQs (OWH) Cancer ...

168

Organochlorine Compounds and Risk of Breast Cancer  

Cancer.gov

Dr. Tongzhang Zheng, of Yale University, New Haven, CT, and colleagues conducted a hospital-based case-control study in Connecticut to investigate risk for breast cancer associated with exposure to organochlorine compounds. Levels of organochlorine compounds are being measured in breast adipose (fatty) tissue and blood serum obtained from women who had surgery or biopsies for breast cancer or benign breast disease.

169

Photodynamic therapy of breast cancer with photosense  

NASA Astrophysics Data System (ADS)

Photodynamic Therapy (PDT) using photosensitizer Photosense (PS) in dose 0.5 mg per kg of body weight have been provided in 24 patients with breast cancer. In 22 patients with T1-T2N0M0 primary tumor was treated as the preoperative treatment, radical mastectomy has been fulfilled 7-10 days after PDT with subsequent histological examination. 2 patients had recurrencies of breast cancer with lymph node metastases after radiotherapy. Fluorescent diagnostics of tumor, accumulation of PS in tumor, adjacent tissue, skin before and during PDT was fulfilled with spectranalyzer LESA-01. We used semiconductive laser for PDT - ? = 672+2nm, P=1,5 W, interstitial irradiation 2-24 hours after PS injection has been done in light dose 150-200 J/cm3, 1-3 irradiations with interval 24-48 hours and total light dose 400-600 J/cm3 depending mostly of size and fluorescent data. Partial regression of tumor with pathomorphosis of 2-4 degrees has been found in 19 cases. Our experience shows pronounced efficacy of PDT for treating breast cancer as preoperative modality and as palliation in cases of recurrencies.

Vakoulovskaya, Elena G.; Shental, Victor V.; Oumnova, Loubov V.; Vorozhcsov, Georgiu N.

2003-06-01

170

Screening for “early” breast cancer  

Microsoft Academic Search

The only means available today to reduce the mortality from breast cancer is by detection of localized disease. So doing involves mass screening of apparently well women. For best results, both the clinician and the radiologist must be involved and develop expertise because early cancers are often detectable on palpation alone or on mammography alone. Cooperation of the clinician and

Philip Strax

1977-01-01

171

Endothelin-1 Enriched Tumor Phenotype Predicts Breast Cancer Recurrence  

PubMed Central

Introduction. Breast cancer recurrence can develop years after primary treatment. Crosstalk between breast cancer cells and their stromal microenvironment may influence tumor progression. Our primary study aim was to determine whether endothelin-1 (ET-1) expression in tumor and stroma predicts breast cancer relapse. The secondary aim was to determine ET-1/endothelin receptor A (ETAR) role on signaling pathways and apoptosis in breast cancer. Experimental Design. Patients with histologically documented stages I–III invasive breast cancer were included in the study. ET-1 expression by immunohistochemistry (IHC) in tumor cells and stroma was analyzed. Association between ET-1 expression and clinical outcome was assessed using multivariate Cox proportional hazard model. Kaplan-Meier curves were used to estimate disease-free survival (DFS). In addition, the effect of ET-1/ETAR on signaling pathways and apoptosis was evaluated in MCF-7 and MDA-MB-231 breast cancer cells. Results. With a median followup of 7 years, ET-1 non-enriched tumor phenotype had a significant association with favorable disease-free survival (HR = 0.16; 95% CI 0.03–0.77; P value <0.02). ER negativity, advanced stage of disease and ET-1-enriched tumor phenotype were all associated with a higher risk for recurrence. Experimental study demonstrated that ET-1 stimulation promoted Akt activation in MCF-7 and MDA-MB-231 cells. Furthermore, silencing of ETAR induced apoptosis in both hormone receptor negative and hormone receptor positive breast cancer cells. Conclusions. We found ET-1 expression in tumor and stroma to be an independent prognostic marker for breast cancer recurrence. Prospective studies are warranted to examine whether ET-1 expression in tumor/stroma could assist in stratifying patients with hormone receptor positive breast cancer for adjuvant therapy. PMID:23844294

Sikorskii, Alla; Gallo, Kathleen A.; Wiese, David A.; Madhukar, Burra V.; Chivu, Simona C.; Chitneni, Shalini; Dimitrov, Nikolay V.

2013-01-01

172

ENVIRONMENTAL FACTORS AFFECTING BREAST CANCER SUSCEPTIBILITY  

EPA Science Inventory

Environmental Factors Affecting Breast Cancer Susceptibility Suzanne. E. Fenton US EPA, ORD, MD-67 NHEERL, Reproductive Toxicology Division, Research Triangle Park, NC 27711. Breast cancer is still the most common malignancy afflicting women in the Western world. Alt...

173

Abortion, Miscarriage, and Breast Cancer Risk  

MedlinePLUS

... NCI Publications Español RSS Feed Abortion, Miscarriage, and Breast Cancer Risk Reviewed: January 12, 2010 Introduction A woman’s ... that may influence a woman’s chances of developing breast cancer later in life. As a result, over several ...

174

Tamoxifen lowers breast cancer risk long term.  

PubMed

Investigators for the International Breast Cancer Intervention Study-I reported that tamoxifen reduced the incidence of breast cancer by 29% in women at high risk of the disease after a median follow-up of 16 years. PMID:25656902

2015-02-01

175

Breast Cancer and Estrogen-Alone Update  

MedlinePLUS

... Current Issue Past Issues Research News From NIH Breast Cancer and Estrogen-Alone Update Past Issues / Summer 2006 ... hormone therapy does not increase the risk of breast cancer in postmenopausal women, according to an updated analysis ...

176

Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer  

PubMed Central

Our understanding of breast cancer heterogeneity at the protein level is limited despite proteins being the ultimate effectors of cellular functions. We investigated the heterogeneity of breast cancer (41 primary tumors and 15 breast cancer cell lines) at the protein and phosphoprotein levels to identify activated oncogenic pathways and developing targeted therapeutic strategies. Heterogeneity was observed not only across histological subtypes, but also within subtypes. Tumors of the Triple negative breast cancer (TNBC) subtype distributed across four different clusters where one cluster (cluster ii) showed high deregulation of many proteins and phosphoproteins. The majority of TNBC cell lines, particularly mesenchymal lines, resembled the cluster ii TNBC tumors. Indeed, TNBC cell lines were more sensitive than non-TNBC cell lines when treated with targeted inhibitors selected based on upregulated pathways in cluster ii. In line with the enrichment of the upregulated pathways with onco-clients of Hsp90, we found synergy in combining Hsp90 inhibitors with several kinase inhibitors, particularly Erk5 inhibitors. The combination of Erk5 and Hsp90 inhibitors was effective in vitro and in vivo against TNBC leading to upregulation of pro-apoptotic effectors. Our studies contribute to proteomic profiling and improve our understanding of TNBC heterogeneity to provide therapeutic opportunities for this disease. PMID:24762669

Miranda, Mariska; Shi, Wei; Simpson, Peter T.; Song, Sarah; Vargas, Ana Cristina; Saunus, Jodi M.; Smart, Chanel E.; Mariasegaram, Mythily; Wiegmans, Adrian P.; Chenevix-Trench, Georgia; Lakhani, Sunil R.

2014-01-01

177

Breast Cancer Research at NASA  

NASA Technical Reports Server (NTRS)

Isolation of human mammary epithelial cells (HMEC) from breast cancer susceptible tissue. Outgrowth of cells from duct element in upper right corner cultured in a standard dish; most cells spontaneously die during early cell divisions, but a few will establish long-term growth. NASA's Marshall Space Flight Center (MSFC) is sponsoring research with Bioreactors, rotating wall vessels designed to grow tissue samples in space, to understand how breast cancer works. This ground-based work studies the growth and assembly of human mammary epithelial cell (HMEC) from breast cancer susceptible tissue. Radiation can make the cells cancerous, thus allowing better comparisons of healthy vs. tunorous tissue. Credit: Dr. Robert Tichmond, NASA/Marshall Space Flight Center (MSFC).

1998-01-01

178

Breast Cancer Research at NASA  

NASA Technical Reports Server (NTRS)

Isolation of human mammary epithelial cells (HMEC) from breast cancer susceptible tissue. Isolate of long-term growth human mammary epithelial cells (HMEC) from outgrowth of duct element; cells shown soon after isolation and early in culture in a dish. NASA's Marshall Space Flight Center (MSFC) is sponsoring research with Bioreactors, rotating wall vessels designed to grow tissue samples in space, to understand how breast cancer works. This ground-based work studies the growth and assembly of human mammary epithelial cell (HMEC) from breast cancer susceptible tissue. Radiation can make the cells cancerous, thus allowing better comparisons of healthy vs. tunorous tissue. Credit: Dr. Robert Tichmond, NASA/Marshall Space Flight Center (MSFC).

1998-01-01

179

Breast Cancer Research at NASA  

NASA Technical Reports Server (NTRS)

Isolation of human mammary epithelial cells (HMEC) from breast cancer susceptible tissue. Same long-term growth human mammary epithelial cells (HMEC), but after 3 weeks in concinuous culture. Note attempts to reform duct elements, but this time in two dimensions in a dish rather that in three demensions in tissue. NASA's Marshall Space Flight Center (MSFC) is sponsoring research with Bioreactors, rotating wall vessels designed to grow tissue samples in space, to understand how breast cancer works. This ground-based work studies the growth and assembly of human mammary epithelial cell (HMEC) from breast cancer susceptible tissue. Radiation can make the cells cancerous, thus allowing better comparisons of healthy vs. tunorous tissue. Credit: Dr. Robert Tichmond, NASA/Marshall Space Flight Center (MSFC).

1998-01-01

180

Entinostat and Anastrozole in Treating Postmenopausal Women With Triple-Negative Breast Cancer That Can Be Removed by Surgery  

ClinicalTrials.gov

Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Triple-negative Breast Cancer

2013-10-07

181

Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy  

ClinicalTrials.gov

Male Breast Cancer; Neurotoxicity; Peripheral Neuropathy; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer

2014-03-17

182

Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations  

PubMed Central

Introduction Breast carcinoma is the main malignant tumor occurring in patients with Cowden disease, a cancer-prone syndrome caused by germline mutation of the tumor suppressor gene PTEN characterized by the occurrence throughout life of hyperplastic, hamartomatous and malignant growths affecting various organs. The absence of known histological features for breast cancer arising in a PTEN-mutant background prompted us to explore them for potential new markers. Methods We first performed a microarray study of three tumors from patients with Cowden disease in the context of a transcriptomic study of 74 familial breast cancers. A subsequent histological and immunohistochemical study including 12 additional cases of Cowden disease breast carcinomas was performed to confirm the microarray data. Results Unsupervised clustering of the 74 familial tumors followed the intrinsic gene classification of breast cancer except for a group of five tumors that included the three Cowden tumors. The gene expression profile of the Cowden tumors shows considerable overlap with that of a breast cancer subgroup known as molecular apocrine breast carcinoma, which is suspected to have increased androgenic signaling and shows frequent ERBB2 amplification in sporadic tumors. The histological and immunohistochemical study showed that several cases had apocrine histological features and expressed GGT1, which is a potential new marker for apocrine breast carcinoma. Conclusions These data suggest that activation of the ERBB2-PI3K-AKT pathway by loss of PTEN at early stages of tumorigenesis promotes the formation of breast tumors with apocrine features. PMID:20712882

2010-01-01

183

Prevention of ER-Negative Breast Cancer  

Microsoft Academic Search

The successful demonstration that the selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene reduce the risk\\u000a of breast cancer has stimulated great interest in using drugs to prevent breast cancer in high-risk women. In addition, recent\\u000a results from breast cancer treatment trials suggest that aromatase inhibitors may be even more effective at preventing breast\\u000a cancer than are SERMs. However, while

Yuxin Li; Powel H. Brown

184

BRCA1 and Breast Cancer  

NSDL National Science Digital Library

This two-part animation explains the role of the BRCA1 protein in DNA repair and the development of breast cancer. BRCA1 is a tumor suppressor, and mutations in the BRCA1 gene can lead to breast cancer and other forms of cancer. Part 1 of the animation, ÃÂThe function of BRCA1,ÃÂ provides an overview of how the BRCA1 protein functions in healthy cells to detect and repair DNA damage. Part 2, ÃÂMutations in BRCA1 Can Cause Cancer,ÃÂ explains how individuals who inherit a single mutated copy of BRCA1 are at an increased risk of cancer, and how cancer develops when the second copy of BRCA1 becomes mutated. Animation is closed captioned. Run times of each animation part: approximately 1 minute 15 seconds.

2010-11-18

185

Oestrogen exposure and breast cancer risk  

Microsoft Academic Search

Epidemiological and experimental evidence implicates oestrogens in the aetiology of breast cancer. Most established risk factors for breast cancer in humans probably act through hormone-related pathways, and increased concentrations of circulating oestrogens have been found to be strongly associated with increased risk for breast cancer in postmenopausal women. This article explores the evidence for the hypothesis that oestrogen exposure is

Ruth C Travis; Timothy J Key

2003-01-01

186

Bay Area Breast Cancer SPORE Newsletter  

E-print Network

Bay Area Breast Cancer SPORE Newsletter Special Interest Articles: ·Hormone receptor negative breast cancer: Improving the effectiveness of chemotherapy by targeting immune cells Page 1, cont. Page 6 (article from Breast Cancer Connections) Page 8 Editor: Karla Kerlikowske, MD Professor of Medicine

Walter, Peter

187

Breast Cancer Awareness Day October 7, 2009  

E-print Network

Breast Cancer Awareness Day October 7, 2009 All are welcome to the different events organized by the Purdue Breast Cancer Discovery Group. Sigma Xi Distinguished Lecture "Genes and the microenvironment: the two faces of breast cancer" Deans Auditorium (PFEN241) Pfendler Hall ­ Purdue University 12

Ginzel, Matthew

188

Breast Cancer Research Finding Answers. Finding Cures.  

E-print Network

Breast Cancer Research Finding Answers. Finding Cures. Thanks to improvements in treatment and early detection, more and more women are surviving breast cancer. In fact, the five-year survival rate for women with breast cancer today is 90%, up from only 63% in the 1960s. While progress has clearly been

Kowalczykowski, Stephen C.

189

Does diet affect breast cancer risk?  

Microsoft Academic Search

The role of specific dietary factors in breast cancer causation is not completely resolved. Results from prospective studies do not support the concept that fat intake in middle life has a major relation to breast cancer risk. However, weight gain in middle life contributes substantially to breast cancer risk. Alcohol is the best established dietary risk factor, probably by increasing

Michelle D Holmes; Walter C Willett

2004-01-01

190

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)  

ClinicalTrials.gov

Breast Tumor; Breast Cancer; Cancer of the Breast; Estrogen Receptor- Negative Breast Cancer; HER2- Negative Breast Cancer; Progesterone Receptor- Negative Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer; Triple-negative Metastatic Breast Cancer; Metastatic Breast Cancer

2014-06-16

191

Loss of primary cilia occurs early in breast cancer development  

PubMed Central

Background Primary cilia are microtubule-based organelles that protrude from the cell surface. Primary cilia play a critical role in development and disease through regulation of signaling pathways including the Hedgehog pathway. Recent mouse models have also linked ciliary dysfunction to cancer. However, little is known about the role of primary cilia in breast cancer development. Primary cilia expression was characterized in cancer cells as well as their surrounding stromal cells from 86 breast cancer patients by counting cilia and measuring cilia length. In addition, we examined cilia expression in normal epithelial and stromal cells from reduction mammoplasties as well as histologically normal adjacent tissue for comparison. Results We observed a statistically significant decrease in the percentage of ciliated cells on both premalignant lesions as well as in invasive cancers. This loss of cilia does not correlate with increased proliferative index (Ki67-positive cells). However, we did detect rare ciliated cancer cells present in patients with invasive breast cancer and found that these express a marker of basaloid cancers that is associated with poor prognosis (Cytokeratin 5). Interestingly, the percentage of ciliated stromal cells associated with both premalignant and invasive cancers decreased when compared to stromal cells associated with normal tissue. To understand how cilia may be lost during cancer development we analyzed the expression of genes required for ciliogenesis and/or ciliary function and compared their expression in normal versus breast cancer samples. We found that expression of ciliary genes were frequently downregulated in human breast cancers. Conclusions These data suggest that primary cilia are lost early in breast cancer development on both the cancer cells and their surrounding stromal cells. PMID:24987519

2014-01-01

192

Understanding Lymphedema (For Cancers Other Than Breast Cancer)  

MedlinePLUS

... My Saved Articles » My ACS » Understanding Lymphedema -- For Cancers Other Than Breast Cancer Download Printable Version [PDF] » Lymphedema can be caused ... Find Support Programs and Services in Your Area Cancer Information Cancer Basics Cancer Prevention & Detection Signs & Symptoms ...

193

Breast Cancer Organization of Screening Programs  

Cancer.gov

Skip to Main Content Search International Cancer Screening Network Sponsored by the National Cancer Institute Home | About ICSN | Collaborative Projects | Meetings | Cancer Sites | Publications | Contact Us Breast Cancer: Mortality Rates | Screening

194

Breast Cancer Research at NASA  

NASA Technical Reports Server (NTRS)

NASA's Marshall Space Flight Center (MSFC) is sponsoring research with Bioreactors, rotating wall vessels designed to grow tissue samples in space, to understand how breast cancer works. This ground-based work studies the growth and assembly of human mammary epithelial cells (HMEC) from breast cancer susceptible tissue. Radiation can make the cells cancerous, thus allowing better comparisons of healthy vs. tunourous tissues. Here, two High-Aspect Ratio Vessels turn at about 12 rmp to keep breast tissue constructs suspended inside the culture media. Syringes allow scientists to pull for analysis during growth sequences. The tube in the center is a water bubbler that dehumidifies the air to prevent evaporation of the media and thus the appearance of destructive bubbles in the bioreactor.

1998-01-01

195

Mammographic density, MRI background parenchymal enhancement and breast cancer risk  

PubMed Central

Mammographic density (MD), representing connective and epithelial tissue (fibroglandular tissue, FGT) is a major risk factor for breast cancer. In an analysis of an autopsy series (Bartow SA, Pathak DR, Mettler FA. Radiographic microcalcification and parenchymal patterns as indicators of histologic “high-risk” benign breast disease. Cancer 1990; 66: 1721–1725, Bartow SA, Pathak DR, Mettler FA et al. Breast mammographic pattern: a concatenation of confounding and breast cancer risk factors. Am J Epidemiol 1995; 142: 813–819), MD was found to be strongly correlated with the collagen and epithelial content of the breast (Li T, Sun L, Miller N et al. The association of measured breast tissue characteristics with MD and other risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 343–349), and another report showed that breast epithelium was highly concentrated in the areas of collagen concentration (Hawes D, Downey S, Pearce CL et al. Dense breast stromal tissue shows greatly increased concentration of breast epithelium but no increase in its proliferative activity. Breast Cancer Res 2006; 8: R24). Collagen comprises the overwhelming majority of the FGT, occupying an area on the slides obtained from the autopsy series some 15 times the area of glandular tissue. The relationship of MD with breast cancer risk appears likely to be due to a major extent to increasing epithelial cell numbers with increasing MD. FGT is also seen in breast magnetic resonance imaging (breast MRI) and, as expected, it has been shown that this measure of FGT (MRI-FGT) is highly correlated with MD. A contrast-enhanced breast MRI shows that normal FGT ‘enhances’ (background parenchymal enhancement, BPE) after contrast agent is administered(Morris EA. Diagnostic breast MR imaging: current status and future directions. Radiol Clin North Am 2007; 45: 863–880, vii., Kuhl C. The current status of breast MR imaging. Part I. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice. Radiology 2007; 244: 356–378), and a recent study suggests that BPE is also a major breast cancer risk factor, possibly as important as, and independent of MD (King V, Brooks JD, Bernstein JL et al. BPE at breast MR imaging and breast cancer risk. Radiology 2011; 260: 50–60). BPE is much more sensitive to the effects of menopause and tamoxifen than is FGT (King V, Gu Y, Kaplan JB et al. Impact of menopausal status on BPE and fibroglandular tissue on breast MRI. Eur Radiol 2012; 22: 2641–2647, King V, Kaplan J, Pike MC et al. Impact of tamoxifen on amount of fibroglandular tissue, BPE, and cysts on breast MRI. Breast J 2012; 18: 527–534). Changes in MD and BPE may be most useful in predicting response to chemopreventive agents aimed at blocking breast cell proliferation. More study of the biological basis of the effects of MD and BPE is needed if we are to fully exploit these factors in developing chemopreventive approaches to breast cancer. PMID:24131968

Pike, M. C.; Pearce, C. L.

2013-01-01

196

Mammographic density, MRI background parenchymal enhancement and breast cancer risk.  

PubMed

Mammographic density (MD), representing connective and epithelial tissue (fibroglandular tissue, FGT) is a major risk factor for breast cancer. In an analysis of an autopsy series (Bartow SA, Pathak DR, Mettler FA. Radiographic microcalcification and parenchymal patterns as indicators of histologic "high-risk" benign breast disease. Cancer 1990; 66: 1721-1725, Bartow SA, Pathak DR, Mettler FA et al. Breast mammographic pattern: a concatenation of confounding and breast cancer risk factors. Am J Epidemiol 1995; 142: 813-819), MD was found to be strongly correlated with the collagen and epithelial content of the breast (Li T, Sun L, Miller N et al. The association of measured breast tissue characteristics with MD and other risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 343-349), and another report showed that breast epithelium was highly concentrated in the areas of collagen concentration (Hawes D, Downey S, Pearce CL et al. Dense breast stromal tissue shows greatly increased concentration of breast epithelium but no increase in its proliferative activity. Breast Cancer Res 2006; 8: R24). Collagen comprises the overwhelming majority of the FGT, occupying an area on the slides obtained from the autopsy series some 15 times the area of glandular tissue. The relationship of MD with breast cancer risk appears likely to be due to a major extent to increasing epithelial cell numbers with increasing MD. FGT is also seen in breast magnetic resonance imaging (breast MRI) and, as expected, it has been shown that this measure of FGT (MRI-FGT) is highly correlated with MD. A contrast-enhanced breast MRI shows that normal FGT 'enhances' (background parenchymal enhancement, BPE) after contrast agent is administered(Morris EA. Diagnostic breast MR imaging: current status and future directions. Radiol Clin North Am 2007; 45: 863-880, vii., Kuhl C. The current status of breast MR imaging. Part I. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice. Radiology 2007; 244: 356-378), and a recent study suggests that BPE is also a major breast cancer risk factor, possibly as important as, and independent of MD (King V, Brooks JD, Bernstein JL et al. BPE at breast MR imaging and breast cancer risk. Radiology 2011; 260: 50-60). BPE is much more sensitive to the effects of menopause and tamoxifen than is FGT (King V, Gu Y, Kaplan JB et al. Impact of menopausal status on BPE and fibroglandular tissue on breast MRI. Eur Radiol 2012; 22: 2641-2647, King V, Kaplan J, Pike MC et al. Impact of tamoxifen on amount of fibroglandular tissue, BPE, and cysts on breast MRI. Breast J 2012; 18: 527-534). Changes in MD and BPE may be most useful in predicting response to chemopreventive agents aimed at blocking breast cell proliferation. More study of the biological basis of the effects of MD and BPE is needed if we are to fully exploit these factors in developing chemopreventive approaches to breast cancer. PMID:24131968

Pike, M C; Pearce, C L

2013-11-01

197

[Reliability of extemporaneous histological sentinel lymph node examination during breast surgery for neoplasia].  

PubMed

Lymphatic mapping and sentinel lymph node (SLN) biopsy for breast cancer is rapidly becoming the standard of care. This is mainly due to the accuracy of the procedure, with a significant decrease in morbidity compared with the standard level III node dissection. We present our experience with SLN biopsy and a small series in which we performed an immediate histologic evaluation of the SLN: in case of positive SLN, a complete lymph node dissection was carried out in the same operative time, thus reducing the need of a second operation. In our experience, we had a 100% accordance between immediate and definitive results: we had neither false positive, which could lead to overtreat the patients with an unnecessary lymph node dissection, nor false negative. PMID:12903593

Tinti, A; Lucertini, M; Costantini, P G; Coschiera, P; Spinelli; Stafoggia, P

2003-01-01

198

Tamoxifen Therapy for Breast Cancer and Endometrial Cancer Risk  

Microsoft Academic Search

Background: Tamoxifen is effective in treating breast cancer, reduces breast cancer incidence among high-risk women, and is associated with increased endometrial cancer risk. This study was designed to examine the possible modifying effects of endometrial cancer risk factors on the tamoxifen- endometrial cancer association. Methods: We conducted a case-control study of endometrial cancer (324 case patients and 671 individually matched

Leslie Bernstein; Dennis Deapen; James R. Cerhan; Stephen M. Schwartz; Jonathan Liff; Jeffrey A. Perlman; Leslie Ford

1999-01-01

199

Immunohistochemical reactions of primary neuroendocrine breast cancer.  

PubMed

We performed immunohistochemical analysis of neuroendocrine breast cancer. The significance of this approach to differential diagnosis of this cancer form by detection of specific markers is demonstrated. The incidence of diagnosis of neuroendocrine breast cancer has increased 8-fold over 5 years. Neuroendocrine breast cancer is responsible for 3.4% of all breast cancer cases. The disease is significantly more incident in patients over 60. Neuroendocrine breast cancer is characterized by high expression of neuron-specific enolase (100%) and chromagranin A (57%). The data indicate that irrespective of the location, macroscopic picture, and immunohistochemical profile of cytokeratins and steroid hormones, breast cancer is characterized by clear-cut expression of neuroendocrine markers in different combinations. Immunohistochemical detection of these markers makes it possible to detect the hormone-secreting elements and evaluate their role in the tumor pool, which is essential for the differential diagnosis of neuroendocrine breast cancer, including studies of puncture biopsy specimens. PMID:25567197

Kirillina, M P; Loskutova, K S; Innokent'eva, A S; Lushnikova, E L; Nepomnyashchikh, L M

2015-01-01

200

Far Beyond the Usual Biomarkers in Breast Cancer: A Review  

PubMed Central

Research investigating biomarkers for early detection, prognosis and the prediction of treatment responses in breast cancer is rapidly expanding. However, no validated biomarker currently exists for use in routine clinical practice, and breast cancer detection and management remains dependent on invasive procedures. Histological examination remains the standard for diagnosis, whereas immunohistochemical and genetic tests are utilized for treatment decisions and prognosis determinations. Therefore, we conducted a comprehensive review of literature published in PubMed on breast cancer biomarkers between 2009 and 2013. The keywords that were used together were breast cancer, biomarkers, diagnosis, prognosis and drug response. The cited references of the manuscripts included in this review were also screened. We have comprehensively summarized the performance of several biomarkers for diagnosis, prognosis and predicted drug responses of breast cancer. Finally, we have identified 15 biomarkers that have demonstrated promise in initial studies and several miRNAs. At this point, such biomarkers must be rigorously validated in the clinical setting to be translated into clinically useful tests for the diagnosis, prognosis and prediction of drug responses of breast cancer. PMID:25057307

dos Anjos Pultz, Brunna; da Luz, Felipe Andrés Cordero; de Faria, Paulo Rogério; Oliveira, Ana Paula Lima; de Araújo, Rogério Agenor; Silva, Marcelo José Barbosa

2014-01-01

201

Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer  

ClinicalTrials.gov

Ductal Breast Carcinoma in Situ; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Ductal Breast Carcinoma With Predominant Intraductal Component; Lobular Breast Carcinoma in Situ; Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate; Mucinous Ductal Breast Carcinoma; Papillary Ductal Breast Carcinoma; Progesterone Receptor-positive Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Tubular Ductal Breast Carcinoma

2014-07-07

202

Paclitaxel (Taxol) in breast cancer.  

PubMed

Paclitaxel (Taxol) is a diterpine plant compound that was isolated initially from the bark of the western yew tree, Taxus brevifolia, but can now be produced by semisynthesis from a renewable source. Paclitaxel is the first new agent in the past decade to have confirmed single agent activity in breast cancer in excess of 50%. A 28% response rate has been reported in doxorubicin-refractory patients. Ongoing studies include attempts to combine paclitaxel with other drugs used for breast cancer treatment and with radiation. PMID:7908664

Arbuck, S G; Dorr, A; Friedman, M A

1994-02-01

203

Estrogen metabolism and breast cancer.  

PubMed

There is currently accumulating evidence that endogenous estrogens play a critical role in the development of breast cancer. Estrogens and their metabolites have been studied in both pre- and postmenopausal women with more consistent results shown in the latter population, in part because of large hormonal variations during the menstrual cycle and far fewer studies having been performed in premenopausal women. In this review we describe in detail estrogen metabolism and associated genetic variations, and provide a critical review of the current literature regarding the role of estrogens and their metabolites in breast cancer risk. PMID:24784887

Samavat, Hamed; Kurzer, Mindy S

2015-01-28

204

Hormonal prevention of breast cancer.  

PubMed

Breast cancer prevention can be provided by using SERMs or aromatase inhibitors depending on the ovarian status, with a global risk reduction of 50 to 60%. Prophylactic annexectomy offered to reduce ovarian risk in BRCA mutation carriers also lowers breast cancer risk by 50%. Main side effects include deep vein thrombosis for SERMs, hot flushes and joint pain (although less frequently than initially suspected) with aromatase inhibitors. Other strategies based on progesterone, insulin or prolactin signaling modulation may be offered in the future. Criteria for candidate selection remain to be established. PMID:24997772

Thomin, Anne; Friszer, Stéphanie; Fajac, Anne; Daraï, Émile; Chabbert-Buffet, Nathalie

2014-07-01

205

Study Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer (GeparSepto)  

ClinicalTrials.gov

Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer

2014-02-10

206

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer  

ClinicalTrials.gov

Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Inflammatory Breast Cancer; Male Breast Cancer; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Stage IIIB Breast Cancer; Stage IV Breast Cancer

2011-07-08

207

Everolimus and Hormone Therapy in Treating Patients With Advanced Hormone Receptor Positive Breast Cancer That Has Progressed or Recurred on Everolimus and Exemestane Therapy  

ClinicalTrials.gov

Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer

2014-12-02

208

Breast Cancer Death Rates Down 34% Since 1990  

MedlinePLUS

... News » Filed under: Breast Cancer Report: Breast Cancer Death Rates Down 34% Since 1990 Article date: October ... report from the American Cancer Society finds that death rates from breast cancer in the United States ...

209

Mass screening for breast cancer with sonomammography: a prospective study.  

PubMed

A prospective study was performed to assess the reliability of sonographic mammography in mass screening for breast lesions and diagnosis of small, presumably early, breast cancers. 1350 women underwent a sonomammographic examination of the breasts. Sonomammographic images were described in terms of their elementary constituents. Final diagnosis was obtained through cytological, and, when indicated, histological analysis. This ultimately led to the diagnosis of 13 breast cancers. Statistical analysis of the elementary sonomammographic image data using a logistic regression found two criteria to be highly associated with cancer. These were: (1) jagged aspect of the margins extending to the anterior or posterior walls; (2) major axis of the lesion not parallel to the skin surface. When combined, these two criteria have a 100% sensitivity and 99.6% specificity. The conclusions of the present study were validated for the screening of young women and may be applied to the screening of small lesions. However, these conclusions should be restricted to tumors 5 mm or more in diameter and of the common histological type, i.e. the infiltrating ductal carcinomas. Within these limitations, sonographic mammography can be considered a reliable technique for mass screening for breast cancer. PMID:3208967

Rotten, D; Levaillant, J M; Le Floch, J P; Constancis, E; André, J M

1988-07-01

210

19p13.1 is a triple negative-specific breast cancer susceptibility locus  

PubMed Central

The 19p13.1 breast cancer susceptibility locus is a modifier of breast cancer risk in BRCA1 mutation carriers and is also associated with risk of ovarian cancer. Here we investigated 19p13.1 variation and risk of breast cancer subtypes, defined by estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) status, using 48,869 breast cancer cases and 49,787 controls from the Breast Cancer Association Consortium (BCAC). Variants from 19p13.1 were not associated with breast cancer overall or with ER-positive breast cancer but were significantly associated with ER-negative breast cancer risk [rs8170 Odds Ratio (OR)=1.10, 95% Confidence Interval (CI) 1.05 – 1.15, p=3.49 × 10-5] and triple negative (TN) (ER, PR and HER2 negative) breast cancer [rs8170 OR=1.22, 95% CI 1.13 – 1.31, p=2.22 × 10-7]. However, rs8170 was no longer associated with ER-negative breast cancer risk when TN cases were excluded [OR=0.98, 95% CI 0.89 – 1.07, p=0.62]. In addition, a combined analysis of TN cases from BCAC and the Triple Negative Breast Cancer Consortium (TNBCC) (n=3,566) identified a genome-wide significant association between rs8170 and TN breast cancer risk [OR=1.25, 95% CI 1.18 – 1.33, p=3.31 × 10-13]. Thus, 19p13.1 is the first triple negative-specific breast cancer risk locus and the first locus specific to a histological subtype defined by ER, PR, and HER2 to be identified. These findings provide convincing evidence that genetic susceptibility to breast cancer varies by tumor subtype and that triple negative tumors and other subtypes likely arise through distinct etiologic pathways. PMID:22331459

Stevens, Kristen N.; Fredericksen, Zachary; Vachon, Celine M.; Wang, Xianshu; Margolin, Sara; Lindblom, Annika; Nevanlinna, Heli; Greco, Dario; Aittomäki, Kristiina; Blomqvist, Carl; Chang-Claude, Jenny; Vrieling, Alina; Flesch-Janys, Dieter; Sinn, Hans-Peter; Wang-Gohrke, Shan; Nickels, Stefan; Brauch, Hiltrud; Ko, Yon-Dschun; Fischer, Hans-Peter; Schmutzler, Rita K.; Meindl, Alfons; Bartram, Claus R.; Schott, Sarah; Engel, Christof; Godwin, Andrew K.; Weaver, JoEllen; Pathak, Harsh B.; Sharma, Priyanka; Brenner, Hermann; Müller, Heiko; Arndt, Volker; Stegmaier, Christa; Miron, Penelope; Yannoukakos, Drakoulis; Stavropoulou, Alexandra; Fountzilas, George; Gogas, Helen J.; Swann, Ruth; Dwek, Miriam; Perkins, Annie; Milne, Roger L.; Benítez, Javier; Zamora, M Pilar; Pérez, José Ignacio Arias; Bojesen, Stig E.; Nielsen, Sune F.; Nordestgaard, Børge G; Flyger, Henrik; Guénel, Pascal; Truong, Thérèse; Menegaux, Florence; Cordina-Duverger, Emilie; Burwinkel, Barbara; Marmé, Frederick; Schneeweiss, Andreas; Sohn, Christof; Sawyer, Elinor; Tomlinson, Ian; Kerin, Michael J.; Peto, Julian; Johnson, Nichola; Fletcher, Olivia; Silva, Isabel dos Santos; Fasching, Peter A.; Beckmann, Matthias W.; Hartmann, Arndt; Ekici, Arif B.; Lophatananon, Artitaya; Muir, Kenneth; Puttawibul, Puttisak; Wiangnon, Surapon; Schmidt, Marjanka K; Broeks, Annegien; Braaf, Linde M; Rosenberg, Efraim H; Hopper, John L.; Apicella, Carmel; Park, Daniel J.; Southey, Melissa C.; Swerdlow, Anthony J.; Ashworth, Alan; Orr, Nicholas; Schoemaker, Minouk J.; Anton-Culver, Hoda; Ziogas, Argyrios; Bernstein, Leslie; Dur, Christina Clarke; Shen, Chen-Yang; Yu, Jyh-Cherng; Hsu, Huan-Ming; Hsiung, Chia-Ni; Hamann, Ute; Dünnebier, Thomas; Rüdiger, Thomas; Ulmer, Hans Ulrich; Pharoah, Paul P.; Dunning, Alison M; Humphreys, Manjeet K.; Wang, Qin; Cox, Angela; Cross, Simon S.; Reed, Malcom W.; Hall, Per; Czene, Kamila; Ambrosone, Christine B.; Ademuyiwa, Foluso; Hwang, Helena; Eccles, Diana M.; Garcia-Closas, Montserrat; Figueroa, Jonine D.; Sherman, Mark E.; Lissowska, Jolanta; Devilee, Peter; Seynaeve, Caroline; Tollenaar, R.A.E.M.; Hooning, Maartje J.; Andrulis, Irene L.; Knight, Julia A.; Glendon, Gord; Mulligan, Anna Marie; Winqvist, Robert; Pylkäs, Katri; Jukkola-Vuorinen, Arja; Grip, Mervi; John, Esther M.; Miron, Alexander; Alnæs, Grethe Grenaker; Kristensen, Vessela; Børresen-Dale, Anne-Lise; Giles, Graham G.; Baglietto, Laura; McLean, Catriona A; Severi, Gianluca; Kosel, Matthew L.; Pankratz, V.S.; Slager, Susan; Olson, Janet E.; Radice, Paolo; Peterlongo, Paolo; Manoukian, Siranoush; Barile, Monica; Lambrechts, Diether; Hatse, Sigrid; Dieudonne, Anne-Sophie; Christiaens, Marie-Rose; Chenevix-Trench, Georgia; Beesley, Jonathan; Chen, Xiaoqing; Mannermaa, Arto; Kosma, Veli-Matti; Hartikainen, Jaana M.; Soini, Ylermi; Easton, Douglas F.; Couch, Fergus J.

2012-01-01

211

Metabolism of histamine in tissues of primary ductal breast cancer.  

PubMed

Histamine performs an important role in the pathologic and physiologic aspects of the breast gland. Among monoamines, histamine demonstrates the greatest proliferative activity in breast cancer. The aim of the study was to evaluate histamine concentration in plasma and tissues of breast cancer dependent on the activity of histamine metabolism enzymes in neoplasmatic tissues of the breast gland. Ninety-five women aged 38 to 70 years were divided into 2 groups. The control group (group I) consisted of 30 healthy women. Group II consisted of 65 women with primary ductal breast cancer. The concentration of histamine in plasma was assessed by immunoenzymatic method. The concentration of histamine in cancerous tissues of the breast and the metabolism of histamine enzymes, specially histidine decarboxylase, decarboxylase of aromatic L-amino acids, N-histamine methyltransferase, monoamine oxydase B, and diamine oxydase, were determined using isotope technique. In the course of 24 hours, excretion of N-methylimidazoleacetic acid was evaluated by the methods of chromatography. The statistical analysis was made based on Statistica Pl Ed (StatSoft, Cracow, Poland, 1998). A significant increase in the concentration of histamine in plasma (P < .01) and tissues of ductal breast cancers (P < .001), and in the activity of histidine decarboxylase (P < .01), aromatic L-amino acids (P < .05), and histamine methyltransferase (P < .05) was found. Activity of monoamine oxidase B (P < .01) and diamine oxidase (P < 0.01) and excretion of N-methylimidazoleacetic acid were significantly decreased compared with the control group (P < 0.001). The conclusions are as follows: (1) Concentration of histamine in the plasma of women is dependent on the concentration of histamine in the tissues of ductal breast cancers. (2) The significant increase of histamine in cancerous tissues of ductal breast cancer could suggest the participation of this monoamine in the development of breast cancer. (3) The increase of histamine concentrations in ductal breast cancer tissues can be connected with the disturbances of the balance between synthesis and enzymatic inactivation of this monoamine. (4) The concentration of histamine in the plasma of women with ductal breast cancers is dependent on the number of involved lymph nodes and the grade of histologic malignancy. PMID:19375125

von Mach-Szczypi?ski, Jaros?aw; Stanosz, Stanis?aw; Sieja, Krzysztof; Stanosz, Ma?gorzata

2009-06-01

212

Case Report of Pulmonary Sarcoidosis Suspected to be Pulmonary Metastasis in a Patient with Breast Cancer  

PubMed Central

Standard endocrine therapy and chemotherapy can induce long-term remission in breast cancer patients; however, breast cancer can recur at any site. Pulmonary nodules with lymphadenopathy in advanced cancer patients are likely to be assumed as metastases. A 44-year-old woman with a history of breast cancer was presented to our institution with abnormal findings on 18-fluorodeoxyglucose positron emission tomography imaging, which suggested lung metastasis. She had previously been diagnosed with breast cancer (T1N2M0, Stage IIIa, intraductal carcinoma, triple negative cancer). Histological analysis of the mediastinal lymph node biopsy demonstrated sarcoidosis, showing a chronic, non-caseating, granulomatous inflammation. Our case highlights the need for non-malignant diagnoses in those with prior malignancies, and the need for histological evaluations in the event of first recurrence following potentially curative therapy. PMID:25038768

Kim, Hye Sook; Lee, Suk-young; Oh, Sang Cheul; Choi, Chul Won; Kim, Jun Suk; Seo, Jae Hong

2014-01-01

213

Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy  

ClinicalTrials.gov

Ductal Breast Carcinoma in Situ; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Lobular Breast Carcinoma in Situ; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer

2014-08-18

214

What Are the Key Statistics about Breast Cancer in Men?  

MedlinePLUS

... breast cancer in men? What are the key statistics about breast cancer in men? The American Cancer ... Symptoms of Cancer Treatments & Side Effects Cancer Facts & Statistics News About Cancer Expert Voices Blog Programs & Services ...

215

Identification of different subtypes of breast cancer using tissue microarray.  

PubMed

Breast cancer may be classified into luminal A, luminal B, HER2+/ER-, basal-like and normal-like subtypes based on gene expression profiling or immunohistochemical (IHC) characteristics. The main aim of the present study was to classify breast cancer into molecular subtypes based on immunohistochemistry findings and correlate the subtypes with clinicopathological factors. Two hundred and seventeen primary breast carcinomas tumor tissues were immunostained for ER, PR, HER2, CK5/6, EGFR, CK8/18, p53 and Ki67 using tissue microarray technique. All subtypes were significantly associated with Malay ethnic background (p=0.035) compared to other racial origins. The most common subtypes of breast cancers were luminal A and was significantly associated with low histological grade (p<0.000) and p53 negativity (p=0.003) compared to HER2+/ER-, basal-like and normal-like subtypes with high histological grade (p<0.000) and p53 positivity (p=0.003). Luminal B subtype had the smallest mean tumor size (p=0.009) and also the highest mean number of lymph nodes positive (p=0.032) compared to other subtypes. All markers except EGFR and Ki67 were significantly associated with the subtypes. The most common histological type was infiltrating ductal carcinoma, NOS. Majority of basal-like subtype showed comedo-type necrosis (68.8%) and infiltrative margin (81.3%). Our studies suggest that IHC can be used to identify the different subtypes of breast cancer and all subtypes were significantly associated with race, mean tumor size, mean number of lymph node positive, histological grade and all immunohistochemical markers except EGFR and Ki67. PMID:21655659

Munirah, M A; Siti-Aishah, M A; Reena, M Z; Sharifah, N A; Rohaizak, M; Norlia, A; Rafie, M K M; Asmiati, A; Hisham, A; Fuad, I; Shahrun, N S; Das, S

2011-01-01

216

Neoadjuvant therapy for breast cancer.  

PubMed

Neoadjuvant treatment of breast cancer refers to the use of different treatment modalities prior to surgical excision of the tumor. It has been accepted as a treatment option for patients with nonmetastatic disease, because it renders inoperable tumors operable and increases the rates of breast-conserving surgery, while achieving similar long-term clinical outcomes as adjuvant treatment. The neoadjuvant setting is being increasingly perceived as a research platform, where the biologic effects of traditional anticancer agents can be delineated, prognostic and predictive biomarkers can be identified, and the development of targeted agents can be expedited. Surrogate endpoints that can predict long-term clinical outcome and are evaluable early on, such as the pathologic complete response, offer valuable opportunities for rapid assessment of anticancer agents. Additionally, efforts for molecular profiling of the post-neoadjuvant residual disease hold the potential to lead to personalized therapy for breast cancer patients with early-stage high-risk disease. PMID:25386936

Zardavas, Dimitrios; Piccart, Martine

2015-01-14

217

Unusual Aggressive Breast Cancer: Metastatic Malignant Phyllodes Tumor  

PubMed Central

For the year of 2012, it has been estimated that breast cancer will account for the greatest number of newly diagnosed cancers and the second highest proportion of cancer related deaths among women. Breast cancer, while often lumped together as one disease, represents a diverse group of malignancies with different imaging findings, histological appearances and behavior. While most invasive primary breast cancers are epithelial derived adenocarcinomas, rare neoplasms such as the phyllodes tumor may arise from mesenchymal tissue. Compared to the breast adenocarcinoma, the phyllodes tumor tends to affect a younger population, follows a different clinical course, is associated with different imaging and histological findings and is managed distinctively. There may be difficulty in differentiating the phyllodes tumor from a large fibroadenoma, but the mammographer plays a key role in reviewing the clinical and imaging data in order to arrive at the correct diagnosis. Early diagnosis with proper surgical management can often cure non-metastatic phyllodes tumors. However, in rare cases where metastasis occurs, prognosis tends to be poor. This report describes the presentation, imaging findings and management of a metastatic malignant phyllodes tumor. PMID:23705037

Singer, Adam; Tresley, Jonathan; Velazquez-Vega, Jose; Yepes, Monica

2013-01-01

218

Dietary Folate Intake and Breast Cancer Risk: Results from the Shanghai Breast Cancer Study1  

Microsoft Academic Search

Folate is involved in DNA synthesis, repair, and methylation. It has been hypothesized that high intake of folate may reduce the risk of human cancers, including cancer of the breast. Using data from a population- based case-control study of breast cancer conducted in urban Shanghai during 1996 -1998, we evaluated the association of dietary folate intake and breast cancer risk

Martha J. Shrubsole; Fan Jin; Qi Dai; Xiao-Ou Shu; John D. Potter; James R. Hebert; Yu-Tang Gao; Wei Zheng

2001-01-01

219

The ALTTO Breast Cancer Trial  

Cancer.gov

A collection of material about the Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation, or ALTTO, study that will compare the targeted agents lapatinib and trastuzumab alone, in sequence, or in combination as adjuvant therapy for HER2-positive breast cancer.

220

Pictures of Breast Cancer Diagnoses  

NSDL National Science Digital Library

This webpage by breastcancer.org, provides a number of diagrams relative to various methods of breast cancer diagnosis. The site also shows PET scan, mammogram, ultrasound, and MRI images from different perspectives; illustrations of abnormal lymph nodes are also shown. Lastly, webpage contains a link to additional information about screening and testing options.

2007-04-24

221

Breast Cancer Family Registries Publications  

Cancer.gov

Le Calvez-Kelm F, Lesueur F, Damiola F, Vallee M, Voegele C, Babikyan D, Durand G, Forey N, McKay-Chopin S, Robinot N, Nguyen-Dumont T, Thomas A, Byrnes GB, Breast Cancer Family Registry T, Hopper JL, Southey MC, Andrulis IL, John EM, Tavtigian SV.

222

Breast Cancer Research at NASA  

NASA Technical Reports Server (NTRS)

Isolation of human mammary epithelial cells (HMEC) from breast cancer susceptible tissue; A: Duct element recovered from breast tissue digest. B: Outgrowth of cells from duct element in upper right corner cultured in a standard dish; most cells spontaneousely die during early cell divisions, but a few will establish long-term growth. C: Isolate of long-term frowth HMEC from outgrowth of duct element; cells shown soon after isolation and in early full-cell contact growth in culture in a dish. D: same long-term growth HMEC, but after 3 weeks in late full-cell contact growth in a continuous culture in a dish. Note attempts to reform duct elements but this in two demensions in a dish rather than in three dimensions in tissue. NASA's Marshall Space Flight Center (MSFC) is sponsoring research with Bioreactors, rotating wall vessels designed to grow tissue samples in space, to understand how breast cancer works. This ground-based work studies the growth and assembly of human mammary epithelial cell (HMEC) from breast cancer susceptible tissue. Radiation can make the cells cancerous, thus allowing better comparisons of healthy vs. tunorous tissue. Credit: Dr. Robert Richmond, NASA/Marshall Space Flight Center (MSFC).

1998-01-01

223

BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different  

PubMed Central

No longer is histology solely predictive of cancer treatment and outcome. There is an increasing influence of tumor genomic characteristics on therapeutic options. Both breast and ovarian cancers are at higher risk of development in patients with BRCA 1/2-germline mutations. Recent data from The Cancer Genome Atlas and others have shown a number of genomic similarities between triple negative breast cancers (TNBCs) and ovarian cancers. Recently, poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in hereditary BRCA 1/2-mutated and sporadic breast and ovarian cancers. In this review, we will summarize the current literature regarding the genomic and phenotypic similarities between BRCA 1/2-mutation related cancers, sporadic TNBCs, and sporadic ovarian cancers. We will also review Phase I, II, and III data using PARP inhibitors for these malignancies and compare and contrast the results with respect to histology. PMID:24579064

Burgess, Melissa; Puhalla, Shannon

2014-01-01

224

Retinoid, Retinoic Acid Receptor ? and Breast Cancer  

Microsoft Academic Search

Retinoids have been reported to inhibit the growth of several breast cancer cell lines in culture and to reduce breast tumor growth in animal models. Furthermore, retinoic acid (RA) can augment the action of other breast cancer cell growth inhibitors both in vitro and in vivo. Clinically, interest has increased in the potential use of retinoids for the prevention and

Qifeng Yang; Takeo Sakurai; Kennichi Kakudo

2002-01-01

225

Biorepositories for the Breast Cancer Prevention Trial  

Cancer.gov

The National Surgical Adjuvant Breast and Bowel Project (NSABP) has a serum and lymphocyte bank with specimens on more than 90% of the 33,000 women in the Breast Cancer Prevention Trial (BCPT) and Study of Tamoxifen and Raloxifene (STAR). They also have tumor blocks on the majority of the breast cancers that have occurred in women on these studies.

226

Electromagnetic imaging for breast cancer research  

Microsoft Academic Search

Breast cancer is a serious potential health problem for all women. The current screening and imaging techniques such as X-ray mammography, clinical examination, ultrasound, and MRI, even combined in some way, provide only 73% accuracy in detecting breast cancer. This motivates researchers with biomedical background to investigate new techniques to advance the screening techniques aiming for early detection of breast

Magda El-Shenawee

2011-01-01

227

Zinc isotopic compositions of breast cancer tissue.  

PubMed

An early diagnostic biomarker for breast cancer is essential to improve outcome. High precision isotopic analysis, originating in Earth sciences, can detect very small shifts in metal pathways. For the first time, the natural intrinsic Zn isotopic compositions of various tissues in breast cancer patients and controls were determined. Breast cancer tumours were found to have a significantly lighter Zn isotopic composition than the blood, serum and healthy breast tissue in both groups. The Zn isotopic lightness in tumours suggests that sulphur rich metallothionein dominates the isotopic selectivity of a breast tissue cell, rather than Zn-specific proteins. This reveals a possible mechanism of Zn delivery to Zn-sequestering vesicles by metallothionein, and is supported by a similar signature observed in the copper isotopic compositions of one breast cancer patient. This change in intrinsic isotopic compositions due to cancer has the potential to provide a novel early biomarker for breast cancer. PMID:25489714

Larner, Fiona; Woodley, Laura N; Shousha, Sami; Moyes, Ashley; Humphreys-Williams, Emma; Strekopytov, Stanislav; Halliday, Alex N; Rehkämper, Mark; Coombes, R Charles

2015-01-24

228

Estimation of volumetric breast density for breast cancer risk prediction  

Microsoft Academic Search

Mammographic density (MD) has been shown to be a strong risk predictor for breast cancer. Compared to subjective assessment by a radiologist, computer-aided analysis of digitized mammograms provides a quantitative and more reproducible method for assessing breast density. However, the current methods of estimating breast density based on the area of bright signal in a mammogram do not reflect the

Olga Pawluczyk; Martin J. Yaffe; Norman F. Boyd; Roberta A. Jong

2000-01-01

229

Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer  

ClinicalTrials.gov

Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; HER2-positive Breast Cancer; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Stage IA Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer

2012-12-12

230

Breast Cancer and the Environment Research Program  

Cancer.gov

The Breast Cancer and the Environment Research Program (BCERP), a joint effort co-funded by the National Institute of Environmental Health Sciences (NIEHS) and the National Cancer Institute (NCI), is the next phase of a program that began with the Breast Cancer and the Environment Research Centers (BCERC) in 2003. The BCERP supports a multidisciplinary network of scientists, clinicians, and community partners to examine the effects of environmental exposures that may predispose a woman to breast cancer throughout her life.

231

Breast Cancer Rates by Race and Ethnicity  

MedlinePLUS

... Right to Know Campaign Stay Informed Rates by Race and Ethnicity for Other Kinds of Cancer All ... Skin Uterine Cancer Home Breast Cancer Rates by Race and Ethnicity Language: English Español (Spanish) Share Compartir ...

232

Are males with early breast cancer treated differently from females with early breast cancer in Australia and New Zealand?  

Microsoft Academic Search

Breast cancer in males is much rare than in females so in practice, male breast cancer treatment is likely to follow the guidelines developed for female breast cancer patients. The objective of this study is to compare the characteristics and treatment pattern of male breast cancer patients with comparable subgroups of female breast cancer patients using data submitted to the

Jim Wang; James Kollias; Claire Marsh; Guy Maddern

2009-01-01

233

Presence of mouse mammary tumour?like virus gene sequences may be associated with morphology of specific human breast cancer  

PubMed Central

Background Mouse mammary tumour virus (MMTV) has a proven role in breast carcinogenesis in wild mice and genetically susceptible in?bred mice. MMTV?like env gene sequences, which indicate the presence of a replication?competent MMTV?like virus, have been identified in some human breast cancers, but rarely in normal breast tissues. However, no evidence for a causal role of an MMTV?like virus in human breast cancer has emerged, although there are precedents for associations between specific histological characteristics of human cancers and the presence of oncogenic viruses. Aim To investigate the possibility of an association between breast cancer and MMTV?like viruses. Methods Histological characteristics of invasive ductal human breast cancer specimens were compared with archival MMTV?associated mammary tumours from C3H experimental mice. The presence of MMTV?like env DNA sequences in the human breast cancer specimens was determined by polymerase chain reaction and confirmed by Southern hybridisation. Results MMTV?like env gene sequences were identified in 22 of 59 (37.3%) human breast cancer specimens. Seventeen of 43 (39.5%) invasive ductal carcinoma breast cancer specimens and 4 of 16 (25%) ductal carcinoma in situ specimens had some histological characteristics, which were similar to MMTV?associated mouse mammary tumours. However, these similarities were not associated with the presence or absence of MMTV?like gene sequences in the human breast tumour specimens. A significant (p?=?0.05) correlation was found between the grade of the human breast cancer and similarity to the mouse mammary tumours. The lower the grade, the greater the similarity. Conclusion Some human breast cancer specimens, in which MMTV?like env DNA sequences have been identified, were shown to have histological characteristics (morphology) similar to MMTV?associated mouse mammary tumours. These observations are compatible with, but not conclusive of, an association between the presence of MMTV?like env DNA sequences and some human breast cancers. PMID:16698952

Lawson, J S; Tran, D D; Carpenter, E; Ford, C E; Rawlinson, W D; Whitaker, N J; Delprado, W

2006-01-01

234

Dietary fat and risk of breast cancer  

PubMed Central

Background Breast cancer is one of the major public health problems among women worldwide. A number of epidemiological studies have been carried out to find the role of dietary fat and the risk of breast cancer. The main objective of the present communication is to summarize the evidence from various case-control and cohort studies on the consumption of fat and its subtypes and their effect on the development of breast cancer. Methods A Pubmed search for literature on the consumption of dietary fat and risk of breast cancer published from January 1990 through December 2003 was carried out. Results Increased consumption of total fat and saturated fat were found to be positively associated with the development of breast cancer. Even though an equivocal association was observed for the consumption of total monounsaturated fatty acids (MUFA) and the risk of breast cancer, there exists an inverse association in the case of oleic acid, the most abundant MUFA. A moderate inverse association between consumption of n-3 fatty acids and breast cancer risk and a moderate positive association between n-6 fatty acids and breast cancer risk were observed. Conclusion Even though all epidemiological studies do not provide a strong positive association between the consumption of certain types of dietary fat and breast cancer risk, at least a moderate association does seem to exist and this has a number of implications in view of the fact that breast cancer is an increasing public health concern. PMID:16022739

Binukumar, Bhaskarapillai; Mathew, Aleyamma

2005-01-01

235

Breast cancer risk factors and second primary malignancies among women with breast cancer  

Microsoft Academic Search

Purpose  To examine the association between breast cancer risk factors and second primary cancers (independent diagnoses occurring\\u000a at least 12 months after the initial breast cancer diagnosis) among breast cancer survivors.\\u000a \\u000a \\u000a \\u000a Methods  In this population-based study, cancer outcomes among breast cancer survivors first diagnosed during 1987–2000 were investigated.\\u000a Invasive breast cancer cases were identified from the statewide tumor registry and interviewed regarding their

Amy Trentham-Dietz; Polly A. Newcomb; Hazel B. Nichols; John M. Hampton

2007-01-01

236

Progesterone metabolites in breast cancer.  

PubMed

In the 70 years since progesterone (P) was identified in corpus luteum extracts, its metabolism has been examined extensively in many tissues and cell lines from numerous species. In addition to the reproductive tissues and adrenals, every other tissue that has been investigated appears to have one or more P-metabolizing enzyme, each of which is specific for a particular site on the P molecule. In the past, the actions of the P metabolizing enzymes generally have been equated to a means of reducing the P concentration in the tissue microenvironment, and the products have been dismissed as inactive waste metabolites. In human breast tissues and cell lines, the following P-metabolizing enzymes have been identified: 5alpha-reductase, 3alpha-hydroxysteroid oxidoreductase (3alpha-HSO), 3beta-HSO, 20alpha-HSO, and 6alpha-hydroxylase. Rather than providing diverse pathways for inactivating and controlling the concentration of P in breast tissue microenvironments, it is proposed that the enzymes act directly on P to produce two types of autocrines/paracrines with opposing regulatory roles in breast cancer. Evidence is reviewed which shows that P is directly converted to the 4-pregnenes, 3alpha-hydroxy-4-pregnen-20-one (3alpha-dihydroprogesterone; 3alphaHP) and 20alpha-dihydroprogesterone (20alphaHP), by the actions of 3alpha-HSO and 20alpha-HSO respectively and to the 5alpha-pregnane, 5alpha-pregnane-3,20-dione(5alpha-dihydroprogesterone; 5alphaP), by the irreversible action of 5alpha-reductase. In vitro studies on a number of breast cell lines indicate that 3alphaHP promotes normalcy by downregulating cell proliferation and detachment, whereas 5alphaP promotes mitogenesis and metastasis by stimulating cell proliferation and detachment. The hormones bind to novel, separate, and specific plasma membrane-based receptors and influence opposing actions on mitosis, apoptosis, and cytoskeletal and adhesion plaque molecules via cell signaling pathways. In normal tissue, the ratio of 4-pregnenes:5alpha-pregnanes is high because of high P 3alpha- and 20alpha-HSO activities/expression and low P 5alpha-reductase activity/expression. In breast tumor tissue and tumorigenic cell lines, the ratio is reversed in favor of the 5alpha-pregnanes because of altered P-metabolizing enzyme activities/expression. The evidence suggests that the promotion of breast cancer is related to changes in in situ concentrations of cancer-inhibiting and -promoting P metabolites. Current estrogen-based theories and therapies apply to only a fraction of all breast cancers; the majority (about two-thirds) of breast cancer cases are estrogen-insensitive and have lacked endocrine explanations. As the P metabolites, 5alphaP and 3alphaHP, have been shown to act with equal efficacy on all breast cell lines tested, regardless of their tumorigenicity, estrogen sensitivity, and estrogen receptor/progesterone receptor status, it is proposed that they offer a new hormonal basis for all forms of breast cancer. New diagnostic and therapeutic possibilities for breast cancer progression, control, regression, and prevention are suggested. PMID:16954427

Wiebe, John P

2006-09-01

237

Antiperspirants/Deodorants and Breast Cancer  

MedlinePLUS

... Underarm cosmetics and breast cancer. Journal of Applied Toxicology 2003; 23(2):89–95. [PubMed Abstract] Darbre ... parabens) in human breast tumours. Journal of Applied Toxicology 2004; 24(1):1–4. [PubMed Abstract] Darbre ...

238

Anticipation in hereditary breast cancer.  

PubMed

To determine whether familial breast cancer occurs at a younger age in successive generations, we reviewed the clinical records of 435 Ashkenazi women with breast cancer referred to our cancer genetic clinic. Ninety-eight who reported a maternal history of breast cancer were selected for further investigation. All women were genotyped for founder BRCA1/2 mutations (185delAG, 5382insC and 6174delT). Mean age at dignosis was 55.35 +/- 14.21 years in the maternal generation and 48.17 +/- 9.32 years in the daughters (t = - 4.144; p < 0.001). Seventeen women carried a BRCA1 mutation and 12 the 6174delT mutation in BRCA2. Among carriers of the BRCA1 mutation, mean age at diagnosis in the mothers' generation (44 +/- 10.18 years) did not differ from that recorded in the daughters (40.76 +/- 76 years). Among BRCA2 mutation carriers and non-carriers, the mean age at diagnosis in the daughters' generation (41.4 +/- 7.2 and 50.7 +/- 8.8 years, respectively) was younger than in the mothers (61.75 +/- 14.1 and 57.08 +/- 13.7 years, respectively) (t = - 4.29; p < 0.001 for BRCA2 carriers and t = -3.76; p < 0.001 for non-BRCA1/2 carriers). Daughters who were carriers of BRCA1/2 mutations developed breast cancer at a significantly younger age than non-carriers, whilst in the mothers' generation, carriers of BRCA1 mutations developed breast cancer at a significantly younger age than carriers of BRCA2 mutations and non-carriers. BRCA1 mutations predispose to breast cancer at an early age in both mothers and daughters, whereas mutations in BRCA2 were associated with significantly younger age at diagnosis in the second generation. This observation could be related to gene-environmental interactions causing anticipation in BRCA2 mutation carriers. PMID:12220452

Dagan, E; Gershoni-Baruch, R

2002-08-01

239

The non-breast-cancer death rate among breast cancer patients  

Microsoft Academic Search

Non-breast-cancer deaths currently account for almost half of deaths among breast carcinoma patients in the 15 years following\\u000a diagnosis. Understanding the trends of non-breast-cancer death is vital for calibrating treatment and survival expectations,\\u000a and for understanding the consequences of potentially toxic therapies. To observe trends over time in non-breast-cancer relative\\u000a survival—the non-breast-cancer survival rates of breast cancer patients relative to the

Devon Bush; Barbara Smith; Jerry Younger; James S. Michaelson

2011-01-01

240

Perspectives of breast cancer thermotherapies.  

PubMed

In this article, the use of different types of thermotherapies to treat breast cancer is reviewed. While hyperthermia is most commonly used as an adjuvant in combination with radiotherapy, chemotherapy, targeted therapy or cryotherapy to enhance the therapeutic effect of these therapies, thermoablation is usually carried out alone to eradicate small breast tumors. A recently developed thermotherapy, called magnetic hyperthermia, which involves localized heating of nanoparticles under the application of an alternating magnetic field, is also presented. The advantages and drawbacks of these different thermotherapies are highlighted. PMID:24959300

Alphandéry, Edouard

2014-01-01

241

Perspectives of Breast Cancer Thermotherapies  

PubMed Central

In this article, the use of different types of thermotherapies to treat breast cancer is reviewed. While hyperthermia is most commonly used as an adjuvant in combination with radiotherapy, chemotherapy, targeted therapy or cryotherapy to enhance the therapeutic effect of these therapies, thermoablation is usually carried out alone to eradicate small breast tumors. A recently developed thermotherapy, called magnetic hyperthermia, which involves localized heating of nanoparticles under the application of an alternating magnetic field, is also presented. The advantages and drawbacks of these different thermotherapies are highlighted. PMID:24959300

Alphandéry, Edouard

2014-01-01

242

Tamoxifen and Breast Density in Women at Increased Risk of Breast Cancer  

Microsoft Academic Search

Background: Although mammographic breast density is as- sociated with the risk of breast cancer and is influenced by hormone levels, the effects of tamoxifen on breast density in healthy women and whether tamoxifen-induced density changes are associated with breast cancer risk are unclear. We investigated mammographic breast density in healthy women with an increased risk of breast cancer at baseline

Jack Cuzick; Jane Warwick; Elizabeth Pinney; Ruth M. L. Warren; Stephen W. Duffy

243

How can grafted breast cancer models be optimized?  

PubMed Central

Breast cancer is the most frequent spontaneous malignancy diagnosed in women and is characterized by a broad histological diversity. Progression of the disease has a metastasizing trend and can be resistant to hormonal and chemotherapy. Animal models have provided some understanding of these features and have allowed new treatments to be proposed. However, these models need to be revised because they have some limitations in predicting the clinical efficacy of new therapies. In this review, we discuss the biological criteria to be taken into account for a realistic animal model of breast cancer graft (tumor implantation site, animal immune status, histological diversity, modern imaging). We emphasize the need for more stringent monitoring criteria, and suggest adopting the human RECIST (Response Evaluation Criteria in Solid Tumors) criteria to evaluate treatments in animal models. PMID:22057217

Mollard, Séverine; Mousseau, Yoanne; Baaj, Yasser; Richard, Laurence; Cook-Moreau, Jeanne; Monteil, Jacques; Funalot, Benoît

2011-01-01

244

78 FR 61805 - National Breast Cancer Awareness Month, 2013  

Federal Register 2010, 2011, 2012, 2013, 2014

...Proclamation 9028 of September 30, 2013 National Breast Cancer Awareness Month, 2013 By the President of...America stands in solidarity with those battling breast cancer and those at risk for breast cancer. This disease touches every corner of...

2013-10-04

245

76 FR 62285 - National Breast Cancer Awareness Month, 2011  

Federal Register 2010, 2011, 2012, 2013, 2014

...8724 of October 3, 2011 National Breast Cancer Awareness Month, 2011 By the...commitment to preventing and treating breast cancer, and to supporting those courageously...early detection, and treatment of breast cancer. Still, this year,...

2011-10-07

246

77 FR 60605 - National Breast Cancer Awareness Month, 2012  

Federal Register 2010, 2011, 2012, 2013, 2014

...8874 of October 1, 2012 National Breast Cancer Awareness Month, 2012 By the...States of America A Proclamation Breast cancer touches the lives of Americans...000 women will be diagnosed with breast cancer this year, and tens of...

2012-10-04

247

What Are the Risk Factors for Breast Cancer in Men?  

MedlinePLUS

... in men? What are the risk factors for breast cancer in men? A risk factor is anything that ... old when they are diagnosed. Family history of breast cancer Breast cancer risk is increased if other members ...

248

No Link Between Migraine, Breast Cancer Risk, Study Says  

MedlinePLUS

... sharing features on this page, please enable JavaScript. No Link Between Migraine, Breast Cancer Risk, Study Says ... raise the risk for breast cancer. "There is no association between migraine and breast cancer risk," said ...

249

Selected National Cancer Institute Breast Cancer Research Topics | NIH MedlinePlus the Magazine  

MedlinePLUS

... Sciences are jointly funding three Breast Cancer and Environment Research Centers (BCERCs) to conduct interdisciplinary research on the effects of early environmental exposures on breast development and breast cancer risk. The Breast Cancer Surveillance ...

250

Fertility after breast cancer treatment.  

PubMed

In many countries of the developed world, there is an increasing trend toward delay in childbearing from 30 to 40 years of age for various reasons. This is unfortunately concordant with an increasing incidence of breast cancer in women who have not yet completed their family. The current choice for premenopausal women with breast cancer is adjuvant therapy which includes cytotoxic chemotherapy, ovarian ablation (by surgery, irradiation, or chemical ovarian suppression), anti-estrogen therapy, or any combination of these. Although the use of adjuvant therapies with cytotoxic drugs can significantly reduce mortality, it raises issues of the long-term toxicity, such as induction of an early menopause and fertility impairment. The risk of infertility is a potential hardship to be faced by the patients following treatment of breast cancer. The offspring of patients who became pregnant after completion of chemotherapy have shown no adverse effects and congenital anomalies from the treatment, but sometimes high rates of abortion (29%) and premature deliveries with low birth weight (40%) have been demonstrated. Therefore, the issue of recent cytotoxic treatment remains controversial and further research is required to define a "safety period" between cessation of treatment and pregnancy. Preservation of fertility in breast cancer survivors of reproductive age has become an important issue regarding the quality of life. Currently, there are several potential options, including all available assisted technologies, such as in vitro fertilization and embryo transfer, in vitro maturation, oocyte and embryo cryopreservation, and cryopreservation of ovarian tissue. Because increased estrogen levels are thought to be potentially risky in breast cancer patients, recently developed ovarian stimulation protocols with the aromatase inhibitor letrozole and tamoxifen appear to provide safe stimulation with endogenous estrogen. Embryo cryopreservation seems to be the most established fertility preservation strategy, providing a 25-35% chance of pregnancy. In addition, oocyte freezing can be considered as an alternative in patients who are single and in those who do not wish a sperm donor. Although ovarian tissue harvesting appears to be safe, experience regarding ovarian transplantation is still limited due to low utilization, so the true value of this procedure remains to be determined. Nevertheless, in clinical situations in which chemotherapy needs to be started in young patients facing premature ovarian failure, ovarian tissue preservation seems to be a promising option for restoring fertility, especially in conjunction with other options like immature oocyte retrieval, in vitro maturation of oocytes, oocyte vitrification, or embryo cryopreservation. It seems that in vitro maturation is a useful strategy because it improves oocyte or cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation. PMID:24315568

Kasum, Miro; Beketi?-Oreškovi?, Lidija; Peddi, Parvin F; Oreškovi?, Slavko; Johnson, Rebecca H

2014-02-01

251

Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer  

Microsoft Academic Search

Triple-negative breast cancer, defined as that with negative expression of estrogen and progesterone receptors and cerbB2, accounted for 11% of invasive breast cancers in our study, drawn from an original cohort of 7048 women diagnosed with breast cancer from the files of the Department of Pathology, Singapore General Hospital, over 14 years. Women with triple-negative breast cancer were generally postmenopausal,

Aye Aye Thike; Poh Yian Cheok; Ana Richelia Jara-Lazaro; Benita Tan; Patrick Tan; Puay Hoon Tan

2010-01-01

252

Bridging Bench to Bedside: Beating Breast Cancer  

E-print Network

Bridging Bench to Bedside: Beating Breast Cancer September 18, 2013 2:00 ­ 4:00 PM Reception. Speakers in the symposium will cover: (1) basic research in breast cancer metastasis, (2) drug discovery basic research ideas to drugs and inhibitors as therapeutic interventions for cancer treatment

253

Genetics of Breast and Gynecologic Cancers (PDQ®)  

Cancer.gov

Expert-reviewed information summary about the genetics of breast and gynecologic cancers, including information about specific genes and family cancer syndromes. The summary also contains information about interventions that may influence the risk of developing breast and gynecologic cancers in individuals who may be genetically susceptible to these diseases. Psychosocial issues associated with genetic testing are also discussed.

254

New Molecular Targets of Breast Cancer Therapy  

Microsoft Academic Search

Background: The development of new chemotherapeutic agents and concepts of radiation therapy, administered as primary, adjuvant and palliative therapy, has led to new perspectives in breast cancer therapy. Apart from conventional chemotherapy, recently developed novel agents interfere with molecular mechanisms that are altered in cancer cells. Those targets are not necessarily breast cancer-specific. In this review we will focus on

Georg Sauer; Helmut Deissler; Christian Kurzeder; Rolf Kreienberg

2002-01-01

255

Electric power, melatonin, and breast cancer  

SciTech Connect

In this paper, the epidemiology of breast cancer will be discussed, followed by a brief description of the effect of electric fields on melatonin and the relation of melatonin to mammary cancer in rats. Finally, there will be a consideration of factors such as alcohol that affect melatonin and their relation to breast cancer risk. 55 refs.

Stevens, R.G.

1987-08-01

256

FDA Approves New Breast Cancer Drug  

MedlinePLUS

... this page, please enable JavaScript. FDA Approves New Breast Cancer Drug Ibrance is targeted for postmenopausal women with ... Preidt Wednesday, February 4, 2015 Related MedlinePlus Pages Breast Cancer Cancer Chemotherapy WEDNESDAY, Feb. 4, 2015 (HealthDay News) -- ...

257

Environmental cadmium and breast cancer risk  

PubMed Central

Breast cancer is the most prevalent women's cancer, with an age-adjusted incidence of 122.9 per 100,000 US women. Cadmium, a ubiquitous carcinogenic pollutant with multiple biological effects, has been reported to be associated with breast cancer in one US regional case-control study. We examined the association of breast cancer with urinary cadmium (UCd), in a case-control sample of women living on Long Island (LI), NY (100 with breast cancer and 98 without), a region with an especially high rate of breast cancer (142.7 per 100,000 in Suffolk County) and in a representative sample of US women (NHANES 1999-2008, 92 with breast cancer and 2,884 without). In a multivariable logistic model, both samples showed a significant trend for increased odds of breast cancer across increasing UCd quartiles (NHANES, p=0.039 and LI, p=0.023). Compared to those in the lowest quartile, LI women in the highest quartile had increased risk for breast cancer (OR=2.69; 95% CI=1.07, 6.78) and US women in the two highest quartiles had increased risk (OR=2.50; 95% CI=1.11, 5.63 and OR=2.22; 95% CI=.89, 5.52, respectively). Further research is warranted on the impact of environmental cadmium on breast cancer risk in specific populations and on identifying the underlying molecular mechanisms. PMID:21071816

Gallagher, Carolyn M.; Chen, John J.; Kovach, John S.

2010-01-01

258

Using Near-Infrared Light To Detect Breast Cancer  

E-print Network

Using Near-Infrared Light To Detect Breast Cancer Using Near-Infrared Light To Detect Breast Cancer News 25 T he idea of using light to non- invasively detect breast cancer has been revisited in the past of selectively labeling breast tumors may open new opportunities in the optical detection of breast cancer

Fantini, Sergio

259

From the Cover: Prospective identification of tumorigenic breast cancer cells  

Microsoft Academic Search

Breast cancer is the most common malignancy in United States women, accounting for >40,000 deaths each year. These breast tumors are comprised of phenotypically diverse populations of breast cancer cells. Using a model in which human breast cancer cells were grown in immunocompromised mice, we found that only a minority of breast cancer cells had the ability to form new

Muhammad Al-Hajj; Max S. Wicha; Adalberto Benito-Hernandez; Sean J. Morrison; Michael F. Clarke

2003-01-01

260

Consistent mutation status within histologically heterogeneous lung cancer lesions.  

PubMed

Mattsson J S M, Imgenberg-Kreuz J, Edlund K, Botling J & Micke P (2012) Histopathology 61, 744-748 Consistent mutation status within histologically heterogeneous lung cancer lesions Aims:? Activating epidermal growth factor receptor (EGFR) and KRAS mutations characterize molecular subgroups of non-small-cell lung cancer (NSCLC) with a strong predictive value for response to EGFR inhibitor therapy. However, the temporal occurrence and clonal stability of these mutations during the course of cancer progression are debated. The aim of this study was to characterize the presence of EGFR and KRAS mutations in histologically different areas of primary NSCLC lesions. Methods and results:? Formalin-fixed paraffin-embedded cancer specimens from six cases with EGFR mutations and five cases with KRAS mutations were selected from a pool of primary resected NSCLC patients. From each tumour, three morphologically distinct areas were manually microdissected and analysed for the presence of mutations. The results demonstrated consistent EGFR and KRAS mutation status in the different histological areas of all primary tumours. Conclusions:? The results support the concept that activating EGFR and KRAS mutations are oncogenic events that are consistently present throughout the primary tumour independently of histological heterogeneity. Thus, for molecular diagnostics, any part of the tumour is likely to be representative for EGFR and KRAS mutation testing. PMID:22458769

Mattsson, Johanna Sofia Margareta; Imgenberg-Kreuz, Juliana; Edlund, Karolina; Botling, Johan; Micke, Patrick

2012-03-28

261

Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer  

ClinicalTrials.gov

Male Breast Cancer; Recurrent Breast Cancer; Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer

2014-10-14

262

Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients  

ClinicalTrials.gov

Anxiety Disorder; Depression; Ductal Breast Carcinoma in Situ; Lobular Breast Carcinoma in Situ; Psychosocial Effects of Cancer and Its Treatment; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer

2014-12-29

263

Clinical proteomics in breast cancer: a review  

Microsoft Academic Search

Breast cancer imposes a significant healthcare burden on women worldwide. Early detection is of paramount importance in reducing\\u000a mortality, yet the diagnosis of breast cancer is hampered by the lack of an adequate detection method. In addition, better\\u000a breast cancer prognostication may improve selection of patients eligible for adjuvant therapy. Hence, new markers for early\\u000a diagnosis, accurate prognosis and prediction

Marie-Christine W. Gast; Jan H. M. Schellens; Jos H. Beijnen

2009-01-01

264

The breast cancer epidemic: 10 facts.  

PubMed

Breast cancer, affecting one in eight American women, is a modern epidemic. The increasing frequency of breast cancer is widely recognized. However, the wealth of compelling epidemiological data on its prevention is generally not available, and as a consequence, is largely unknown to the public. The purpose of this report is to review the epidemiological evidence of preventable causes of breast cancer. [Table: see text]. PMID:25249706

Schneider, A Patrick; Zainer, Christine M; Kubat, Christopher Kevin; Mullen, Nancy K; Windisch, Amberly K

2014-08-01

265

Milestones in breast cancer treatment.  

PubMed

Modern treatment started in the 1880s with Halsted's mastectomy. The next milestone-a century later-was breast-conserving surgery, with equivalent survival but better esthetic outcomes than mastectomy. Sentinel node biopsy, introduced in the 1990s, was a milestone that permitted avoidance of axillary dissection if the sentinel node was disease-free. Chemotherapy was established for early breast cancer in the 1980s and its efficacy continues to improve; however side effects remain a concern, particularly since chemotherapy does not benefit most patients. External whole breast irradiation was introduced with conservative surgery, as it reduces recurrences. By the 2000s, 3-week regimens had been shown equivalent to standard 6-week regimens-easing pressure on patients and radiation centers. Intraoperative partial breast irradiation is potentially more beneficial as it permits complete local treatment in a single session; however, trials show that patients must be very carefully selected. From the 1990s irradiation technology was combined with imaging and computer technologies to produce equipment that directs radiation to more precisely defined target volumes, allowing increased dose to the target and markedly reduced dose to nearby tissues. Irradiation systems are evolving rapidly but are being implemented without data on long-term morbidity or efficacy, while costs rise steeply. The first targeted treatment was tamoxifen, a selective estrogen receptor inhibitor. Since its widespread use starting in the 1980s, tamoxifen has saved the lives or prolonged the survival of millions with estrogen-positive disease; it is cheap and has limited (but not negligible) side effects. The same cannot be said of newer targeted treatments like trastuzumab and pertuzumab, which, although effective against human epidermal growth factor receptor 2-positive cancer, come with important side effects and huge costs. Breast cancer mortality is declining in rich countries, but treatments have become more demanding and more expensive, so the outlook for the increasing numbers of women worldwide who develop the disease is uncertain. PMID:25494903

Zurrida, Stefano; Veronesi, Umberto

2015-01-01

266

The global breast cancer burden.  

PubMed

Breast cancer now represents the most common female malignancy in both the developing and developed world, and is the primary cause of death among women globally. Despite well-documented reductions in mortality from breast cancer during the past two decades, incidence rates continue to increase and do so more rapidly in countries that historically had low rates. This has emphasized the importance of survivorship issues and optimal management of disease chronicity. This article reviews current trends of incidence and mortality in both a western and global context, and considers pertinent changes in underlying etiological risk factors. The latter not only offer clues regarding changes in incidence patterns, but also provides rationale and guidance for strategies that could potentially reduce the burden of this disease. The relevance of lifestyle adjustments and screening interventions for primary and secondary prevention, respectively, are discussed with reference to different healthcare resource settings. PMID:22764767

Benson, John R; Jatoi, Ismail

2012-06-01

267

Endocrine therapy of breast cancer  

SciTech Connect

This book results from a meeting of the ESO (European School of Oncology) Task Force on endocrine aspects of breast cancer. The contributions stem from some of the most outstanding researchers in Europe and highlight mainly methodological issues and new avenues for future research. The chapters on basic research deal primarily with experimental strategies for studying the relationship between steroid hormones, growth factors, and oncongenes. The clinically oriented chapters treat the methodology of clinical trials. Provocative questions are raised, such as: What are the pitfalls in endocrine trials. What does statistical proof mean. How can we consider a quality of life endpoint in the adjuvant setting. Two special reports deal with the controversial issues of chemoprevention in high-risk normal women and the optimization of the hormonal contribution to the adjuvant therapy of breast cancer. Topics considered included oncogenic transformations, radiotherapy, steroid hormones, cell proliferation, tamoxifen, and preventive medicine.

Cavalli, F.

1986-01-01

268

Pathology of breast cancer in women irradiated for acute postpartum mastitis. [X rays  

SciTech Connect

The gross and microscopic pathology of breast cancers in women irradiated for acute postpartum mastitis was compared to the breast cancers found in the sisters of the irradiated women. In considering the lesions in the two populations, the size, location, histologic type, histologic grade, inflammatory response, lymphatic and blood vascular invasion, nipple involvement, axillary lymph node metastases, and menopausal status at the time of diagnosis were statistically indistinguishable. The only parameter that was different in the two populations was the desmoplastic response to the malignant lesion. The control population had more marked fibrosis within the cancers compared with the irradiated women.

Dvoretsky, P.M.; Woodard, E.; Bonfiglio, T.A.; Hempelmann, L.H.; Morse, I.P.

1980-11-15

269

Implications of Functional Proteomics in Breast Cancer  

PubMed Central

Breast cancer is one of the major public health problems of the Western world. Recent advances in genomics and gene expression-profiling approaches have enriched our understanding of this heterogeneous disease. However, progress in functional proteomics in breast cancer research has been relatively slow. Allied with genomics, the functional proteomics approach will be important in improving diagnosis through better classification of breast cancer and in predicting prognosis and response to different therapies, including chemotherapy, hormonal therapy, and targeted therapy. In this review, we will present functional proteomic approaches with a focus on the recent clinical implications of utilizing the reverse-phase protein array platform in breast cancer research. PMID:24664486

Chae, Young Kwang

2014-01-01

270

Presenting Painless Breast Cancer Detection!  

NSDL National Science Digital Library

This lesson culminates the unit with the Go Public phase of the legacy cycle. In the associated activity, students depict a tumor amidst healthy body tissue using a Microsoft Excel® graph. In addition, students design a brochure for both patients and doctors advertising a new form of painless yet reliable breast cancer detection. Together, the in-class activity and the take-home assignment function as an assessment of what students have learned throughout the unit.

VU Bioengineering RET Program, School of Engineering,

271

Organotropism of Breast Cancer Metastasis  

Microsoft Academic Search

Breast cancer causes mortality by metastasizing to a variety of vital organs, such as bone, lung, brain and liver. Effective\\u000a therapeutic intervention of this deadly process relies on a better mechanistic understanding of metastasis organotropism.\\u000a Recent studies have confirmed earlier speculations that metastasis is a non-random process and is dependent on intricate tumor-stroma\\u000a interactions at the target organ. Both the

Xin Lu; Yibin Kang

2007-01-01

272

Adolescent meat intake and breast cancer risk.  

PubMed

The breast is particularly vulnerable to carcinogenic influences during adolescence due to rapid proliferation of mammary cells and lack of terminal differentiation. We investigated consumption of adolescent red meat and other protein sources in relation to breast cancer risk in the Nurses' Health Study II cohort. We followed prospectively 44,231 women aged 33-52 years who, in 1998, completed a detailed questionnaire about diet during adolescence. Relative risks (RR) and 95% confidence intervals (95%CI) were estimated using Cox proportional hazard regression. We documented 1132 breast cancer cases during 13-year follow-up. In multivariable Cox regression models with major breast cancer risk factors adjustment, greater consumption of total red meat in adolescence was significantly associated with higher premenopausal breast cancer risk (highest vs. lowest quintiles, RR, 1.43; 95%CI, 1.05-1.94; Ptrend ?=?0.007), but not postmenopausal breast cancer. Adolescent intake of poultry was associated with lower risk of breast cancer overall (RR, 0.76; 95%CI, 0.60-0.97; for each serving/day). Adolescent intakes of iron, heme iron, fish, eggs, legumes and nuts were not associated with breast cancer. Replacement of one serving/day of total red meat with one serving of combination of poultry, fish, legumes, and nuts was associated with a 15% lower risk of breast cancer overall (RR, 0.85; 95%CI, 0.74-0.96) and a 23% lower risk of premenopausal breast cancer (RR, 0.77; 95%CI, 0.64-0.92). In conclusion, higher consumption of red meat during adolescence was associated with premenopausal breast cancer. Substituting other dietary protein sources for red meat in adolescent diet may decrease premenopausal breast cancer risk. PMID:25220168

Farvid, Maryam S; Cho, Eunyoung; Chen, Wendy Y; Eliassen, A Heather; Willett, Walter C

2015-04-15

273

ARID1A: a potential prognostic factor for breast cancer.  

PubMed

The aim of this study is to explore the expression of BAF250a protein in breast cancer and its association with the clinical and pathological characteristics and prognosis of breast cancer. The expression status of BAF250a protein was detected by Western blot analysis and immunohistochemical staining. The relationship between BAF250a proteins and clinicopathological parameters in 496 breast cancer specimens was analyzed. Western blot analysis showed that BAF250a protein had a lower expression in breast cancer specimens than in matched normal breast tissue (104.38?±?11.65 vs. 55.94?±?10.27; P?=?0.004, t test). Among the 496 enrolled breast cancer patients, BAF250a protein expression was absent in 324 (65.3 %). Universal and multiple analyses indicated that BAF250a protein expression loss was significantly related to histological grade, metastatic nodes, tumor node metastasis (TNM) stage, and the expression of estrogen receptor (ER), progesterone receptor (PR), c-erbB-2, and p53 (all P?breast cancer treatment. PMID:24430365

Zhao, Jing; Liu, Caigang; Zhao, Zuowei

2014-05-01

274

Breast Cancer Research at NASA  

NASA Technical Reports Server (NTRS)

Epithelial and fibroblast cell coculture: Long-term growth human mammary epithelial cells (HMEC) admixed in coculture with fibroblast from the same initial breast tissue grown as 3-dimenstional constructions in the presence of attachment beads in the NASA Bioreactor. A: A typical constrct about 2.0 mm in diameter without beads on the surface. The center of these constrcts is hollow, and beads are organized about the irner surface. Although the coculture provides smaller constructs than the monoculture, the metabolic of the organized cells is about the same. B, C, D: Closer views of cells showing that the shape of cells and cell-to-cell interactions apprear different in the coculture than in the monoculture constructs. NASA's Marshall Space Flight Center (MSFC) is sponsoring research with Bioreactors, rotating wall vessels designed to grow tissue samples in space, to understand how breast cancer works. This ground-based work studies the growth and assembly of human mammary epithelial cell (HMEC) from breast cancer susceptible tissue. Radiation can make the cells cancerous, thus allowing better comparisons of healthy vs. tunorous tissue. Credit: Dr. Robert Richmond, NASA/Marshall Space Flight Center (MSFC).

1998-01-01

275

Pilates for breast cancer survivors.  

PubMed

Pilates has been advocated for rehabilitation of breast cancer survivors despite little scientific evidence. The authors of this article have examined the feasibility of a Pilates program in postmastectomy breast cancer survivors and the impact on physical and psychological parameters. Fifteen breast cancer survivors were recruited in a one-arm study of 12 weeks of Pilates exercises. The authors assessed recruitment, adherence, and attrition, and measured changes in shoulder and neck range of motion, posture, height, arm volume, quality of life, mood, and body image from pre- to postintervention. Of 26 eligible patients, 15 enrolled, 13 completed the study, and 10 performed more than 50% of the recommended sessions. Statistically significant improvements emerged for shoulder abduction and internal rotation on the affected side, neck rotation toward the unaffected side, and neck flexion. The affected side arm volume and the interlimb volume discrepancy increased. Significant improvements were reported in quality of life, mood, and body image. The improvements in physical and psychological outcomes are promising and deserve further evaluation in a randomized, controlled study. The increase in affected arm volume also warrants additional investigation. PMID:22459522

Stan, Daniela L; Rausch, Sarah M; Sundt, Kathleen; Cheville, Andrea L; Youdas, James W; Krause, David A; Boughey, Judy C; Walsh, Molly F; Cha, Stephen S; Pruthi, Sandhya

2012-04-01

276

Breast Cancer 2012 – New Aspects  

PubMed Central

Treatment options as well as the characteristics for therapeutic decisions in patients with primary and advanced breast cancer are increasing in number and variety. New targeted therapies in combination with established chemotherapy schemes are broadening the spectrum, however potentially promising combinations do not always achieve a better result. New data from the field of pharmacogenomics point to prognostic and predictive factors that take not only the properties of the tumour but also inherited genetic properties of the patient into consideration. Current therapeutic decision-making is thus based on a combination of classical clinical and modern molecular biomarkers. Also health-economic aspects are more frequently being taken into consideration so that health-economic considerations may also play a part. This review is based on information from the recent annual congresses. The latest of these are the 34th San Antonio Breast Cancer Symposium 2011 and the ASCO Annual Meeting 2012. Among their highlights are the clinically significant results from the CLEOPATRA, BOLERO-2, EMILIA and SWOG S0226 trials on the therapy for metastatic breast cancer as well as further state-of-the-art data on the adjuvant use of bisphosphonates within the framework of the ABCSG-12, ZO-FAST, NSABP-B34 and GAIN trials. PMID:25324576

Kolberg, H.-C.; Lüftner, D.; Lux, M. P.; Maass, N.; Schütz, F.; Fasching, P. A.; Fehm, T.; Janni, W.; Kümmel, S.

2012-01-01

277

Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery  

ClinicalTrials.gov

Ductal Breast Carcinoma In Situ; Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Invasive Cribriform Breast Carcinoma; Invasive Ductal Carcinoma, Not Otherwise Specified; Lobular Breast Carcinoma In Situ; Mucinous Breast Carcinoma; Papillary Breast Carcinoma; Progesterone Receptor Positive; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Tubular Breast Carcinoma

2015-01-08

278

Detecting Breast Cancer  

NSDL National Science Digital Library

Students are introduced to the unit challenge: To develop a painless means of identifying cancerous tumors. Solving the challenge depends on an understanding of the properties of stress and strain. After learning the challenge question, students generate ideas and consider the knowledge required to solve the challenge. Then they read an expert's opinion on ultrasound imaging and the potentials for detecting cancerous tumors. This interview helps to direct student research and learning towards finding a solution.

VU Bioengineering RET Program, School of Engineering,

279

Prognosis of Breast Cancer using Genetic Programming  

E-print Network

diseases. They grow at different rates and respond to different treatments. That is why people with cancer need treatment that is aimed at their kind of cancer. Therefore, it is important to identify the type of cancer accurately, so that the correct treatment can be started. Breast cancer is a cancer that starts

Ludwig, Simone

280

Progress in the Biological Understanding and Management of Breast Cancer-Associated Central Nervous System Metastases  

PubMed Central

Metastasis to the central nervous system (CNS) is a devastating neurological complication of systemic cancer. Brain metastases from breast cancer have been documented to occur in approximately 10%–16% of cases over the natural course of the disease with leptomeningeal metastases occurring in approximately 2%–5% of cases of breast cancer. CNS metastases among women with breast cancer tend to occur among those who are younger, have larger tumors, and have a more aggressive histological subtype such as the triple negative and HER2-positive subtypes. Treatment of CNS metastases involves various combinations of whole brain radiation therapy, surgery, stereotactic radiosurgery, and chemotherapy. We will discuss the progress made in the treatment and prevention of breast cancer-associated CNS metastases and will delve into the biological underpinnings of CNS metastases including evaluating the role of breast tumor subtype on the incidence, natural history, prognostic outcome, and impact of therapeutic efficacy. PMID:23740934

Gonzalez-Angulo, Ana M.

2013-01-01

281

Current and emerging treatment options in triple-negative breast cancer  

Microsoft Academic Search

Triple-negative breast cancer is defined by the lack of estrogen receptor, progesterone receptor and HER2 expression with\\u000a immunohistochemical analysis. Triple-negative breast cancers are poorly differentiated, characterized by high histological\\u000a grade and occur at a younger age. Treatment options are limited as these tumors are naturally resistant to existing targeted\\u000a therapies, i.e., endocrine treatment and trastuzumab. An improved understanding of the

Omer Dizdar; Kadri Altundag

2010-01-01

282

Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?  

Microsoft Academic Search

Adjuvant chemotherapy reduces the risk of relapse and mortality for women with early-stage breast cancer. However, many women diagnosed with early-stage breast cancer experience the toxic effects associated with adjuvant chemotherapy without any meaningful benefit. There are a variety of clinicopathological factors—including hormone receptor expression, histology, and proliferation markers such as Ki-67—that can be used to try to identify patients

Fatima Cardoso; Philippe L. Bedard

2011-01-01

283

Anastrozole in Treating Aromatase Inhibitor Musculoskeletal Symptoms in Female Patients With Stage I-III Breast Cancer  

ClinicalTrials.gov

Estrogen Receptor-positive Breast Cancer; Musculoskeletal Complications; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer

2014-09-16

284

Male breast cancer: is the scenario changing  

PubMed Central

Background The overall incidence of male breast cancer is around 1% of all breast cancers and is on the rise. In this review we aim to present various aspects of male breast cancer with particular emphasis on incidence, risk factors, patho-physiology, treatment, prognostic factors, and outcome. Methods Information on all aspects of male breast cancer was gathered from available relevant literature on male breast cancer from the MEDLINE database over the past 32 years from 1975 to 2007. Various reported studies were scrutinized for emerging evidence. Incidence data were also obtained from the IARC, Cancer Mondial database. Conclusion There is a scenario of rising incidence, particularly in urban US, Canada and UK. Even though more data on risk factors is emerging about this disease, more multi-institutional efforts to pool data with large randomized trials to show treatment and survival benefits are needed to support the existing vast emerging knowledge about the disease. PMID:18558006

Contractor, Kaiyumars B; Kaur, Kanchan; Rodrigues, Gabriel S; Kulkarni, Dhananjay M; Singhal, Hemant

2008-01-01

285

Development of Breast Cancer Risk Prediction Model  

Cancer.gov

Development of Breast Cancer Risk Prediction Model Mano S. Selvan, Joe Ensor, John Cook, Constance Johnson, Christopher Amos, Melissa Bondy, Therese Bevers, Donald A. Berry. The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd.,

286

Reproductive History and Breast Cancer Risk  

Cancer.gov

A fact sheet that describes what is known about the relationship between pregnancy, miscarriage, abortion, and the risk of breast cancer. It also briefly describes what is known about reproductive history and the risk of other cancer types.

287

Genetics and molecular biology of breast cancer  

SciTech Connect

This volume contains the abstracts of oral presentations and poster sessions presented at the Cold Springs Harbor Meeting on Cancer Cells, this meeting entitled Genetics and Molecular Biology of Breast Cancer.

King, M.C. [California Univ., Berkeley, CA (United States); Lippman, M. [Georgetown Univ. Medical Center, Washington, DC (United States)] [comps.

1992-12-31

288

Donor Immune Cells Attack Metastatic Breast Cancer  

Cancer.gov

In patients with metastatic breast cancer, immune cells from a genetically matched donor can attack and shrink tumors, researchers from the National Cancer Institute (NCI) announced today at the Annual Meeting of the American Society of Clinical Oncology in Chicago.

289

Breast Cancer Prevention Trial - April 21, 1998  

Cancer.gov

"Breast Cancer Prevention Trial" Department of Health & Human Services National Institutes of Health Statement of Richard D. Klausner, M.D. Director, National Cancer Institute Before the Senate Appropriations Subcommittee on Labor, Health, Human

290

Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study  

Microsoft Academic Search

Objective  Chronic inflammation is suspected to have a role in breast carcinogenesis. Results of studies of non-steroidal anti-inflammatory\\u000a drugs (NSAIDs) and breast cancer have been inconsistent. Timing of exposure and analysis of individual NSAIDs should be considered.\\u000a \\u000a \\u000a \\u000a \\u000a Methods  We conducted a population-based case–control study in western New York State between 1996 and 2001. Cases, 35–79 years, had\\u000a incident, primary, histologically confirmed breast cancer

Theodore M. Brasky; Matthew R. Bonner; Kirsten B. Moysich; Christine B. Ambrosone; Jing Nie; Meng Hua Tao; Stephen B. Edge; Bhaskar V. S. Kallakury; Catalin Marian; Maurizio Trevisan; Peter G. Shields; Jo L. Freudenheim

2010-01-01

291

The dream and reality of histology agnostic cancer clinical trials.  

PubMed

Emerging technologies and progress in data processing allowed for new insights on gene expression, genomics and epigenomics, and mechanisms of cancer genesis and progression. The development of new therapeutic strategies should therefore be triggered by the understanding of the underlying biology through sophisticated clinical trials. Therefore, the methodology and the design of cancer clinical trials as well as the methods of their implementation are under profound changes. Targeting specific pathways has open the hope of a more focused and personalized medicine which has the potential to bring more efficient and tailored treatments to patients. It has been questioned therefore whether clinical trials traditionally designed for specific tumor types could not re-visited towards trials gathering patients based on molecular features rather than pure pathology criteria. The complexity of the cancer biology being the result of so many different interactive mechanisms whether driving or not the process of cancer cells is an additional level of complexity to approach more inclusive clinical trial access. Nevertheless, a number of innovative solutions to address biological challenges across histologies have been initiated and the question of whether histology agnostic trials could be conceived is a logical next question. This paper questions the advantages and the limits of clinical trials performed across tumor types bearing similar selected molecular features and looks further into the feasibility of such histology agnostic trials. PMID:25349876

Lacombe, Denis; Burock, Susen; Bogaerts, Jan; Schoeffski, Patrick; Golfinopoulos, Vassilis; Stupp, Roger

2014-09-12

292

Biomechanical breast modeling to improve patient positioning during breast cancer radiotherapy  

E-print Network

Biomechanical breast modeling to improve patient positioning during breast cancer radiotherapy S irradiation for cases of early stage breast cancer. Delivering higher doses to more localized volumes demands, France Keywords: Finite Element model; breast soft tissues; partial breast irradiation; breast phantom. 1

Paris-Sud XI, Université de

293

Breast Cancer Detection  

NASA Technical Reports Server (NTRS)

NASA's Jet Propulsion Laboratory has come up with a technique to decrease exposure to harmful x-rays in mammographies or breast radiography. Usually, physicians make more than one exposure to arrive at an x-ray film of acceptable density. Now the same solar cells used to convert sunlight into electricity on space satellites can make a single exposure sufficient. When solar cell sensor is positioned directly beneath x-ray film, it can determine exactly when film has received sufficient radiation and has been exposed to optimum density. At that point associated electronic equipment sends signal to cut off x-ray source. Reduction of mammography to single exposures not only reduced x-ray hazard significantly, but doubled the number of patient examinations handled by one machine. The NASA laboratory used this control system at the Huntington Memorial Hospital with overwhelming success.

1976-01-01

294

Breast tomosynthesis: A new tool for diagnosing breast cancer.  

PubMed

Breast cancer continues to be the most common malignant tumor in women in occidental countries. Mammography is currently the technique of choice for screening programs; however, although it has been widely validated, mammography has its limitations, especially in dense breasts. Breast tomosynthesis is a revolutionary advance in the diagnosis of breast cancer. It makes it possible to define lesions that are occult in the glandular tissue and therefore to detect breast tumors that are impossible to see on conventional mammograms. In considering the combined use of mammography and tomosynthesis, many factors must be taken into account apart from cancer detection; these include additional radiation, the recall rate, and the time necessary to carry out and interpret the two tests. In this article, we review the technical principles of tomosynthesis, it main uses, and the future perspective for this imaging technique. PMID:24598575

Martínez Miravete, P; Etxano, J

2014-03-01

295

Stages of Breast Cancer  

MedlinePLUS

... are made by a computer linked to an x-ray machine. A dye may be injected into a vein ... is a cancer treatment that uses high-energy x-rays or other types of radiation ... therapy uses a machine outside the body to send radiation toward the ...

296

The Reproductive Factors Linked to Breast Cancer Risk  

E-print Network

The Reproductive Factors Linked to Breast Cancer Risk The breast is a reproductive organ, so it makes sense that breast cancer risk would be related to reproductive variables. A woman's own estrogen contributes to the normal development and functioning of the breast, as well as to breast cancer risk. Being

Danforth, Bryan Nicholas

297

Risk determination and prevention of breast cancer.  

PubMed

Breast cancer is an increasing public health problem. Substantial advances have been made in the treatment of breast cancer, but the introduction of methods to predict women at elevated risk and prevent the disease has been less successful. Here, we summarize recent data on newer approaches to risk prediction, available approaches to prevention, how new approaches may be made, and the difficult problem of using what we already know to prevent breast cancer in populations. During 2012, the Breast Cancer Campaign facilitated a series of workshops, each covering a specialty area of breast cancer to identify gaps in our knowledge. The risk-and-prevention panel involved in this exercise was asked to expand and update its report and review recent relevant peer-reviewed literature. The enlarged position paper presented here highlights the key gaps in risk-and-prevention research that were identified, together with recommendations for action. The panel estimated from the relevant literature that potentially 50% of breast cancer could be prevented in the subgroup of women at high and moderate risk of breast cancer by using current chemoprevention (tamoxifen, raloxifene, exemestane, and anastrozole) and that, in all women, lifestyle measures, including weight control, exercise, and moderating alcohol intake, could reduce breast cancer risk by about 30%. Risk may be estimated by standard models potentially with the addition of, for example, mammographic density and appropriate single-nucleotide polymorphisms. This review expands on four areas: (a) the prediction of breast cancer risk, (b) the evidence for the effectiveness of preventive therapy and lifestyle approaches to prevention, (c) how understanding the biology of the breast may lead to new targets for prevention, and (d) a summary of published guidelines for preventive approaches and measures required for their implementation. We hope that efforts to fill these and other gaps will lead to considerable advances in our efforts to predict risk and prevent breast cancer over the next 10 years. PMID:25467785

Howell, Anthony; Anderson, Annie S; Clarke, Robert B; Duffy, Stephen W; Evans, D Gareth; Garcia-Closas, Montserat; Gescher, Andy J; Key, Timothy J; Saxton, John M; Harvie, Michelle N

2014-01-01

298

Flax and Breast Cancer: A Systematic Review.  

PubMed

Background. Flax is a food and dietary supplement commonly used for menopausal symptoms. Flax is known for its lignan, ?-linolenic acid, and fiber content, components that may possess phytogestrogenic, anti-inflammatory, and hormone modulating effects, respectively. We conducted a systematic review of flax for efficacy in improving menopausal symptoms in women living with breast cancer and for potential impact on risk of breast cancer incidence or recurrence. Methods. We searched MEDLINE, Embase, the Cochrane Library, and AMED from inception to January 2013 for human interventional or observational data pertaining to flax and breast cancer. Results. Of 1892 records, we included a total of 10 studies: 2 randomized controlled trials, 2 uncontrolled trials, 1 biomarker study, and 5 observational studies. Nonsignificant (NS) decreases in hot flash symptomatology were seen with flax ingestion (7.5 g/d). Flax (25 g/d) increased tumor apoptotic index (P < .05) and decreased HER2 expression (P < .05) and cell proliferation (Ki-67 index; NS) among newly diagnosed breast cancer patients when compared with placebo. Uncontrolled and biomarker studies suggest beneficial effects on hot flashes, cell proliferation, atypical cytomorphology, and mammographic density, as well as possible anti-angiogenic activity at doses of 25 g ground flax or 50 mg secoisolariciresinol diglycoside daily. Observational data suggests associations between flax and decreased risk of primary breast cancer (adjusted odds ratio [AOR] = 0.82; 95% confidence interval [CI] = 0.69-0.97), better mental health (AOR = 1.76; 95% CI = 1.05-2.94), and lower mortality (multivariate hazard ratio = 0.69; 95% CI = 0.50-0.95) among breast cancer patients. Conclusions. Current evidence suggests that flax may be associated with decreased risk of breast cancer. Flax demonstrates antiproliferative effects in breast tissue of women at risk of breast cancer and may protect against primary breast cancer. Mortality risk may also be reduced among those living with breast cancer. PMID:24013641

Flower, Gillian; Fritz, Heidi; Balneaves, Lynda G; Verma, Shailendra; Skidmore, Becky; Fernandes, Rochelle; Kennedy, Deborah; Cooley, Kieran; Wong, Raimond; Sagar, Stephen; Fergusson, Dean; Seely, Dugald

2013-09-01

299

Male breast cancer: a review  

PubMed Central

Male breast cancer (MBC) is rare, with the peak age of onset at 71 years. BRCA2 mutations are more frequent than BRCA1 with 20% of cases giving a family history. Risk factors for MBC are poorly understood and include working in high-ambient temperatures and exhaust fume exposure. MBC is associated with hyperoestrogenic states found in liver disease, Klinefelter’s syndrome, gonadal dysfunction or obesity. Most information on treatment of MBC is derived from large randomized trials carried out in female patients. The small numbers of MBC seen in any unit annually has precluded significant trials being carried out. Diagnosis and treatment of MBC is similar to that of female patients, but men tend to be treated with mastectomy rather than breast-conserving surgery. The mainstay of adjuvant therapy or palliative treatment for advanced disease is endocrine, mostly tamoxifen. Prognosis of male patients is equal to that of stage-matched women, but men tend to fare worse because of delay in presentation, leading to a large proportion of patients presenting with stage III or IV disease. Increased input is needed for psychological support for male breast cancer patients. Specific therapeutic questions about MBC need international trials to obtain meaningful answers. PMID:22276005

Fentiman, IS

2009-01-01

300

Molecular chemotherapy for breast cancer.  

PubMed

Gene therapy for breast cancer initially involves local or systemic delivery. Local delivery may be intrapleural or via direct injection to lesions. However, systemic delivery remains the greatest challenge with targeting, although methods using antibodies or growth factor receptor ligands have been demonstrated in preclinical models. This review focuses on the next step of using tissue-specific promoters such as Muc-1, CEA, PSA, HER-2, Myc, L-plastin and secretory leukoproteinase inhibitor promoters. All of these have demonstrated differential upregulation in breast cancer and additional specificity may be obtained by using physiological stimuli that are more frequently expressed in cancers, such as glucose regulated promoters and hypoxia response elements or radiation inducible elements. Amongst the later are the EGR-1, p21 and tissue type plaminogen activator promoters. Potential therapy genes include the prodrug activation system 5-fluorocytosine and other analogues of antimetabolites, but all of these need gap junctions to transfer the phosphorylated metabolites. Other approaches involving more freely diffusible products include cyclophosphamide, ifosfamide and thymidine phosphorylase to activate 5-deoxy-5-fluoruridine to fluorouracil. The bystander effect is important both for cell killing and for immunological and antivascular effects. Breast cancer is one type of tumour where a major clinical research effort is underway using local delivery methods. For prodrug activation systems, the use of human enzymes is desirable to prevent an immunological response that would eventually eliminate cells producing the prodrug activation system. The use of alkylating agents has an advantage over antimetabolites in that they are cytotoxic to cycling and noncycling cells, and the cytotoxic products can diffuse across cell membranes without the need for gap junctions. They also have a much steeper dose response curve than antimetabolites. PMID:10084362

Patterson, A; Harris, A L

1999-02-01

301

The Genomic Signature of Breast Cancer Prevention  

Microsoft Academic Search

Early pregnancy imprints in the breast permanent genomic changes or a signature that reduces the susceptibility of this organ to cancer. The breast attains its maximum development during pregnancy and\\u000a lactation. After menopause, the breast regresses in both nulliparous and parous women containing lobular structures designated\\u000a Lob.1. The Lob 1 found in the breast of nulliparous women and of parous

Jose Russo; Gabriela Balogh; Daniel Mailo; Patricia A. Russo; Rebecca Heulings; Irma H. Russo

302

Perinatal factors increase breast cancer risk  

Microsoft Academic Search

Emerging evidence suggests that breast cancer may originate during early life. In particular, offspring of mothers who during pregnancy exhibited behaviors that are associated with increased incidence of breast cancer, may be at risk. These behaviors include intake of high fat diet or alcohol, or stressful life style. We have found that neonatal exposure to handling that leads to improved

Leena Hilakivi-Clarke; Robert Clarke; Marc E. Lippman

1994-01-01

303

Melatonin and Breast Cancer: A Prospective Study  

Microsoft Academic Search

Background: Experimental data from animals suggest a pro- tective role for the pineal hormone melatonin in the etiology of breast cancer, but results from the few retrospective case- control studies that examined the association in hu- mans have been inconsistent. To determine whether low levels of endogenous melatonin are associated with an in- creased risk for developing breast cancer, we

Ruth C. Travis; Diane S. Allen; Ian S. Fentiman; Timothy J. Key

2004-01-01

304

Discovery helps show how breast cancer spreads  

Cancer.gov

Researchers at Washington University School of Medicine in St. Louis (home of the Alvin J. Siteman Cancer Center) have discovered why breast cancer patients with dense breasts are more likely than others to develop aggressive tumors that spread. The finding opens the door to drug treatments that prevent metastasis.

305

Healthy Lifestyle May Boost Breast Cancer Survival  

MedlinePLUS

... page, please enable JavaScript. Healthy Lifestyle May Boost Breast Cancer Survival Proper diet, exercise, weight control among factors ... Preidt Thursday, October 16, 2014 Related MedlinePlus Pages Breast Cancer Healthy Living THURSDAY, Oct. 16, 2014 (HealthDay News) -- ...

306

After Breast Cancer, Depression Risk Lingers  

MedlinePLUS

... features on this page, please enable JavaScript. After Breast Cancer, Depression Risk Lingers Study finds survivors more likely ... 2015) Tuesday, October 28, 2014 Related MedlinePlus Pages Breast Cancer Depression TUESDAY, Oct. 28, 2014 (HealthDay News) -- Women ...

307

Breast Cancer Family Registry (BCFR) Cohort  

Cancer.gov

The Breast Cancer Family Registry (BCFR) Cohort is an international resource of multi-generational families, data, and biospecimens established in 1995 for interdisciplinary collaborative research on the genetic epidemiology of breast cancer. Questionnaire data, clinical data and (when available) biospecimens have been collected for over 30,000 women and men from nearly 12,000 families.

308

Improving Breast Cancer Care for Older Women  

Cancer.gov

Earlier diagnosis, improved treatment, and the overall increase in average lifespan continue to expand the number of breast cancer survivors who are aged 65 and older. This population is already estimated to be one million of the total 2.3 million breast cancer survivors.

309

THE LONG ISLAND BREAST CANCER STUDY (LIBCSP)  

EPA Science Inventory

The NIEHS and the NCI are collaborating on the Long Island Breast Cancer Study Project (LIBCSP), which is designed to conduct epidemiologic research on the role of environmental factors in the etiology of breast cancer in women who live in Nassau and Suffolk counties, New York. T...

310

Predicting Posttraumatic Growth in Breast Cancer Survivors  

Microsoft Academic Search

Wide variability exists with respect to how breast cancer survivors respond to common psychological and psychosocial challenges of their disease, ranging from posttraumatic stress disorder to posttraumatic growth. This cross-sectional study examined contextual, disease-related, and intraindividual predictors of posttraumatic growth in 224 randomly selected breast cancer survivors. A series of hierarchical regression analyses found that age at diagnosis, marital status,

Keith M. Bellizzi; Thomas O. Blank

2006-01-01

311

GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer  

ClinicalTrials.gov

Estrogen Receptor Negative Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Triple Negative Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer

2014-12-15

312

Breast cancer radiotherapy and cardiac risk  

Microsoft Academic Search

Breast cancer is the leading cause of morbidity and mortality in women in the developed world and its incidence in the developing\\u000a world is on the rise. Management of breast cancer requires a multimodality approach and an integration of the services of\\u000a surgery, radiation, and medical oncology. Radiotherapy after mastectomy or breast conservation leads to reduction in local\\u000a recurrence by

Anusheel Munshi; Kaustav Talapatra; Debanarayan Dutta

2010-01-01

313

Vanderbilt study finds more breast cancer patients opting for mastectomy  

Cancer.gov

Far more breast cancer patients are choosing to undergo mastectomy, including removal of both breasts, instead of choosing breast conservation surgery even when they have early stage disease that is confined to one breast, a Vanderbilt study shows.

314

Cancer Detection and Prevention 26 (2002) 192196 Mastalgia and breast cancer: a protective association?  

E-print Network

Cancer Detection and Prevention 26 (2002) 192­196 Mastalgia and breast cancer: a protective to breast cancer risk. We have examined the association between mastalgia and breast cancer in the patient breast cancer risk factor information, 1532 (28%) reported breast pain as an incidental complaint

Apkarian, A. Vania

315

Breast cancer treatment and sexual dysfunction: Moroccan women's perception  

PubMed Central

Background This exploratory prospective study evaluated women's responses to questions that asked them to describe how their body image and sexual functioning had changed since their breast cancer diagnosis to treatment. Methods A questionnaire concerning body image scale and various sexual problems experienced after diagnosis and treatment was anonymously completed by 120 women in the outpatient clinic of our hospital's Division of medical Oncology. To be eligible, subjects had to be sexually active and had histology proven breast cancer. They also had to have received treatment for breast cancer. Results 100% of participants have never spoken with their doctor about this subject. 84% of the participants continued sexual activity after treatment, but there was an increase in the incidence of sexual functioning problems which resulted in a slight reduction in the quality of their sex lives. 65% of the women experienced dyspareunia followed by lubrication difficulties (54%) and the absence or reduction of sexual desire (48% and 64%, respectively) while, 37% had lack of satisfaction (37%). Female orgasmic disorder and brief intercourse and arousal were reported respectively by 40% and 38% of the subjects. The sexual dysfunctions were absent before diagnosis and management of breast cancer in 91.5% subjects and of these 100% subjects complained of a deterioration of the symptomatology after the various treatments. 90% of the dysfunctions were observed after chemotherapy, 9% after surgery and 3% after radiotherapy; none of the subjects indicated the onset of dysfunctions to have been associated with hormonotherapy. 100% expressed not having received sufficient information about how the disease and treatment (including surgery) might affect their sexual life. Conclusion Breast cancer and its treatment may result in significant difficulties with sexual functioning and sexual life. Addressing these problems is essential to improve the quality of life of Moroccan women with breast cancer. PMID:21668971

2011-01-01

316

Breast Density, Hormone Replacement, and Breast Cancer Risk  

Cancer.gov

Research has shown that women age 45 or older who have at least 75 percent dense tissue on a mammogram are at an elevated risk of developing breast cancer. Reasons for this are not completely understood.

317

High frequency of lobular breast cancer in distant metastases to the orbit  

PubMed Central

Metastasis to the periocular soft tissue of the orbit is a rare manifestation of metastatic cancer. Infiltrating lobular breast cancer (ILBC) is a special breast cancer subtype, which accounts for 10–15% of all mammary carcinomas and for ?1% of all malignancies. Here, we report on a high frequency of lobular breast cancer in patients with orbital metastases identified in an original series of metastatic tumor specimens and by a systematic literature review. A series of 14 orbital metastases was compiled from formalin-fixed paraffin-embedded archival tissues. All cases were subjected to histological re-review and detailed immunophenotypical characterization. In addition, we performed a meta-analysis of 68 previously published case reports describing orbital metastases, with special reference to breast cancer subtypes. Based on clinical history, histomorphology, immunophenotype, and/or comparison with matched primary tumors, orbital metastases were derived from breast cancer in 8/14 cases, seven of which were classified as metastatic lobular breast cancer. Other entities included non-small cell lung cancer (4/14), infiltrating ductal breast cancer (1/14), prostate cancer (1/14) and adenocarcinoma of the esophagus (1/14). In line with this original series of orbital metastases, lobular breast cancer was the most common malignancy in 72 patients with orbital metastases described in 68 independent case reports. In conclusion, lobular breast cancer represents the cancer subtype with the highest prevalence among orbital metastases. The high frequency of ILBC in orbital metastases illustrates the special metastatic behavior of this tumor entity and may have implications for the understanding of the organotropism of metastatic lobular breast cancer. PMID:25355547

Raap, Mieke; Antonopoulos, Wiebke; Dämmrich, Maximilian; Christgen, Henriette; Steinmann, Diana; Länger, Florian; Lehmann, Ulrich; Kreipe, Hans; Christgen, Matthias

2015-01-01

318

Diet and breast cancer: a systematic review.  

PubMed

Abstract Breast cancer occurs as a result between genes-diet interactions. Concerning diet, only alcohol is widely recognized for being most consistently associated with breast cancer risk. The purpose of this review is to report through a systematic way the current scientific evidence relating breast cancer and diet, through original-research studies published in English language during the last decade, assessing the consumption of specific foodstuffs/food-nutrients in relation to the disease. The available literature suggests that soy food intake seems to be inversely associated with the disease, while no association seems to be reported for dietary carbohydrates and dietary fiber intake. The consumption of dietary fat, is probably suggestive of an increase in breast cancer risk, while studies evaluating the role of fruit/vegetable, meat as well as dietary patterns and breast cancer risk, provide inconsistent results. Diet seems to be modestly associated with the disease, highlighting the need for more studies to be conducted. PMID:25198160

Mourouti, Niki; Kontogianni, Meropi D; Papavagelis, Christos; Panagiotakos, Demosthenes B

2015-02-01

319

Lymphedema: What Every Woman with Breast Cancer Should Know  

MedlinePLUS

... saved articles window. My Saved Articles » My ACS » Lymphedema: What Every Woman With Breast Cancer Should Know ... for breast cancer may be at risk for lymphedema in the arm, breast, and chest. Here we ...

320

The genetics of breast and ovarian cancer.  

PubMed Central

A number of genes are known to be involved in inherited susceptibility to breast and/or ovarian cancer. In the context of high-risk families the most important genes are BRCA1 on chromosome 17q, which is associated with a high penetrance of both breast and ovarian cancer, and BRCA2 on chromosome 13q, which causes a high risk of breast cancer but a lower risk of ovarian cancer. Other high-risk cancer genes that confer increased risks of breast or ovarian cancer in addition to other cancers include the hereditary non-polyposis colorectal cancer genes and the TP53 gene, which causes breast cancer as part of the Li-Fraumeni syndrome. The predisposing mutations in these genes are relatively rare in the population. More common genes which are associated with an increased, but lower, risk of breast cancer are the ataxiatelangiectasia gene and the HRAS1 gene. This paper reviews recent progress in mapping and cloning of these susceptibility genes, and provides estimates of the cancer risks associated with each gene and the frequency of predisposing mutations. PMID:7547224

Ford, D.; Easton, D. F.

1995-01-01

321

Breast Cancer Research at NASA  

NASA Technical Reports Server (NTRS)

Epithelial cell monoculture: Long-term growth of human mammary epithelial cells (HMEC) grown in monoculture as 3-dimensional constructions in the presence of attachment beads in the NASA Bioreactor. A: A typical construct about 3.5 mm (less than 1/8th inch) in diameter with slightly dehydrted, crinkled beads contained on the surface as well as within the 3-dimensional structure. B: The center of these constructs is hollow. Crinkling of the beads causes a few to fall out, leaving crater-like impressiions in the construct. The central impression shows a small hole that accesses the hollow center of the construct. C: A closeup view of the cells and the hole the central impression. D: Closer views of cells in the construct showing sell-to-cell interactions. NASA's Marshall Space Flight Center (MSFC) is sponsoring research with Bioreactors, rotating wall vessels designed to grow tissue samples in space, to understand how breast cancer works. This ground-based work studies the growth and assembly of human mammary epithelial cell (HMEC) from breast cancer susceptible tissue. Radiation can make the cells cancerous, thus allowing better comparisons of healthy vs. tunorous tissue. Credit: Dr. Robert Richmond, NASA/Marshall Space Flight Center (MSFC).

1998-01-01

322

Breast cancer detection using automated whole breast ultrasound and mammography in radiographically dense breasts  

Microsoft Academic Search

Purpose  Mammography, the standard method of breast cancer screening, misses many cancers, especially in dense-breasted women. We compared\\u000a the performance and diagnostic yield of mammography alone versus an automated whole breast ultrasound (AWBU) plus mammography\\u000a in women with dense breasts and\\/or at elevated risk of breast cancer.\\u000a \\u000a \\u000a \\u000a \\u000a Methods  AWBU screening was tested in 4,419 women having routine mammography (Trial Registration: ClinicalTrials.gov Identifier:

Kevin M. Kelly; Judy Dean; W. Scott Comulada; Sung-Jae Lee

2010-01-01

323

Breast magnetic resonance imaging  

Microsoft Academic Search

Breast MRI is becoming an important tool for the improved management of breast cancer. The technical attributes of high contrast, high-resolution breast MRI acquisitions are summarized. The fundamentals of image interpretation are outlined, including lesion enhancement, morphological features, and extent categories. The indications for breast MRI include compromised mammography, staging of disease within the breast and adjacent structures, difficult histology,

Steven E Harms

1998-01-01

324

Optical transillumination spectroscopy of breast tissue for cancer risk assessment  

Microsoft Academic Search

Breast cancer is the most commonly occurring cancer in women. The lifetime risk of being diagnosed with breast cancer is approximately 1 in 10 thereby the highest out of all cancers. Breast cancer screening programs have been shown to decrease the mortality rates of women between ages 50-69, since cancers are detected at an earlier, more favourable stage. It is

Lothar Lilge; Kristina Blyschak; Michelle Simick; Roberta A. Jong

2003-01-01

325

Genomic Prediction of Locoregional Recurrence After Mastectomy in Breast Cancer  

E-print Network

Genomic Prediction of Locoregional Recurrence After Mastectomy in Breast Cancer Skye H. Cheng) recurrence in breast cancer after mastectomy. Patients and Methods A total of 94 breast cancer patients who Using gene expression profiles to develop prediction tree models effectively identifies breast cancer

West, Mike

326

Breast Cancer Research and ISSN 0167-6806  

E-print Network

1 23 Breast Cancer Research and Treatment ISSN 0167-6806 Breast Cancer Res Treat DOI 10.1007/s10549-012-2266-3 Cognitive function and breast cancer: promise and potential insights from functional brain imaging Patricia function and breast cancer: promise and potential insights from functional brain imaging Patricia A. Reuter

327

Advanced Breast Cancer ER+ HER2+ Triple Negative  

E-print Network

Legend Advanced Breast Cancer ER+ HER2+ Triple Negative Brain Metastases / Leptomeningeal dz Non in HER2 Positive Breast Cancer 127511 - Neratinib for HER2 positive Breast Cancer and Brain Metastases 117526 - Immunotherapy with Globo H-KLH (OPT-822) for Metastatic Breast Cancer No Interventional Clinical

Walter, Peter

328

Estrogen receptor prevents p53-dependent apoptosis in breast cancer  

E-print Network

Estrogen receptor prevents p53-dependent apoptosis in breast cancer Shannon T. Baileya,b,c,1) More than two-thirds of breast cancers express the estrogen receptor (ER) and depend on estrogen in the treatment of ER+ breast cancers of all stages. In contrast to ER- breast cancers, which frequently harbor

Liu, Xiaole Shirley

329

The efficacy of surgical treatment of breast cancer  

Microsoft Academic Search

The purpose of the analysis was to resolve the two opposing claims regarding the efficacy of surgical treatment of breast cancer, namely the course of the disease is not affected by surgery because breast cancer is an incurable systemic disease, as shown by a previous analysis, results of randomized breast cancer treatment trials and long-term follow-up of breast cancer patients;

D. J. Benjamin

1996-01-01

330

Breast cancer rates in populations of single women  

Microsoft Academic Search

The well known associations of breast cancer with fertility patterns and diet are interdependent and it is difficult to estimate the extent to which breast cancer is related to diet. This was attempted by analysing breast cancer rates in populations of single (never married) women for which the contribution of childbearing would be small. Age specific breast cancer rates for

G Hems; A Stuart

1975-01-01

331

The HERS Breast Cancer Foundation supports all women healing from breast  

E-print Network

The HERS Breast Cancer Foundation supports all women healing from breast cancer by providing postFoundation.org We are the only non-profit breast cancer organization to hope Bras for Body & Soul® The program. The program provides a private, understanding environment for breast cancer survivors to be properly fitted

Bejerano, Gill

332

Contact Details Journeying Beyond Breast Cancer  

E-print Network

Home About Contact Details Facebook Search Journeying Beyond Breast Cancer making sense of the cancer experience Feeds: Posts Comments Cancer-fighting fountain pen May 20, 2009 by JBBC A research team be used both as a research tool in the development of next-generation cancer treatments

Espinosa, Horacio D.

333

Bisphosphonate Use After Estrogen Receptor–Positive Breast Cancer and Risk of Contralateral Breast Cancer  

PubMed Central

Background A growing body of evidence suggests that nitrogenous bisphosphonates may reduce the risk of developing a first breast cancer and may prevent metastases among breast cancer survivors. However, their impact on risk of second primary contralateral breast cancer is uncertain. Methods Within a nested case–control study among women diagnosed with a first primary estrogen receptor–positive invasive breast cancer at ages 40–79 years, we assessed the association between post-diagnostic bisphosphonate use and risk of second primary contralateral breast cancer. We used multivariable-adjusted conditional logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) comparing 351 contralateral breast cancer case subjects with 662 control subjects (ie, breast cancer patients not diagnosed with contralateral breast cancer) who were incidence density–matched on county; race/ethnicity; and age at, year of, and stage at first breast cancer diagnosis. We performed sensitivity analyses with respect to bisphosphonate type and confounding by indication. All statistical tests were two-sided. Results Current use of any nitrogenous bisphosphonate and use specifically of alendronate were both associated with reduced risks of contralateral breast cancer compared with never use (OR = 0.41, 95% CI = 0.20 to 0.84 and OR = 0.39, 95% CI = 0.18 to 0.88, respectively). The risk of contralateral breast cancer further declined with longer durations of bisphosphonate use among current users (Ptrend = .03). Results were similar in analyses restricted to patients with a history of osteoporosis or osteopenia. Conclusions Bisphosphonate use was associated with a substantial reduction in risk of contralateral breast cancer. If this finding is confirmed in additional studies, nitrogenous bisphosphonate therapy may be a feasible approach for contralateral breast cancer risk reduction. PMID:22021667

Malone, Kathleen E.; Tang, Mei-Tzu C.; Newcomb, Polly A.

2011-01-01

334

Characteristics of BRCA1/2 Mutation-Positive Breast Cancers in Korea: A Comparison Study Based on Multicenter Data and the Korean Breast Cancer Registry  

PubMed Central

Purpose Mutations in BRCA genes are the main cause of hereditary breast cancer in Korea. The aim of this study was to investigate the characteristics of breast cancers involving BRCA1 (BRCA1 group) and BRCA2 (BRCA2 group) mutations. Methods We retrospectively reviewed the medical records of patients with BRCA1 (BRCA1 group) or BRCA2 (BRCA2 group) mutation positive breast cancer from multiple centers and compared the data to that of the Korean Breast Cancer Society registry (registry group). Results The patients of the BRCA1 group were diagnosed at a younger age (median age, 37 years) and had tumors of higher histological (61.3% with histological grade 3) and nuclear (37.5% with nuclear grade 3) grade than those of the registry group. In addition, the frequency of ductal carcinoma in situ in the BRCA1 group was lower (3.7%) than in the registry group, and the BRCA1 group were more likely to be triple-negative breast cancer (61.3%). Patients in the BRCA2 group were also younger at diagnosis (mean age, 41 years) and were more likely to have involvement of the axillary node than the registry group (45.5% vs. 33.5%, p=0.002). The BRCA1 and BRCA2 groups did not show a correlation between tumor size and axillary node involvement. Conclusion We report the characteristics of BRCA mutation positive breast cancer patients in the Korean population through multicenter data and nation-wide breast cancer registry study. However, BRCA-mutated breast cancers appear highly complex, and further research on their molecular basis is needed in Korea. PMID:25013433

Yu, Jong-Han; Son, Byung Ho; Kim, Sung-Won; Park, Sue K.; Lee, Min Hyuk; Kim, Lee Su; Noh, Woo-Chul; Kim, Eun-Kyu; Yoon, Dae Sung; Lee, Jeeyeon; Jung, Jin Hyang; Jung, Sang Seol; Gong, Gyungyup; Ahn, Sei-Hyun

2014-01-01

335

Do Women with Breast Cancer Overestimate Their Risk for Cancer in the Unaffected Breast?  

MedlinePLUS

... the Unaffected Breast? The full report is titled “Perceptions, Knowledge, and Satisfaction With Contralateral Prophylactic Mastectomy Among ... included questions related to decision making, knowledge, risk perception, and breast cancer worry. What did the researchers ...

336

Esophageal cancer as second primary tumor after breast cancer radiotherapy  

Microsoft Academic Search

Background: An increased risk of esophageal cancer has been reported in survivors of breast cancer treated with radiotherapy. This study further characterizes this association.Methods: Through hospital databases, 118 patients (109 men, 9 women) treated for esophageal cancer between 1985 and 1993 were identified, of whom 37 had 60 synchronous or metachronous cancers. 5 women had primary esophageal cancer after having

Beatrix Scholl; Ernane D Reis; Abderrahim Zouhair; Igor Chereshnev; Jean-Claude Givel; Michel Gillet

2001-01-01

337

PET-CT in Breast Cancer  

Microsoft Academic Search

\\u000a Breast cancer is the most frequently diagnosed malignancy and the second leading cause of cancer death in women. Approximately\\u000a one in nine women will suffer from breast cancer during her lifetime, and there are almost 40,000 women per year dying of\\u000a this disease in the USA as reported by Eubank and Mankoff (Semin Nucl Med 35(2):84–99, 2005). The incidence of

Mehmet S. Erturk; Rick Tetrault; Annick D. Van den Abbeele

338

Estimation of volumetric breast density for breast cancer risk prediction  

NASA Astrophysics Data System (ADS)

Mammographic density (MD) has been shown to be a strong risk predictor for breast cancer. Compared to subjective assessment by a radiologist, computer-aided analysis of digitized mammograms provides a quantitative and more reproducible method for assessing breast density. However, the current methods of estimating breast density based on the area of bright signal in a mammogram do not reflect the true, volumetric quantity of dense tissue in the breast. A computerized method to estimate the amount of radiographically dense tissue in the overall volume of the breast has been developed to provide an automatic, user-independent tool for breast cancer risk assessment. The procedure for volumetric density estimation consists of first correcting the image for inhomogeneity, then performing a volume density calculation. First, optical sensitometry is used to convert all images to the logarithm of relative exposure (LRE), in order to simplify the image correction operations. The field non-uniformity correction, which takes into account heel effect, inverse square law, path obliquity and intrinsic field and grid non- uniformity is obtained by imaging a spherical section PMMA phantom. The processed LRE image of the phantom is then used as a correction offset for actual mammograms. From information about the thickness and placement of the breast, as well as the parameters of a breast-like calibration step wedge placed in the mammogram, MD of the breast is calculated. Post processing and a simple calibration phantom enable user- independent, reliable and repeatable volumetric estimation of density in breast-equivalent phantoms. Initial results obtained on known density phantoms show the estimation to vary less than 5% in MD from the actual value. This can be compared to estimated mammographic density differences of 30% between the true and non-corrected values. Since a more simplistic breast density measurement based on the projected area has been shown to be a strong indicator of breast cancer risk (RR equals 4), it is believed that the current volumetric technique will provide an even better indicator. Such an indicator can be used in determination of the method and frequency of breast cancer screening, and might prove useful in measuring the effect of intervention measures such as drug therapy or dietary change on breast cancer risk.

Pawluczyk, Olga; Yaffe, Martin J.; Boyd, Norman F.; Jong, Roberta A.

2000-04-01

339

Radioimmunodetection and therapy of breast cancer.  

PubMed

Breast cancer is the second most-common cause of cancer death in women in the United States. Although more than 60% of patients can now be cured by initial treatment, the rest, although perhaps receiving palliation with currently available therapy, will die of their disease. Early detection of micrometastasis and improved treatment strategies are needed. Monoclonal antibody (mAb)-based imaging and tumor targeted therapy holds the potential to impact these problems. The most significant results of systemically administered antibody-based radiopharmaceuticals for detection and targeted therapy (radioimmunotherapy [RIT]) of breast cancer give strong evidence that this potential can be realized. Interest in immunoimaging recently has focused on small mAb modules used with 18F, 64Cu, or 124I to detect minimal disease in breast cancer by positron emission tomography or single-photon emission computed tomography. Reported therapy trials in advanced breast cancer have yielded objective responses and minimal toxicity. These studies have spanned several radionuclides as well as several mAb, fragments and approaches, including dose intensification with bone marrow support; combined therapy with other modalities (ie, CM-RIT); biodegradable peptide linkers; and pretargeting. RIT evaluated in clinical breast cancer trials has delivered as much as 4000 cGy to metastatic breast cancer per therapy dose with marrow stem cell support. Preclinical studies have demonstrated further promising strategies for breast cancer. RIT studies must address the key issue: enhancing the therapeutic index (tumor effect verses most sensitive normal tissue (bone marrow) effect). Approaches now include newly engineered mAb, scFv modular constructs, blood clearance on demand, enhanced pretargeting, applications of both alpha and beta emitting radionuclides, and combination therapy using molecular triggers for therapeutic synergy. These strategies for detection and treatment of metastatic breast cancer should lead to notable clinical impact on management and cure of breast cancer. PMID:15765377

DeNardo, Sally J

2005-04-01

340

Many Breast Cancer Patients Lack Info on Their Cancer  

MedlinePLUS

... News) -- Many women with breast cancer lack basic knowledge about their disease, such as their cancer stage ... according to a new study. The lack of knowledge was even more pronounced among minority women, the ...

341

The Adjacent Vessel Sign on Breast MRI: New Data and a Subgroup Analysis for 1,084 Histologically Verified Cases  

PubMed Central

Objective The adjacent vessel sign (AVS) is a descriptor for differentiating malignant from benign breast lesions on breast MRI (bMRI). This investigation was designed to verify the previous reports on the diagnostic accuracy of AVS and to assess correlation between AVS, histopathological diagnosis, lesion size and lesion grade. Materials and Methods This study was approved by the local ethical committee. Experienced radiologists evaluated 1,084 lesions. The exclusion criteria were no histological verification after bMRI and breast interventions that were done up to one year before bMRI (surgery, core biopsy, chemo- or radiation therapy). The native and dynamic contrast-enhanced T1-weighted series were acquired using standardized protocols. The AVS was rated positive if a vessel leading to a lesion could be visualized. Prevalence of an AVS was correlated with the lesions' size, grade and histology using Chi-square-tests. Results The AVS was significantly associated with malignancy (p < 0.001; sensitivity: 47%, specificity: 88%, positive-predictive-value [PPV]: 85%). Malignant lesions > 2 cm more often presented with an AVS than did those malignant lesions < 2 cm (p < 0.0001; sensitivity: 65%, PPV: 90%). There was no correlation of the AVS with the tumor grade. The prevalence of an AVS didn't significantly differ between invasive lobular carcinomas versus ductal carcinomas. In situ cancers were less frequently associated with an AVS (p < 0.001). Conclusion The adjacent vessel sign was significantly associated with malignancy. Thus, it can be used to accurately assess breast lesions on bMRI. In this study, the AVS was particularly associated with advanced and invasive carcinomas. PMID:20191065

Baltzer, Pascal A.T.; Vag, Tibor; Herzog, Aimee; Gajda, Mieczyslaw; Camara, Oumar; Kaiser, Werner A.

2010-01-01

342

Metachronous Double Primary Cancer after Treatment of Breast Cancer  

PubMed Central

Purpose The pattern of double primary cancer after treatment for breast cancer is important for patient survival. Materials and Methods We analyzed 108 cases of metachronous double primary cancer in breast cancer patients treated from 1999 to 2012. Results Metachronous double primary cancers occurred in 108 of 2,657 patients (4.1%) with breast cancer. The median time to the occurrence of second cancer after diagnosis of the first was 58.4±41.2 months (range, 6.9 to 180.2 months). The most common cancer was thyroid cancer, which occurred in 45 patients (41.7%). This was followed by gastric cancer in 16 patients (14.8%), endometrial cancer in 10 patients (9.3%), and cervical cancer in seven patients (6.5%). The relative risk showed a significant increase in endometrial (4.78; 95% confidence interval [CI], 1.66 to 13.79), gastric (2.61; 95% CI, 1.68 to 4.06), and thyroid cancer (1.95; 95% CI, 1.37 to 2.79). At 5 years after diagnosis of breast cancer, secondary cancer occurred in 48 patients (44.4%), with 50.0% of the endometrial, 56.3% of the stomach, and 37.8% of the thyroid cancer cases being diagnosed after 5 years. Median survival after diagnosis of the second cancer was 123.9±11.2 months. The prognosis was mainly influenced by the anatomic site. Conclusion The incidence of endometrial, stomach, and thyroid cancer increased significantly after treatment with primary breast cancer, and survival was dependent on early detection and the type of second primary cancer. A prolonged follow-up examination for metachronous double primary cancer is needed to provide early detection and improve survival time in patients with breast cancer. PMID:25544582

Kim, Jin Young; Song, Hong Suk

2015-01-01

343

Main controversies in breast cancer  

PubMed Central

In this article, we have reviewed available evidence for diagnosis, treatment, and follow-up in female breast cancer (BC). Into daily clinical practice some controversies are occurred. Especially, in the diagnosis field, despite the fact that the optimal age in which screening mammography should start is a subject of intense controversy, there is a shift toward the beginning at the age of 40 although it is suggested that the net benefit is small for women aged 40 to 49 years. In addition, a promising tool in BC screening seems to be breast tomosynthesis. Other tools such as 3D ultrasound and shear wave elastography (SWE) are full of optimism in BC screening although ultrasonography is not yet a first-line screening method and there is insufficient evidence to recommend the systemic use of the SWE for BC screening. As for breast magnetic resonance imaging (MRI), even if it is useful in BC detection in women who have a strong family history of BC, it is not generally recommended as a screening tool. Moreover, based on the lack of randomized clinical trials showing a benefit of presurgical breast MRI in overall survival, it’s integration into breast surgical operations remains debatable. Interestingly, in contrast to fine needle aspiration, core biopsy has gained popularity in presurgical diagnosis. Furthermore, after conservative surgery in patients with positive sentinel lymph nodes, the recent tendency is the shift from axillary dissection to axillary conserving strategies. While the accuracy of sentinel lymph node after neoadjuvant chemotherapy and second BC surgery remains controversial, more time is needed for evaluation and for determining the optimal interval between the two surgeries. Additionally, in the decision between immediate or delayed breast reconstruction, there is a tendency in the immediate use. In the prevention of BC, the controversial issue between tamoxifen and raloxifene becomes clear with raloxifene be more profitable through the toxicities of tamoxifen. However, the prevention of bone metastasis with bisphosphonates is still conflicting. Last but not least, in the follow-up of BC survivors, mammography, history and physical examination are the means of an early detection of BC recurrence. ed. PMID:25114851

Zervoudis, Stephane; Iatrakis, George; Tomara, Eirini; Bothou, Anastasia; Papadopoulos, George; Tsakiris, George

2014-01-01

344

Main controversies in breast cancer.  

PubMed

In this article, we have reviewed available evidence for diagnosis, treatment, and follow-up in female breast cancer (BC). Into daily clinical practice some controversies are occurred. Especially, in the diagnosis field, despite the fact that the optimal age in which screening mammography should start is a subject of intense controversy, there is a shift toward the beginning at the age of 40 although it is suggested that the net benefit is small for women aged 40 to 49 years. In addition, a promising tool in BC screening seems to be breast tomosynthesis. Other tools such as 3D ultrasound and shear wave elastography (SWE) are full of optimism in BC screening although ultrasonography is not yet a first-line screening method and there is insufficient evidence to recommend the systemic use of the SWE for BC screening. As for breast magnetic resonance imaging (MRI), even if it is useful in BC detection in women who have a strong family history of BC, it is not generally recommended as a screening tool. Moreover, based on the lack of randomized clinical trials showing a benefit of presurgical breast MRI in overall survival, it's integration into breast surgical operations remains debatable. Interestingly, in contrast to fine needle aspiration, core biopsy has gained popularity in presurgical diagnosis. Furthermore, after conservative surgery in patients with positive sentinel lymph nodes, the recent tendency is the shift from axillary dissection to axillary conserving strategies. While the accuracy of sentinel lymph node after neoadjuvant chemotherapy and second BC surgery remains controversial, more time is needed for evaluation and for determining the optimal interval between the two surgeries. Additionally, in the decision between immediate or delayed breast reconstruction, there is a tendency in the immediate use. In the prevention of BC, the controversial issue between tamoxifen and raloxifene becomes clear with raloxifene be more profitable through the toxicities of tamoxifen. However, the prevention of bone metastasis with bisphosphonates is still conflicting. Last but not least, in the follow-up of BC survivors, mammography, history and physical examination are the means of an early detection of BC recurrence. ed. PMID:25114851

Zervoudis, Stephane; Iatrakis, George; Tomara, Eirini; Bothou, Anastasia; Papadopoulos, George; Tsakiris, George

2014-08-10

345

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer  

ClinicalTrials.gov

Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer

2015-02-05

346

Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast cancer.  

PubMed

The prognosis of BRCA1/2-associated breast cancer partly depends on histologic characteristics. Most of these breast cancers, however, are poorly differentiated. BRCA1-associated cancers are mainly negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. Consequently, the use of these histologic features for risk stratification in BRCA1/2 breast cancer is limited. We assessed the prognostic value of additional histologic features, including tumor-associated inflammation and tumor-associated stroma in BRCA1/2 breast cancer patients. From the Rotterdam Family Cancer Clinic database, we collected demographics, tumor characteristics, and follow-up data from female BRCA1/2 breast cancer patients. Tumor samples were centrally reviewed including histologic subtype, differentiation grade, tumor-associated inflammation density, amount of tumor-associated stroma, and intratumor necrosis. The impact of these factors on recurrence-free survival (RFS) was evaluated using univariate and multivariate Cox regression, adjusted for established prognostic features and year of diagnosis. We included 138 BRCA1 and 37 BRCA2 breast cancer patients. Median follow-up after diagnosis was 9.7 years. Independent prognostic factors for RFS were tumor size (hazard ratio [HR], 2.47 for >2 versus ?2 cm; 95% confidence interval [95% CI], 1.10-5.57), tumor-associated inflammation (HR, 0.18 for moderate/marked versus absent/mild; 95% CI, 0.05-0.61), and intratumor necrosis (HR, 2.60 for presence versus absence; 95% CI, 1.12-6.05). Established prognostic factors as nodal status and differentiation grade were not significantly related to RFS. Subgroup analyses of 138 BRCA1 and 118 triple-negative breast cancer cases showed similar results. Tumor-associated inflammation density was the strongest predictor for RFS in this series of BRCA1/2 breast cancer patients. This provides a potential risk stratification tool that can easily be implemented in routine histologic examination. PMID:25522926

van Verschuer, Victorien M T; Hooning, Maartje J; van Baare-Georgieva, Radka D; Hollestelle, Antoinette; Timmermans, Anne M; Koppert, Linetta B; Verhoog, Leon C; Martens, John W M; Seynaeve, Caroline; van Deurzen, Carolien H M

2015-02-01

347

Image-Based Histologic Grade Estimation Using Stochastic Geometry Analysis  

E-print Network

Image-Based Histologic Grade Estimation Using Stochastic Geometry Analysis Sokol Petushia Jasper of histologic grading of breast carcinoma due to its subjectivity has tradi- tionally diminished the prognostic value of histologic breast cancer grading. The objective of this study is to assess the effectiveness

Breen, David E.

348

Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7  

Microsoft Academic Search

Cancer histology influences the risk of venous thromboembolism and tissue factor (TF) is the key molecule in cancer-induced hypercoagulability. We investigated the relation between TF expression by pancreatic and breast cancer cells (BXPC3 and MCF7 respectively) and their capacity to trigger in vitro thrombin generation in normal human plasma. Flow cytometry and Western blot analysis for TF expression were performed

Grigoris T. Gerotziafas; Vassiliki Galea; Elisabeth Mbemba; Amir Kartechi; Mouna Sassi; Hela Baccouche; Claudie Prengel; Patrick van Dreden; Mohamed Hatmi; Jean François Bernaudin; Ismail Elalamy

349

Breast Cancer: Surgery at the South Egypt Cancer Institute  

PubMed Central

Breast cancer is the most frequent malignant tumor in women worldwide. In Egypt, it is the most common cancer among women, representing 18.9% of total cancer cases (35.1% in women and 2.2% in men) among the Egypt National Cancer Institute’s (NCI) series of 10,556 patients during the year 2001, with an age-adjusted rate of 49.6 per 100,000 people. In this study, the data of all breast cancer patients presented to the surgical department of the South Egypt cancer Institute (SECI) hospital during the period from Janurary 2001 to December 2008 were reviewed .We report the progress of the availability of breast cancer management and evaluation of the quality of care delivered to breast cancer patients. The total number of patients with a breast lump presented to the SECI during the study period was 1,463 patients (32 males and 1431 females); 616 patients from the total number were admitted at the surgical department .There was a decline in advanced cases. Since 2001, facilities for all lines of comprehensive management have been made accessible for all patients. We found that better management could lead to earlier presentation, and better overall outcome in breast cancer patients.The incidence is steadily increasing with a tendency for breast cancer to occur in younger age groups and with advanced stages. PMID:24281200

Salem, Ahmed A.S.; Salem, Mohamed Abou Elmagd; Abbass, Hamza

2010-01-01

350

Exercise Interventions in Breast Cancer Survivors - Office of Cancer Survivorship  

Cancer.gov

Earlier studies have shown that women who are overweight at the time of breast cancer diagnosis are twice as likely to experience recurrence and death as lighter women. Additionally, women who gained weight (approximately 5 lbs.) after breast cancer diagnosis had a 60-percent increased risk of death compared to women who did not gain weight.

351

Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk  

Microsoft Academic Search

Triple-negative breast cancer accounts for less than 20% of breast cancers overall, but is the predominant subtype among carriers\\u000a of mutations in BRCA1. However, few studies have assessed the association between breast cancer family history and risk of triple-negative breast\\u000a cancer. We examined the relationship between having a family history of breast cancer in first-degree relatives and risk of\\u000a triple-negative

Amanda I. PhippsDiana; Diana S. M. Buist; Kathleen E. Malone; William E. Barlow; Peggy L. Porter; Karla Kerlikowske; Christopher I. Li

2011-01-01

352

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer  

ClinicalTrials.gov

Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Male Breast Cancer; Progesterone Receptor-negative Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer

2014-06-09

353

The etiology of alcohol-induced breast cancer  

Microsoft Academic Search

Breast cancer is the most common cancer in women in the United States, and it is second among cancer deaths in women. Results of most epidemiologic studies, as well as of most experimental studies in animals, have shown that alcohol intake is associated with increased breast cancer risk. Alcohol consumption may cause breast cancer through different mechanisms, including through mutagenesis

Ramona G. Dumitrescu; Peter G. Shields

2005-01-01

354

Antidepressant use and breast cancer risk  

Microsoft Academic Search

Summary\\u000a Background  Antidepressants are among the most commonly prescribed drugs in the United States. Laboratory studies suggest that because\\u000a certain antidepressants increase prolactin levels that they may also increase breast cancer risk. However, human studies evaluating\\u000a use of antidepressants in relation to breast cancer risk have yielded inconsistent results.\\u000a \\u000a \\u000a \\u000a Methods  A population-based case-control study consisting of 975 breast cancer cases 65–79 years of

Chloe Chien; Christopher I. Li; Susan R. Heckbert; Kathleen E. Malone; Denise M. Boudreau; Janet R. Daling

2006-01-01

355

Clinicopathological Characteristics of Triple-negative Breast Cancers in the Northeast Region of Turkey  

PubMed Central

Background: Triple-negative (TN) breast cancer is a subtype of breast cancer characterised by a loss of estrogen receptor (ER), progesterone receptor (PR) expression, and the absence of human epidermal growth factor (HER2) overexpression. Aims: To identify the relationships between clinicopathological characteristics of TN breast cancers in the northeast region of Turkey and disease free survival (DFS) and overall survival (OS). Study Design: Retrospective clinical study. Methods: Seven hundred and eighty non-metastatic breast cancer patients were enrolled in this study. The relationships between TN breast cancer and other breast cancers with respect to clinicopathological characteristics, as well as DFS and OS, were studied. Results: The triple-negative phenotype was detected in 204 patients (27.1%). Patients with triple-negative breast cancer had more grade 2–3 tumours compared to those with other types of breast cancer (92.5% versus 84.3%, p=0.004). Invasive ductal carcinoma histology, on the other hand, was less prevalent in patients with TN breast cancer (77% versus 84.5%, p=0.016). No significant differences were identified between the groups in other clinicopathological variables. Relapse and mortality rates were higher in the TN group during the follow-up of both groups [57 (27.9%) versus 89 (16.2%), p<0.001 for relapse; 27 (13.2%) versus 37 (6.8%), p=0.005 for mortality]. The univariate analysis demonstrated shorter DFS and OS for patients with TN breast cancer compared to those with other types of breast cancer. In the multivariate analysis, patients with TN breast cancer were 2.21 times more likely to develop relapse, while the likelihood of death increased 3.21-fold (p<0.001 and p<0.001). Conclusion: Triple-negative breast cancers demonstrate a more aggressive clinical course compared to other breast cancers. More effective strategies should be developed for the treatment of this subgroup of breast cancer. PMID:25207183

Y?ld?z, Bülent; Fidan, Evren; Özdemir, Feyyaz; Sezen, Orhan; Kavgac?, Halil; Ayd?n, Faz?l

2014-01-01

356

Investigation of systemic folate status, impact of alcohol intake and levels of DNA damage in mononuclear cells of breast cancer patients  

Microsoft Academic Search

Folate is required for DNA synthesis, repair and methylation. Low folate status has been implicated in carcinogenesis, possibly as a result of higher rate of genetic damage. The aim of this study is to compare folate status and levels of DNA damage between breast cancer and benign breast disease control patients. Fasting blood samples from 64 histologically confirmed untreated breast

M M I Hussien; H McNulty; N Armstrong; P G Johnston; R A J Spence; Y Barnett; MMI Hussien

2005-01-01

357

Histological Analysis of ?? T Lymphocytes Infiltrating Human Triple-Negative Breast Carcinomas  

PubMed Central

Breast cancer is the leading cause of cancer death in women and the second most common cancer worldwide after lung cancer. The remarkable heterogeneity of breast cancers influences numerous diagnostic, therapeutic, and prognostic factors. Triple-negative breast carcinomas (TNBCs) lack expression of HER2 and the estrogen and progesterone receptors and often contain lymphocytic infiltrates. Most of TNBCs are invasive ductal carcinomas (IDCs) with poor prognosis, whereas prognostically more favorable subtypes such as medullary breast carcinomas (MBCs) are somewhat less frequent. Infiltrating T-cells have been associated with an improved clinical outcome in TNBCs. The prognostic role of ?? T-cells within CD3+ tumor-infiltrating T lymphocytes remains unclear. We analyzed 26 TNBCs, 14 IDCs, and 12 MBCs, using immunohistochemistry for the quantity and patterns of ?? T-cell infiltrates within the tumor microenvironment. In both types of TNBCs, we found higher numbers of ?? T-cells in comparison with normal breast tissues and fibroadenomas. The numbers of infiltrating ?? T-cells were higher in MBCs than in IDCs. ?? T-cells in MBCs were frequently located in direct contact with tumor cells, within the tumor and at its invasive border. In contrast, most ?? T-cells in IDCs were found in clusters within the tumor stroma. These findings could be associated with the fact that the patient’s prognosis in MBCs is better than that in IDCs. Further studies to characterize these ?? T-cells at the molecular and functional level are in progress. PMID:25540645

Hidalgo, Jose Villacorta; Bronsert, Peter; Orlowska-Volk, Marzenna; Díaz, Liliana B.; Stickeler, Elmar; Werner, Martin; Schmitt-Graeff, Annette; Kayser, Gian; Malkovsky, Miroslav; Fisch, Paul

2014-01-01

358

Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Receiving Paclitaxel  

ClinicalTrials.gov

Chemotherapeutic Agent Toxicity; Pain; Peripheral Neuropathy; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Therapy-related Toxicity

2015-02-06

359

Breast cancer survivors and vitamin D: A review  

Microsoft Academic Search

Recent evidence has suggested a role for vitamin D in breast cancer prevention and survival. Studies have reported an inverse relation between vitamin D intake and the risk of breast cancer, improvements in survival after a diagnosis of breast cancer in women with higher levels of vitamin D, and vitamin D insufficiency in up to 75% of women with breast

Stephanie L. Hines; H. Keels S. Jorn; Kristine M. Thompson; Jan M. Larson

2010-01-01

360

Bilateral breast cancer after cured Hodgkin's disease  

Microsoft Academic Search

Three patients developed bilateral breast cancer at 10 to 24 years after mantle irradiation for locally or systemically advanced Hodgkin's disease (HD). Four of the six cancers in the three patients were detected only by mammography. Pathologically, five of the cancers were intraductal carcinomas (four with an invasive component) with one being a lobular carcinoma. Five of the six lesions

Norwood Anderson; Jacob Lokich

1990-01-01

361

Elusive extranuclear estrogen receptors in breast cancer.  

PubMed

Estrogen receptors at the plasma membrane and cytoplasm have been difficult to detect in breast cancer specimens. New imaging approaches are needed to determine the percentage of cancers expressing extranuclear estrogen receptors and their impact on cancer biology and treatment. PMID:22215901

Levin, Ellis R

2012-01-01

362

[Histological and cytopathological cancer specimens: good practice in operating room].  

PubMed

Concerning good practice for the management of histological cancer specimen, the main recommendations concern: (1) the quality of transmission in information between professionals; (2) the necessity of fresh, unfractionated, oriented surgical samples; (3) the importance of an appropriate storage condition for samples collected for extemporaneous examination, freezing or cell culture; (4) the quality of the deep freezer at temperatures of -80 degrees C or liquid nitrogen for frozen samples storage; (5) the importance of fixing tissues shortly after sample collection in buffered Formal solution in order to prevent cell lysis. PMID:14659622

Benoit, L; Favoulet, P; Collin, F; Arnould, L; Fraisse, J; Cuisenier, J

2003-11-01

363

New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers  

PubMed Central

Breast cancer is the most frequent female malignancy worldwide. Current strategies in breast cancer therapy, including classical chemotherapy, hormone therapy, and targeted therapies, are usually associated with chemoresistance and serious adverse effects. Advances in our understanding of changes affecting the interactome in advanced and chemoresistant breast tumors have provided novel therapeutic targets, including, cyclin dependent kinases, mammalian target of rapamycin, Notch, Wnt and Shh. Inhibitors of these molecules recently entered clinical trials in mono- and combination therapy in metastatic and chemo-resistant breast cancers. Anticancer epigenetic drugs, mainly histone deacetylase inhibitors and DNA methyltransferase inhibitors, also entered clinical trials. Because of the complexity and heterogeneity of breast cancer, the future in therapy lies in the application of individualized tailored regimens. Emerging therapeutic targets and the implications for personalized-based therapy development in breast cancer are herein discussed. PMID:25516852

Kamdje, Armel Hervé Nwabo; Etet, Paul Faustin Seke; Vecchio, Lorella; Tagne, Richard Simo; Amvene, Jeremie Mbo; Muller, Jean-Marc; Krampera, Mauro; Lukong, Kiven Erique

2014-01-01

364

Micropapillary lung cancer with breast metastasis simulating primary breast cancer due to architectural distortion on images.  

PubMed

A 47-year-old Korean woman with right middle lobe lung adenocarcinoma, malignant pleural effusion, and multiple lymph node and bone metastases, after three months of lung cancer diagnosis, presented with a palpable right breast mass. Images of the right breast demonstrated architectural distortion that strongly suggested primary breast cancer. Breast biopsy revealed metastatic lung cancer with a negative result for estrogen receptor (ER), progesterone receptor (PR) and mammaglobin, and a positive result for thyroid transcription factor-1 (TTF-1). We present a case of breast metastasis from a case of lung cancer with an extensive micropapillary component, which was initially misinterpreted as a primary breast cancer due to unusual image findings with architectural distortion. PMID:22438695

Ko, Kyungran; Ro, Jae Yoon; Hong, Eun Kyung; Lee, Seeyeon

2012-01-01

365

Portraits of breast cancer progression  

PubMed Central

Background Clustering analysis of microarray data is often criticized for giving ambiguous results because of sensitivity to data perturbation or clustering techniques used. In this paper, we describe a new method based on principal component analysis and ensemble consensus clustering that avoids these problems. Results We illustrate the method on a public microarray dataset from 36 breast cancer patients of whom 31 were diagnosed with at least two of three pathological stages of disease (atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC). Our method identifies an optimum set of genes and divides the samples into stable clusters which correlate with clinical classification into Luminal, Basal-like and Her2+ subtypes. Our analysis reveals a hierarchical portrait of breast cancer progression and identifies genes and pathways for each stage, grade and subtype. An intriguing observation is that the disease phenotype is distinguishable in ADH and progresses along distinct pathways for each subtype. The genetic signature for disease heterogeneity across subtypes is greater than the heterogeneity of progression from DCIS to IDC within a subtype, suggesting that the disease subtypes have distinct progression pathways. Our method identifies six disease subtype and one normal clusters. The first split separates the normal samples from the cancer samples. Next, the cancer cluster splits into low grade (pathological grades 1 and 2) and high grade (pathological grades 2 and 3) while the normal cluster is unchanged. Further, the low grade cluster splits into two subclusters and the high grade cluster into four. The final six disease clusters are mapped into one Luminal A, three Luminal B, one Basal-like and one Her2+. Conclusion We confirm that the cancer phenotype can be identified in early stage because the genes altered in this stage progressively alter further as the disease progresses through DCIS into IDC. We identify six subtypes of disease which have distinct genetic signatures and remain separated in the clustering hierarchy. Our findings suggest that the heterogeneity of disease across subtypes is higher than the heterogeneity of the disease progression within a subtype, indicating that the subtypes are in fact distinct diseases. PMID:17683614

Dalgin, Gul S; Alexe, Gabriela; Scanfeld, Daniel; Tamayo, Pablo; Mesirov, Jill P; Ganesan, Shridar; DeLisi, Charles; Bhanot, Gyan

2007-01-01

366

DNA Repair and Personalized Breast Cancer Therapy  

PubMed Central

Personalized cancer therapy is likely to be one of the next big advances in our search for a cure for cancer. To be able to treat people in an individualized manner, researchers need to know a great deal about their genetic constitution and the DNA repair status of their tumors. Specific knowledge is required regarding the polymorphisms individuals carry and how these polymorphisms influence responses to therapy. Researchers are actively engaged in biomarker discovery and validation for this purpose. In addition, the design of clinical trials must be reassessed to include new information on biomarkers and drug responses. In this review, we focus on personalized breast cancer therapy. The hypothesis we focus upon in this review is that there is connection between the DNA repair profile of individuals, their breast tumor subtypes, and their responses to cancer therapy. We first briefly review cellular DNA repair pathways that are likely to be impacted by breast cancer therapies. Next, we review the phenotypes of breast tumor subtypes with an emphasis on how a DNA repair deficiency might result in tumorigenesis itself and lead to the chemotherapeutic responses that are observed. Specific examples of breast tumor subtypes and their responses to cancer therapy are given, and we discuss possible DNA repair mechanisms that underlie the responses of tumors to various chemotherapeutic agents. Much is known about breast cancer subtypes and the way each of these subtypes responds to chemotherapy. In addition, we discuss novel design of clinical trials that incorporates rapidly emerging information on biomarkers. PMID:20872853

Li, Shu-Xia; Sjolund, Ashley; Harris, Lyndsay; Sweasy, Joann B.

2010-01-01

367

Screening for breast cancer in a high-risk series  

Microsoft Academic Search

A unique cohort of women at increased risk of breast cancer because of prior X-ray treatment of acute mastitis and their selected high-risk siblings were offered periodic breast cancer screening including physical examination of the breasts, mammography, and thermography. Twelve breast cancers were detected when fewer than four would have been expected based on age-specific breast cancer detection rates from

Elizabeth D. Woodard; Louis H. Hempelmann; Joyce Janus; Wende Logan; Peter Dean

1982-01-01

368

Knowledge of Breast Cancer and Screening Practices  

ERIC Educational Resources Information Center

Objective: To assess young women's breast health knowledge and explore its relation to the use of screening mammography. Methods: A convenience sample of 180 women aged 25-45 residing in Toronto, Canada, with no history of breast cancer and mammography received an information brochure and four questionnaires which assessed their knowledge of…

Vahabi, Mandana

2005-01-01

369

Quantitative Thermography in Breast Cancer Detection  

Microsoft Academic Search

This is a research effort that helps to define thermal infrared imaging as a diagnostic tool in breast cancer detection, which can be used as a complementary modality to traditional mammography. Our approach consists in the non-topological and the hybrid methods of computerized thermogram classification. The principle task is to find the most significant thermopathological features. 1 Introduction The breast

M. Zavisek; A. Drastich; J. Sandera

370

Breast Cancer - Multiple Languages: MedlinePlus  

MedlinePLUS

... this page, please enable JavaScript. Breast Cancer - Multiple Languages Arabic (???????) Bosnian (Bosanski) Chinese - Simplified (????) Chinese - ... Characters not displaying correctly on this page? See language display issues . Return to the MedlinePlus Health Information ...

371

Axillary Lymph Nodes and Breast Cancer  

MedlinePLUS

... fact sheets in this series: • Breast Cancer Surgery • Lymphedema • Prognostic Factors ©2013 Susan G. Komen ® Item No. ... This helps lower the risk of infection and lymphedema (swelling of the arm). Lymphedema Lymphedema [lim-fa- ...

372

Race, Ethnicity Affect Breast Cancer Survival  

MedlinePLUS

... sharing features on this page, please enable JavaScript. Race, Ethnicity Affect Breast Cancer Survival, Study Shows New ... as surviving it, vary greatly depending on your race and ethnicity, a new study indicates. "It had ...

373

Treatment of Breast Cancer Brain Metastases  

PubMed Central

Approximately 10% to 15% of women with metastatic breast cancer will develop brain metastases. Treatment options for these women remain limited, particularly at the time of central nervous system (CNS) relapse following completion of initial CNS-directed therapy. Historically, prior studies have broadly examined systemic treatments for breast cancer brain metastases with mixed, but overall disappointing, results. More recently, studies have increasingly selected patients based on breast cancer subtype and have examined novel, targeted agents that have preclinical suggestion of blood–brain barrier penetration. Correlative science objectives, with both tissue-based and novel imaging endpoints, are more frequently incorporated into trials of this nature, with the goal of enhancing our understanding of possible predictors of response. This review summarizes the current and emerging data on systemic therapy for breast cancer brain metastases and provides a framework for future directions in treating this clinically-challenging entity. PMID:22754605

Freedman, Rachel A.

2012-01-01

374

Adjuvant Aromatase Inhibitor Therapy for Breast Cancer  

Cancer.gov

In this clinical trial, postmenopausal women with hormone receptor-positive breast cancer that has been surgically removed will be randomly assigned to receive either anastrozole or exemestane for five years.

375

Adjuvant Breast Cancer Therapy for Premenopausal Women  

Cancer.gov

In this trial, researchers will study three treatment groups of premenopausal women with endocrine-responsive breast cancer to see which treatment regimen provides the greatest benefits for this population.

376

Optimizing Postoperative Chemotherapy for Breast Cancer  

Cancer.gov

In this trial, women with early-stage breast cancer deemed by their doctors to be at high risk for recurrence will receive adjuvant chemotherapy with either cyclophosphamide and doxorubicin or paclitaxel given four times over an 8-week period.

377

Zoledronic Acid Improves Early Breast Cancer Treatment  

Cancer.gov

The addition of zoledronic acid (Zometa®) to adjuvant endocrine therapy in premenopausal women with early stage breast cancer significantly improves clinical outcomes beyond those achieved with endocrine therapy alone, according to findings presented at the 2008 ASCO meeting in Chicago.

378

Investigation into taxane resistant breast cancer   

E-print Network

One group of chemotherapeutics that are used successfully to treat breast cancer, alone or in combination with other agents, are the taxanes; paclitaxel and docetaxel. They act by interfering with the spindle microtubule ...

Kenicer, Juliet Elisabeth Margaret

2011-11-25

379

Modern surgical treatment of breast cancer  

Microsoft Academic Search

Since the 1950's the treatment of breast cancer has changed substantially. This related surgery has become less disfiguring\\u000a without either impairing survival or increasing recurrences. Adjuvant chemotherapy has also contributed.

Gerson Lesnick

1985-01-01

380

Sentinel node biopsy in breast cancer  

Microsoft Academic Search

Background: Sentinel lymph node biopsy (SNB) in breast cancer may be used in place of axillary lymph node dissection (ALND) if SNB accurately\\u000a stages the axilla. This study assessed the success and accuracy of axillary SNB with isosulfan blue (ISB) and technetium-99\\u000a sulfur colloid (TSC) compared to ALND.\\u000a \\u000a \\u000a Methods: Forty-two women with T1 or T2 breast cancer underwent SNB and

John M. Barnwell; Mark A. Arredondo; Daniel Kollmorgen; John F. Gibbs; Dominick Lamonica; William Carson; Paul Zhang; Janet Winston; Stephen B. Edge

1998-01-01

381

Characteristics of triple-negative breast cancer  

Microsoft Academic Search

Background  Triple-negative breast cancers (TNBC) neither express hormone receptors, nor overexpress HER2. They are associated with poor\\u000a prognosis, as defined by low five-year survival and high recurrence rates after adjuvant therapy. Overall, TNBC share striking\\u000a similarities with basal-like breast cancers (BBC), so a number of studies considered them being the same. The purpose of this\\u000a review is to summarise the latest

Tim C. de Ruijter; Jürgen Veeck; Joep P. J. de Hoon; Manon van Engeland; Vivianne C. Tjan-Heijnen

2011-01-01

382

Adjuvant therapy of triple negative breast cancer  

Microsoft Academic Search

Patients with the triple negative subtype of breast cancer have an overall poor outcome, with earlier relapses, distinct patterns\\u000a of metastases, and lack of specific targets for treatment selection. Classification of these tumors has begun to be modified\\u000a by inclusion of immunohistochemistry for various markers, and gene profiling. Further characterization of this subtype of\\u000a breast cancer may aid in the

Edith A. Perez; Alvaro Moreno-Aspitia; E. Aubrey Thompson; Cathy A. Andorfer

2010-01-01

383

Triple negative breast cancer: unmet medical needs  

Microsoft Academic Search

Triple negative breast cancer (TNBC) is an aggressive clinical phenotype characterized by lack of expression (or minimal expression)\\u000a of estrogen receptor (ER) and progesterone receptor (PR) as well as an absence of human epidermal growth factor receptor-2\\u000a (HER2) overexpression. It shows substantial overlap with basal-type and BRCA1-related breast cancers, both of which also have\\u000a aggressive clinical courses. However, this overlap

Sumanta Kumar Pal; Barrett H. Childs; Mark Pegram

2011-01-01

384

Metastatic Triple-negative Breast Cancer  

Microsoft Academic Search

The triple-negative class (oestrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor 2 [HER2]-negative) comprises about 15% of breast cancer. It is associated with a poor prognosis compared with tumours that are positive for hormone receptors or HER2. Despite being sensitive to chemotherapy, many women with metastatic triple-negative breast cancer (TNBC) relapse quickly, and commonly develop visceral metastasis, including

E. A. Rakha; S. Chan

2011-01-01

385

What is triple-negative breast cancer?  

Microsoft Academic Search

Triple-negative (ER-negative, PR-negative, HER2\\/neu not overexpressed) breast cancer has distinct clinical and pathologic features, and is a clinical problem because of its relatively poor prognosis, aggressive behaviour and lack of targeted therapies, leaving chemotherapy as the mainstay of treatment. Most triple-negative tumours fall into the basal-like molecular subtype of breast cancer, but the terms are not completely synonymous. Among the

William J. Irvin; Lisa A. Carey

2008-01-01

386

Breast cancer prevention: present and future  

Microsoft Academic Search

Increased risk of breast cancer may result from modifiable factors such as endogenous hormone levels, obesity, HRT, and non-lactation, or non-modifiable factors such as genetic susceptibility or increasing age. Those factors that are easiest to modify may have a limited impact on the totality of breast cancer. The Gail model, based on known factors may be useful for estimating life-time

A. K. Salih; I. S. Fentiman

2001-01-01

387

Modern Breast Cancer Detection: A Technological Review  

PubMed Central

Breast cancer is a serious threat worldwide and is the number two killer of women in the United States. The key to successful management is screening and early detection. What follows is a description of the state of the art in screening and detection for breast cancer as well as a discussion of new and emerging technologies. This paper aims to serve as a starting point for those who are not acquainted with this growing field. PMID:20069109

Nover, Adam B.; Jagtap, Shami; Anjum, Waqas; Yegingil, Hakki; Shih, Wan Y.; Shih, Wei-Heng; Brooks, Ari D.

2009-01-01

388

Bringing Breast Cancer Technologies to Market | Poster  

Cancer.gov

Start-up companies are instrumental in bringing the fruits of scientific research to market. Recognizing an opportunity to bring entrepreneurial minds to bear on the diagnosis and treatment of breast cancer, the Avon Foundation for Women partnered with NCI and the Center for Advancing Innovation to launch the Breast Cancer Startup Challenge. The Challenge has brought together teams of university students and entrepreneurs to create strategic business plans to develop and commercialize patented technologies.

389

Gene Expression Profiling in Breast Cancer  

Microsoft Academic Search

\\u000a Breast cancer is a complex genetic disease characterized by the accumulation of multiple molecular alterations. Today, routine\\u000a clinical management of breast cancer is insufficient to reflect the whole clinical heterogeneity of this disease. Recent advances\\u000a in human genome research and gene expression profiling have made it possible to start uncovering biological mechanisms underlying\\u000a clinically useful signatures. Here we highlight gene

Giuseppe Russo; Antonio Giordano

390

Fetal Dose Evaluation During Breast Cancer Radiotherapy  

Microsoft Academic Search

Purpose: The aim of the work was to estimate the radiation dose delivered to the fetus in a pregnant patient irradiated for breast cancer.Methods and Materials: A 45-year woman was treated for left breast cancer using a 6 MV photon beam with two isocentric opposing tangential unwedged fields. Daily dose was 2.3 Gy at 95% isodose line given by two

Christos Antypas; Panagiotis Sandilos; John Kouvaris; Ersi Balafouta; Eleftheria Karinou; Nikos Kollaros; Lambros Vlahos

1998-01-01

391

Thermography in screening for breast cancer  

Microsoft Academic Search

STUDY OBJECTIVE--The aim of the study was to determine whether thermography could be used to identify women with breast cancer or women at risk of developing the disease within five years. DESIGN--Women were screened for breast cancer and a documentary follow up was conducted five years later through general practitioner records. SETTING--The project involved Women resident in the Bath District

K L Williams; B H Phillips; P A Jones; S A Beaman; P J Fleming

1990-01-01

392

Sex hormone binding globulin in breast cancer  

Microsoft Academic Search

The present study was undertaken to determine the significance of sex hormone binding globulin, the major and specific binding\\u000a protein for testosterone and estradiol, in breast cancer. Among breast cancer patients, lower serum levels of Sex hormone\\u000a binding globulin and higher levels of testosterone were observed. Sex hormone binding globulin showed an inverse relationship\\u000a with testosterone and total cholesterol, and

Dayalu Naik S L; Suresh Hedau; Anil Kumar Bahadur; Renuka Saha; Sudershan Kaur; Amitabha Ray

2008-01-01

393

Challenges in managing breast cancer during pregnancy  

PubMed Central

Pregnancy-associated breast cancer (PABC) is defined as breast cancer occurring anytime during gestation, lactation or within one year after delivery. The optimal management of pregnant women with breast cancer is challenging and not well established; the main concern is the effect of the drugs on the developing fetus and long-term complications after in utero exposure to anti-cancer drugs. Surgical resection is the mainstay of treatment for early breast cancer diagnosed during pregnancy. Modified radical mastectomy is standard of care in first trimester, whereas breast-conserving surgery (lumpectomy with lymph node dissection) can be performed preferably in the second and third trimester. Of note, breast-conserving surgery is not contraindicated per se during the first trimester, but owing to the potential impact of delaying radiotherapy. Radiation therapy is not favored during pregnancy. Moreover, tamoxifen is contraindicated during pregnancy; the agent has been associated with birth defects in up to 20% of exposures. Chemotherapy is generally contraindicated during the first trimester because of the possible damage to organogenesis. Anthracyclines-based regimens are the most widely used is breast cancer treatment and were been shown to be associated with favourable safety profile when administered during pregnancy. As for taxanes, more limited data is available. The use of trastuzumab is contraindicated during pregnancy, given the apparent risk of oligo- and/or anhydramnios as well as the unknown long-term sequelae on the fetus. It is obvious that, diagnosis of breast cancer during pregnancy adds complexity to cancer treatment recommendations. In all cases, a multidisciplinary therapeutic approach among obstetricians, gynaecologists, surgical oncologists, radiation oncologists, medical oncologists, pediatricians and hematologists is clearly warranted. PMID:23819029

Psaltopoulou, Theodora; Dimitrakakis, Constantine; Bartsch, Rupert; Dimopoulos, Meletios-Athanassios

2013-01-01

394

Thermoacoustic imaging of prostate cancer: comparison to histology  

NASA Astrophysics Data System (ADS)

Ex vivo imaging of fresh prostate specimens was performed to test the hypothesis that the thermoacoustic (TA) contrast mechanism generated with very high frequency electromagnetic (EM) irradiation is sensitive to prostate cancer. Ex vivo imaging was performed immediately after radical prostatectomy, performed as part of normal care. Irradiation pulsewidth was 700 ns and duty cycle was extremely low. Typical specific absorption rate (SAR) throughout the prostate was 70-90 kW/kg during pulsing, but time-averaged SAR was below 2 W/kg. TA pressure pulses generated by rapid heating due to EM energy deposition were detected using single element transducers. 15g/L glycine powder mixed into DI water served as acoustic couplant, which was chilled to prevent autolysis. Spatial encoding was performed by scanning in tomographic "step-and-shoot" mode, with 3 mm translation between slices and 1.8-degree rotation between tomographic views. Histology slides for 3 cases scanned with 2.25 MHz transducers were marked for comparison to TA reconstructions. These three cases showed little, moderate, and severe involvement in the histology levels surrounding the verumontanum. TA signal strength decreased with percent cancerous involvement. When VHF is used for tissue heating, the TA contrast mechanism is driven by ionic content and we observed suppressed TA signal from diseased prostate tissue in the peripheral zone. For the 45 regions of interest analyzed, a reconstruction value of 0.4 mV provides 100% sensitivity but only 29% specificity.

Patch, S. K.; Griep, S. K.; Jacobsohn, K.; See, W. A.; Hull, D.

2014-03-01

395

Prognosis for Mammographically Occult, Early-Stage Breast Cancer Patients Treated With Breast-Conservation Therapy  

SciTech Connect

Purpose: To compare mammographically occult (MamOcc) and mammographically positive (MamPos) early-stage breast cancer patients treated with breast-conservation therapy (BCT), to analyze differences between the two cohorts. Methods and Materials: Our two cohorts consisted of 214 MamOcc and 2168 MamPos patients treated with BCT. Chart reviews were conducted to assess mammogram reports and method of detection. All clinical-pathologic and outcome parameters were analyzed to detect differences between the two cohorts. Results: Median follow-up was 7 years. There were no differences in final margins, T stage, nodal status, estrogen/progesterone receptor status, or 'triple-negative' status. Significant differences included younger age at diagnosis (p < 0.0001), more positive family history (p = 0.0033), less HER-2+ disease (p = 0.0294), and 1{sup o} histology (p < 0.0001). At 10 years, the differences in overall survival, cause-specific survival, and distant relapse between the two groups did not differ significantly. The MamOcc cohort had more breast relapses (15% vs. 8%; p = 0.0357), but on multivariate analysis this difference was not significant (hazard ratio 1.0, 95% confidence interval 0.993-1.007, p = 0.9296). Breast relapses were mammographically occult in 32% of the MamOcc and 12% of the MamPos cohorts (p = 0.0136). Conclusions: Although our study suggests that there are clinical-pathologic variations for the MamOcc cohort vs. MamPos patients that may ultimately affect management, breast relapse after BCT was not significantly different. Breast recurrences were more often mammographically occult in the MamOcc cohort; consideration should be given to closer follow-up and alternative imaging strategies (ultrasound, breast MRI) for routine posttreatment examination. To our knowledge, this represents the largest series addressing the prognostic significance of MamOcc cancers treated with BCT.

Yang, Tzu-I. J. [Yale University School of Medicine, New Haven, CT (United States); Yang Qifeng [Department of Radiation Oncology, UMDNJ-Robert Wood Johnson School of Medicine, and Cancer Institute of New Jersey, New Brunswick, NJ (United States); Department of Breast Surgery, Qilu Hospital, Shandong University, Jinan (China); Haffty, Bruce G. [Department of Radiation Oncology, UMDNJ-Robert Wood Johnson School of Medicine, and Cancer Institute of New Jersey, New Brunswick, NJ (United States); Moran, Meena S., E-mail: meena.moran@yale.ed [Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT (United States)

2010-01-15

396

A genomic analysis of mouse models of breast cancer reveals molecular features of mouse models and relationships to human breast cancer  

PubMed Central

Introduction Genomic variability limits the efficacy of breast cancer therapy. To simplify the study of the molecular complexity of breast cancer, researchers have used mouse mammary tumor models. However, the degree to which mouse models model human breast cancer and are reflective of the human heterogeneity has yet to be demonstrated with gene expression studies on a large scale. Methods To this end, we have built a database consisting of 1,172 mouse mammary tumor samples from 26 different major oncogenic mouse mammary tumor models. Results In this dataset we identified heterogeneity within mouse models and noted a surprising amount of interrelatedness between models, despite differences in the tumor initiating oncogene. Making comparisons between models, we identified differentially expressed genes with alteration correlating with initiating events in each model. Using annotation tools, we identified transcription factors with a high likelihood of activity within these models. Gene signatures predicted activation of major cell signaling pathways in each model, predictions that correlated with previous genetic studies. Finally, we noted relationships between mouse models and human breast cancer at both the level of gene expression and predicted signal pathway activity. Importantly, we identified individual mouse models that recapitulate human breast cancer heterogeneity at the level of gene expression. Conclusions This work underscores the importance of fully characterizing mouse tumor biology at molecular, histological and genomic levels before a valid comparison to human breast cancer may be drawn and provides an important bioinformatic resource. PMID:25069779

2014-01-01

397

Mammographic features of early breast cancer  

SciTech Connect

Mammographic detection of breast cancer at the earliest possible stage requires optimal radiographic technique and a full knowledge of the subtle features with which very small cancers can present. Although some early cancers are identified as characteristic clusters of calcifications or as spiculated or multinodular (knobby) masses, others demonstrate less typical and sometimes much less obvious mammographic signs: the single dilated duct, focal architectural distortion, asymmetry, and the developing density sign. Although these indirect signs are nonspecific, they provide mammographers with the important opportunity to discover breast cancer at a very early stage, when the likelihood for cure is great.

Sickles, E.A.

1984-09-01

398

Being Pregnant and Diagnosed with Breast Cancer  

PubMed Central

Breast cancer during pregnancy (BCP) is an important subgroup within the young and very young breast cancer patients. It accounts for about 1% of all breast cancers. Due to an increased awareness, the attitude towards breast cancer during pregnancy has changed and, today, women with BCP are more likely to receive standard chemotherapy and have a term delivery instead of being advised to interrupt the pregnancy or undergo an early preterm delivery. This increased knowledge is based on small cohort studies and international collaborations such as the registry by the German Breast Group for BCP and the initiative of the European Society of Gynaecological Oncology (ESGO). Guidelines and recommendations such as the German guidelines by the AGO (Arbeitsgemeinschaft Gynäkologische Onkologie, www.ago-online.org) and the National Comprehensive Cancer Network (NCCN) guidelines include recommendations for BCP. In general, surgery and chemotherapy (beyond the 13th week of gestation) can be safely performed during pregnancy. Chemotherapy should follow the treatment recommendations for breast cancer in young women. Trastuzumab, endocrine treatment, and radiotherapy are not indicated during pregnancy. Preterm delivery should be avoided as far as possible because it bears a higher risk of infant morbidity and mortality. The treatment of BCP should be planned within a multidisciplinary team including perinatologists, obstetricians and neonatologists. PMID:22872793

Loibl, Sibylle; Han, Sileny N.; Amant, Frederic

2012-01-01

399

The Adjunctive Digital Breast Tomosynthesis in Diagnosis of Breast Cancer  

PubMed Central

Purpose. To compare the diagnostic performance of digital breast tomosynthesis (DBT) and digital mammography (DM) for breast cancers. Materials and Methods. Fifty-seven female patients with pathologically proved breast cancer were enrolled. Three readers gave a subjective assessment superiority of the index lesions (mass, focal asymmetry, architectural distortion, or calcifications) and a forced BIRADS score, based on DM reading alone and with additional DBT information. The relevance between BIRADS category and index lesions of breast cancer was compared by chi-square test. Result. A total of 59 breast cancers were reviewed, including 17 (28.8%) mass lesions, 12 (20.3%) focal asymmetry/density, 6 (10.2%) architecture distortion, 23 (39.0%) calcifications, and 1 (1.7%) intracystic tumor. Combo DBT was perceived to be more informative in 58.8% mass lesions, 83.3% density, 94.4% architecture distortion, and only 11.6% calcifications. As to the forced BIRADS score, 84.4% BIRADS 0 on DM was upgraded to BIRADS 4 or 5 on DBT, whereas only 27.3% BIRADS 4A on DM was upgraded on DBT, as BIRADS 4A lesions were mostly calcifications. A significant P value (<0.001) between the BIRADS category and index lesions was noted. Conclusion. Adjunctive DBT gives exquisite information for mass lesion, focal asymmetry, and/or architecture distortion to improve the diagnostic performance in mammography. PMID:23844366

Yang, Tsung-Lung; Liang, Huei-Lung; Huang, Jer-Shyung; Pan, Huay-Ben

2013-01-01

400

Association of PKC? Expression with Clinicopathological Characteristics of Breast Cancer  

PubMed Central

The protein kinase C (PKC) family has been functionally linked to cancer. It has been suggested that atypical PKCs contribute to cell proliferation and cancer progression. With respect to breast cancer, PKC? has been found to play a key role in intracellular transduction of mitogenic and apoptotic signals using mammary cell lines. However, little is known about its function in vivo. Here we examined the correlation between PKC? protein levels and important clinicopathologic factors in breast cancer using patient samples. To conduct the study, 30 invasive ductal carcinoma cases and their paired normal tissues were used for tissue microarray analysis (TMA) and 16 were used for western blot analysis. In addition, the correlation between PKC? expression levels and clinicopathologic characteristics was determined in 176 cases with relevant clinical data. Finally, the correlation between PKC? and epithelial growth factor receptor 2 (HER2) expressions was determined using three breast cancer cell lines by western blot analysis. Both TMA and western blot results showed that PKC? protein was highly expressed in primary tumors but not in paired normal tissue. The correlation study indicated that high PKC? levels were associated with premenopausal patients (p?=?0.019) and worse prognostic factors, such as advanced clinical stage, more lymph node involvement and larger tumor size. Both disease-free survival and overall survival rates were lower in the high PKC? group than those in the low PKC? group. No correlation was observed between PKC? levels and age, histological grade, or estrogen or progesterone receptor expression status. A positive correlation between PKC? and HER2 levels was observed in both tumor samples and cell lines. Our observations link PKC? expression with factors pointing to worse prognosis, higher HER2 levels and a lower survival rate. This suggests that PKC? protein levels may serve as a prognostic marker of breast cancer. PMID:24603690

Yin, Jian; Liu, Zhipei; Li, Haixin; Sun, Jingyan; Chang, Xinzhong; Liu, Jing; He, Shanshan; Li, Binghui

2014-01-01

401

Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer  

ClinicalTrials.gov

Central Nervous System Metastases; Invasive Ductal Breast Carcinoma; Invasive Ductal Breast Carcinoma With Predominant Intraductal Component; Invasive Lobular Breast Carcinoma; Invasive Lobular Breast Carcinoma With Predominant in Situ Component; Liver Metastases; Lobular Breast Carcinoma in Situ; Lung Metastases; Male Breast Cancer; Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate; Mucinous Ductal Breast Carcinoma; Papillary Ductal Breast Carcinoma; Recurrent Breast Cancer; Stage IV Breast Cancer; Tubular Ductal Breast Carcinoma; Tumors Metastatic to Brain

2014-03-11

402

Monitoring Response to Primary Chemotherapy in Breast Cancer using Dynamic Contrast-enhanced Magnetic Resonance Imaging  

Microsoft Academic Search

Purpose. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) allows analysis of both tumor volume and contrast enhancement pattern using a single tool. We sought to investigate whether DCE-MRI could be used to predict histological response in patients undergoing primary chemotherapy (PCT) for breast cancer.

Laura Martincich; Filippo Montemurro; Giovanni De Rosa; Vincenzo Marra; Riccardo Ponzone; Stefano Cirillo; Marco Gatti; Nicoletta Biglia; Ivana Sarotto; Piero Sismondi; Daniele Regge; Massimo Aglietta

2004-01-01

403

Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases  

Microsoft Academic Search

Purpose: To assess the clinical and histological characteristics of breast cancer (BC) occurring after Hodgkin's disease (HD) and give possible therapies and prevention methods.Materials and methods: In a retrospective multicentric analysis, 117 women and two men treated for HD subsequently developed 133 BCs. The median age at diagnosis of HD was 24 years. The HD stages were stage I in

Bruno Cutuli; Christian Borel; Frédéric Dhermain; Stefano M Magrini; Todd H Wasserman; Jeffrey A Bogart; Mariano Provencio; Brigitte de Lafontan; Anne de la Rochefordiere; Enrico Cellai; Yvon Graic; Pierre Kerbrat; Claude Alzieu; Eric Teissier; Jean-Marie Dilhuydy; Hervé Mignotte; Michel Velten

2001-01-01

404

By Jessica Kueck Breast Cancer and BRCA1  

E-print Network

on protein stability Proteomics Why BRCA1 mainly causes breast and ovarian cancer #12;-regulation of upstream proteins Narod, et al. 2004. Nature Reviews Cancer, 4:665-76 Ubiquitination? Phosphorylation 20By Jessica Kueck Breast Cancer and BRCA1 #12;Breast cancer facts breastcancer.org 1 in 8 women

Skop, Ahna

405

International breast cancer & nutrition (IBCN): A global venture  

E-print Network

International breast cancer & nutrition (IBCN): A global venture Sophie A. Lelièvre, DVM, LLM Center for Cancer Research Leader, International Breast Cancer & Nutrition (IBCN) Ellen Gruenbaum, PhD Department Head, Anthropology IBCN C C i bIBCN Core Committee member Breast cancer incidence is rising all

Ginzel, Matthew

406

Breast Cancer Prognosis via Gaussian Mixture Regression Tiago H. Falk  

E-print Network

Breast Cancer Prognosis via Gaussian Mixture Regression Tiago H. Falk Electrical and Computer Eng. Keywords--Prognosis prediction, breast cancer, time-to-recur, auto- matic feature selection, Gaussian, breast cancer continues to be the most common cancer among Canadian women. According to the Canadian Can

Shatkay, Hagit

407

Breast Cancer: Modelling and Detection D.J. GAVAGHANa  

E-print Network

Breast Cancer: Modelling and Detection D.J. GAVAGHANa , J.M. BRADYb , C.P. BEHRENBRUCHb , R cancer, breast carcinoma, to illustrate how the modelling can be used in aiding detection. We to meet some of the major challenges in cancer detection. Keywords: Breast cancer; Tumour; Image

Maini, Philip K.

408

The After Breast Cancer Pooling Project: Rationale, Methodology, and Breast Cancer Survivor Characteristics  

PubMed Central

The After Breast Cancer Pooling Project was established to examine the role of physical activity, adiposity, dietary factors, supplement use, and quality of life (QOL) in breast cancer prognosis. This paper presents pooled and harmonized data on post-diagnosis lifestyle factors, clinical prognostic factors, and breast cancer outcomes from four prospective cohorts of breast cancer survivors (three US-based and one from Shanghai, China) for 18,314 invasive breast cancer cases diagnosed between 1976 and 2006. Most participants were diagnosed with stage I-II breast cancer (84.7%). About 60% of breast tumors were estrogen receptor (ER)+/progesterone receptor (PR)+; 21% were ER?/PR?. Among 8,118 participants with information on HER-2 tumor status, 74.8% were HER-2? and 18.5% were HER-2+. At 1–2 years post-diagnosis (on average) 17.9% of participants were obese (BMI ?30 kg/m2), 32.6% were overweight (BMI 25–29 kg/m2) and 59.9% met the 2008 Physical Activity Guidelines for Americans (? 2.5 hours per week of moderate activity). During follow-up (mean=8.4 years), 3,736 deaths (2,614 from breast cancer), and 3,564 recurrences have been documented. After accounting for differences in year of diagnosis and timing of post-diagnosis enrollment, five-year overall survival estimates were similar across cohorts. This pooling project of 18,000 breast cancer survivors enables the evaluation of associations of post-diagnosis lifestyle factors, QOL, and breast cancer outcomes with an adequate sample size for investigation of heterogeneity by hormone-receptor status and other clinical predictors. The project sets the stage for international collaborations for the investigation of modifiable predictors for breast cancer outcomes. PMID:21710192

Nechuta, Sarah J.; Caan, Bette J.; Chen, Wendy Y.; Flatt, Shirley W.; Lu, Wei; Patterson, Ruth E.; Poole, Elizabeth M.; Kwan, Marilyn L.; Chen, Zhi; Weltzien, Erin; Pierce, John P.; Shu, Xiao Ou

2011-01-01

409

Breast cancer metastasis to the pituitary gland.  

PubMed

Metastatic tumors to the pituitary gland are an unusual complication typically seen in elderly patients with diffuse malignant disease. Breast and lung are the commonest sites of the primary tumor. Prognosis of patients with breast cancer metastasis is poor and depends on the primary neoplastic extension. We report a 54 year-old woman with breast cancer metastasis to the pituitary stalk first diagnosed because of visual disturbance with no other symptoms. Pituitary gland stalk metastasis is a very uncommon find and this case report includes a literature review. PMID:25465612

Magalhães, Julia Fragoso; Bacchin, Renata Prota; Costa, Priscila Scatena; Alves, Gisele Malavazi; Fraige Filho, Fadlo; Stella, Lenira Cristina

2014-11-01

410

Cisplatin Induces Differentiation of Breast Cancer Cells  

PubMed Central

Breast tumors are heterogeneous including cells with stem cell properties and more differentiated cells. This heterogeneity is reflected into the molecular breast cancer subtypes. Breast cancer stem cells are resistant to chemotherapy, thus recent efforts are focusing on identifying treatments that shift them toward a more differentiated phenotype, making them more susceptible to chemotherapy. We examined whether the drug cisplatin induces differentiation in breast cancer cell lines that represent different breast cancer subtypes. We used three cell lines representing triple-negative breast cancers, BT-549 and MDA-MB-231 (claudin-low), and MDA-MB-468 (basal-like), along with estrogen and progesterone receptor positive MCF-7 cells (luminal). Cisplatin was applied at 2.5, 5, 10, and 20??M, and cell viability and proliferation were measured using MTS and BrdU assays, respectively. The effect of cisplatin on the cellular hierarchy was examined by flow cytometry, immunofluorescence and qRT-PCR. Cisplatin treatment of 10 and 20??M reduced cell viability by 36–51% and proliferation capacity by 36–67%. Treatment with cisplatin resulted in 12–67% down-regulation of stem cell markers (CD49f, SSEA4) and 10–130% up-regulation of differentiation markers (CK18, SMA, ?-tubulin). At the mRNA level, CD49f was down-regulated whilst ?-tubulin was up-regulated in the claudin-low cell lines. SSEA4 protein expression decreased upon cisplatin treatment, but SSEA4 mRNA expression increased indicating a differential regulation of cisplatin at the post-transcriptional level. It is concluded that cisplatin reduces breast cancer cell survival and induces differentiation of stem/progenitor cell subpopulations within breast cancer cell lines. These effects indicate the potential of this drug to target specific chemotherapy-resistant cells within a tumor. PMID:23761858

Prabhakaran, Praseetha; Hassiotou, Foteini; Blancafort, Pilar; Filgueira, Luis

2013-01-01

411

The Auckland Breast Cancer Register: a special project of the Auckland Breast Cancer Study Group  

Microsoft Academic Search

Aims The Auckland Breast Cancer Register (ABCR) has been established in response to the need for a comprehensive database of breast cancer cases from the Auckland area. Methods The database records patient demographics, diagnosis, treatment options, prognosis and long-term outcome (annual follow up). Data from 1204 cases, recorded between June 2000 and June 2002 are reported. Results The major findings

Lorraine Neave; Vernon Harvey; Chelleraj Benjamin; Paul Thompson; Ora Pellett; Jeremy Whitlock; Wayne Jones; Garth Poole

412

Harvard study finds breast density tied to specific types of breast cancer:  

Cancer.gov

Women with breasts that appear dense on mammograms are at a higher risk of breast cancer and their tumors are more likely to have certain aggressive characteristics than women with less dense breasts...

413

Cellular iron metabolism in prognosis and therapy of breast cancer  

PubMed Central

Despite many recent advances, breast cancer remains a clinical challenge. Current issues include improving prognostic evaluation and increasing therapeutic options for women whose tumors are refractory to current frontline therapies. Iron metabolism is frequently disrupted in breast cancer, and may offer an opportunity to address these challenges. Iron enhances breast tumor initiation, growth and metastases. Iron may contribute to breast tumor initiation by promoting redox cycling of estrogen metabolites. Up-regulation of iron import and down-regulation of iron export may enable breast cancer cells to acquire and retain excess iron. Alterations in iron metabolism in macrophages and other cells of the tumor microenvironment may also foster breast tumor growth. Expression of iron metabolic genes in breast tumors is predictive of breast cancer prognosis. Iron chelators and other strategies designed to limit iron may have therapeutic value in breast cancer. The dependence of breast cancer on iron presents rich opportunities for improved prognostic evaluation and therapeutic intervention. PMID:23879588

Torti, Suzy V.; Torti, Frank M.

2013-01-01

414

The AURORA initiative for metastatic breast cancer.  

PubMed

Metastatic breast cancer is one of the leading causes of cancer-related mortality among women in the Western world. To date most research efforts have focused on the molecular analysis of the primary tumour to dissect the genotypes of the disease. However, accumulating evidence supports a molecular evolution of breast cancer during its life cycle, with metastatic lesions acquiring new molecular aberrations. Recognising this critical gap of knowledge, the Breast International Group is launching AURORA, a large, multinational, collaborative metastatic breast cancer molecular screening programme. Approximately 1300 patients with metastatic breast cancer who have received no more than one line of systemic treatment for advanced disease will, after giving informed consent, donate archived primary tumour tissue, as well as will donate tissue collected prospectively from the biopsy of metastatic lesions and blood. Both tumour tissue types, together with a blood sample, will then be subjected to next generation sequencing for a panel of cancer-related genes. The patients will be treated at the discretion of their treating physicians per standard local practice, and they will be followed for clinical outcome for 10 years. Alternatively, depending on the molecular profiles found, patients will be directed to innovative clinical trials assessing molecularly targeted agents. Samples of outlier patients considered as 'exceptional responders' or as 'rapid progressors' based on the clinical follow-up will be subjected to deeper molecular characterisation in order to identify new prognostic and predictive biomarkers. AURORA, through its innovative design, will shed light onto some of the unknown areas of metastatic breast cancer, helping to improve the clinical outcome of breast cancer patients. PMID:25225904

Zardavas, D; Maetens, M; Irrthum, A; Goulioti, T; Engelen, K; Fumagalli, D; Salgado, R; Aftimos, P; Saini, K S; Sotiriou, C; Campbell, P; Dinh, P; von Minckwitz, G; Gelber, R D; Dowsett, M; Di Leo, A; Cameron, D; Baselga, J; Gnant, M; Goldhirsch, A; Norton, L; Piccart, M

2014-11-11

415

The AURORA initiative for metastatic breast cancer  

PubMed Central

Metastatic breast cancer is one of the leading causes of cancer-related mortality among women in the Western world. To date most research efforts have focused on the molecular analysis of the primary tumour to dissect the genotypes of the disease. However, accumulating evidence supports a molecular evolution of breast cancer during its life cycle, with metastatic lesions acquiring new molecular aberrations. Recognising this critical gap of knowledge, the Breast International Group is launching AURORA, a large, multinational, collaborative metastatic breast cancer molecular screening programme. Approximately 1300 patients with metastatic breast cancer who have received no more than one line of systemic treatment for advanced disease will, after giving informed consent, donate archived primary tumour tissue, as well as will donate tissue collected prospectively from the biopsy of metastatic lesions and blood. Both tumour tissue types, together with a blood sample, will then be subjected to next generation sequencing for a panel of cancer-related genes. The patients will be treated at the discretion of their treating physicians per standard local practice, and they will be followed for clinical outcome for 10 years. Alternatively, depending on the molecular profiles found, patients will be directed to innovative clinical trials assessing molecularly targeted agents. Samples of outlier patients considered as ‘exceptional responders' or as ‘rapid progressors' based on the clinical follow-up will be subjected to deeper molecular characterisation in order to identify new prognostic and predictive biomarkers. AURORA, through its innovative design, will shed light onto some of the unknown areas of metastatic breast cancer, helping to improve the clinical outcome of breast cancer patients. PMID:25225904

Zardavas, D; Maetens, M; Irrthum, A; Goulioti, T; Engelen, K; Fumagalli, D; Salgado, R; Aftimos, P; Saini, K S; Sotiriou, C; Campbell, P; Dinh, P; von Minckwitz, G; Gelber, R D; Dowsett, M; Di Leo, A; Cameron, D; Baselga, J; Gnant, M; Goldhirsch, A; Norton, L; Piccart, M

2014-01-01

416

PIP breast implants: rupture rate and correlation with breast cancer  

PubMed Central

Aim To evaluate the incidence of Poly Implant Prosthése (PIP) rupture as assessed by magnetic resonance imaging (MRI), the prevalence of the detected signs and the potential correlation with breast carcinoma. Patients and methods 67 patients with silicone breast implants and clinical indications for breast MRI were evaluated for a total of 125 implants: 40 (32%) PIP in 21 patients and 85 non-PIP in 46 patients (68%), the latest considered as control group. A 1.5-T MR imaging device was used in order to assess implant integrity with dedicated sequences and in 6 cases a dynamic study was performed for characterizing breast lesions. Two radiologists with more than 5 years’ experience in the field of MRI evaluated in consensus all MR images searching for the presence of clear signs of intra or extra-capsular implant rupture. Results 20/40 (50%) PIP implants presented signs of intra-capsular rupture: linguine sign in 20 cases (100%), tear-drop sign in 6 (30%). In 12/20 cases (60%), MRI signs of extra-capsular rupture were detected. In the control group, an intra-capsular rupture was diagnosed in 12/85 cases (14%) associated with extra-capsular one in 5/12 cases (42%). Among the six cases with suspected breast lesions, in 2/21 patients with PIP implants (10%) a breast carcinoma was diagnosed (mucinous carcinoma, n=1; invasive ductal carcinoma, n=1). In 4/46 patients (9%) with non-PIP implants, an invasive ductal carcinoma was diagnosed. Conclusion The rupture rate of PIP breast implants is significantly higher than non-PIP (50% vs 14%). MRI represents the most accurate imaging tool for evaluating breast prostheses and the linguine sign is the most common MRI sign to be searched. The incidence of breast carcinoma does not significantly differ between the PIP and non-PIP implants and a direct correlation with breast cancer can not been demonstrated. PMID:25644728

MOSCHETTA, M.; TELEGRAFO, M.; CORNACCHIA, I.; VINCENTI, L.; RANIERI, V.; CIRILLI, A.; RELLA, L.; IANORA, A.A. STABILE; ANGELELLI, G.

2014-01-01

417

Ultrasound for breast cancer screening and staging.  

PubMed

The question then arises whether and for whom BWBS should be recommended. As yet there are no scientific criteria on which to base an answer, and the examination should not be considered the standard of care until its benefits can be established prospectively. We know that mass screening mammography will detect occult cancers in two to seven of every 1000 women screened, depending on patient age and whether the screens are prevalence or incidence examinations. Should we expect a similar yield for survey US? Kopans commented that Kolb's cancer detection rate was lower than would be expected from a mammographic prevalence screen. This was not a reasonable comparison. These women all had negative findings on screening mammography and would normally be told to have repeat screening mammography 1 year later. Kolb's cancer detection rate using US was comparable to a mammographic incidence screen, so the cancer diagnoses of these fortunate women were advanced by 1 year. To maximize the yield, it is obvious that US has little to offer over mammography in women with fatty breasts because mammography is less likely to be falsely negative. The group of patients in whom incidental cancers would be expected to be found more commonly are those with dense breasts who also are at higher-than-average risk either because of a previous personal history of breast cancer (Fig. 2) or a significant family history. Because it would be impractical to consider BWBS for all women with radiographically dense breasts, it would be useful to know what its potential yield would be in the relatively smaller group of high-risk patients. Annual mammography remains the standard of care for breast cancer screening. However, in our practice in Vancouver, I suggest that high-risk women undergo mammography and US annually, recognizing that this goes beyond the standard of care. Instead of having both examinations simultaneously, I recommend that they alternate the two modalities at 6-month intervals. Theoretically, this could increase lead-time in the detection of occult cancers. The usefulness of this approach remains to be determined. BWBS for staging in women known to have breast cancer has tremendous promise and should be considered for any breast cancer patient with dense breast tissue in whom the finding of additional unsuspected foci would change the planned management. The cost of implementation would be substantial but considerably less than staging MRI. A large-scale study comparing these two modalities is needed, including assessment of the impact of identifying additional mammographically occult lesions on breast cancer mortality. PMID:12117185

Gordon, Paula B

2002-05-01

418

RO4929097 And Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer  

ClinicalTrials.gov

Estrogen Receptor-negative Breast Cancer; Extensive Stage Small Cell Lung Cancer; HER2-negative Breast Cancer; HER2-positive Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Recurrent Melanoma; Recurrent Non-small Cell Lung Cancer; Recurrent Small Cell Lung Cancer; Stage IV Breast Cancer; Stage IV Melanoma; Stage IV Non-small Cell Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific

2013-07-01

419

MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer  

PubMed Central

Mouse mammary tumor virus (MMTV) long terminal repeat (LTR)-driven transgenic mice are excellent models for breast cancer as they allow for the targeted expression of various oncogenes and growth factors in neoplastic transformation of mammary glands. Numerous MMTV-LTR-driven transgenic mouse models of breast cancer have been created in the past three decades, including MMTV-neu/ErbB2, cyclin D1, cyclin E, Ras, Myc, int-1 and c-rel. These transgenic mice develop mammary tumors with different latency, histology and invasiveness, reflecting the oncogenic pathways activated by the transgene. Recently, homologous sequences of the env gene of MMTV have been identified in approximately 40% of human breast cancers, but not in normal breast or other types of cancers, suggesting possible involvement of mammary tumor virus in human breast carcinogenesis. Accumulating evidence demonstrates the association of MMTV provirus with progesterone receptor, p53 mutations and advanced-stage breast cancer. Thus, the detection of MMTV-like sequences may have diagnostic value to predict the clinical outcome of breast cancer patients. PMID:19580428

Taneja, Pankaj; Frazier, Donna P; Kendig, Robert D; Maglic, Dejan; Sugiyama, Takayuki; Kai, Fumitake; Taneja, Neetu K; Inoue, Kazushi

2009-01-01

420

Genetically engineered ER?-positive breast cancer mouse models.  

PubMed

The majority of human breast cancers are estrogen receptor-positive (ER+), but this has proven challenging to model in genetically engineered mice. This review summarizes information on 21 mouse models that develop ER+ mammary cancer. Where available, information on cancer pathology and gene expression profiles is referenced to assist in understanding which histological subtype of ER+ human cancer each model might represent. ESR1, CCDN1, prolactin, TGF?, AIB1, ESPL1, and WNT1 overexpression, PIK3CA gain of function, as well as loss of P53 (Trp53) or STAT1 are associated with ER+ mammary cancer. Treatment with the PPAR? agonist efatutazone in a mouse with Brca1 and p53 deficiency and 7,12-dimethylbenz(a)anthracene exposure in combination with an activated myristoylated form of AKT1 also induce ER+ mammary cancer. A spontaneous mutant in nude mice that develops metastatic ER+ mammary cancer is included. Age of cancer development ranges from 3 to 26 months and the percentage of cancers that are ER+ vary from 21 to 100%. Not all models are characterized as to their estrogen dependency and/or response to anti-hormonal therapy. Strain backgrounds include C57Bl/6, FVB, BALB/c, 129S6/SvEv, CB6F1, and NIH nude. Most models have only been studied on one strain background. In summary, while a range of models are available for studies of pathogenesis and therapy of ER+ breast cancers, many could benefit from further characterization, and opportunity for development of new models remains. PMID:24481326

Dabydeen, Sarah A; Furth, Priscilla A

2014-06-01

421

Obesity, cholesterol metabolism, and breast cancer pathogenesis.  

PubMed

Obesity and altered lipid metabolism are risk factors for breast cancer in pre- and post-menopausal women. These pathologic relationships have been attributed in part to the impact of cholesterol on the biophysical properties of cell membranes and to the influence of these changes on signaling events initiated at the membrane. However, more recent studies have indicated that the oxysterol 27-hydroxycholesterol (27HC), and not cholesterol per se, may be the primary biochemical link between lipid metabolism and cancer. The enzyme responsible for production of 27HC from cholesterol, CYP27A1, is expressed primarily in the liver and in macrophages. In addition, significantly elevated expression of this enzyme within breast tumors has also been observed. It is believed that 27HC, acting through the liver X receptor in macrophages and possibly other cells, is involved in maintaining organismal cholesterol homeostasis. It has also been shown recently that 27HC is an estrogen receptor agonist in breast cancer cells and that it stimulates the growth and metastasis of tumors in several models of breast cancer. These findings provide the rationale for the clinical evaluation of pharmaceutical approaches that interfere with cholesterol/27HC synthesis as a means to mitigate the impact of cholesterol on breast cancer pathogenesis. Cancer Res; 74(18); 4976-82. ©2014 AACR. PMID:25060521

McDonnell, Donald P; Park, Sunghee; Goulet, Matthew T; Jasper, Jeff; Wardell, Suzanne E; Chang, Ching-Yi; Norris, John D; Guyton, John R; Nelson, Erik R

2014-09-15

422

Role of denosumab in breast cancer.  

PubMed

Recent advances in adjuvant treatment have improved progression-free and overall survival in patients with early stage breast cancer. However, up to one third of women will experience tumour recurrence, with bone being a common metastatic site. Current treatment options for metastases to bone comprise systemic antitumour therapy, irradiation, surgery and biphosphonates. As osteoclast activation is mediated by the receptor activator of NF-kappaB (RANK)/RANK ligand pathway and inhibited by osteoprotegerin (OPG), it was suggested that inhibition of this system may treat bone metastases. Recombinant Fc-OPG was evaluated in women with osteoporosis and malignant bone disease. The fully human antibody denosumab has demonstrated superior activity in reducing markers of bone turnover; therefore this drug was further developed in clinical settings. In advanced breast cancer, denosumab reduced urinary-N-telopeptide:creatinine ratio with potentially fewer side effects compared with bisphosphonates. Proof of direct antitumor activity is missing. Here we review the development and current status of denosumab in breast cancer. Data were obtained by searching the Medline database and abstracts from the American Society for Clinical Oncology (ASCO) annual meeting, European Cancer organization (ECCO), European Society for Medical Oncology (ESMO) and the San Antonio Breast Cancer Symposium, using search terms including bone metastases, bisphosphonates, breast cancer, denosumab, osteoprotegerin, RANK and skeletal-related events. PMID:19653867

Bartsch, Rupert; Steger, Guenther G

2009-09-01

423

Breast cancer risk and environmental exposures.  

PubMed Central

Although environmental contaminants have potential to affect breast cancer risk, explicit environmental links to this disease are limited. The most well-defined environmental risk factors are radiation exposure and alcohol ingestion. Diet is clearly related to the increased incidence of breast cancer in developed countries, but its precise role is not yet established. Recent studies have implicated exposure to organochlorines including DDT as a risk factor for breast cancer in the United States, Finland, Mexico, and Canada. Other investigations have discovered associations between breast cancer risk and exposures to chemical emissions and some occupational exposures. Several points must be considered in evaluating the relationship of environmental exposure to breast cancer. Among these considerations are the mechanism of tumorigenesis, timing of environmental exposure, and genetic modulation of exposure. Epidemiologic and ecologic investigations must take into account the very complex etiology of breast cancer and the knowledge that tumorigenesis can arise from different mechanisms. Thus crucial exposures as well as reproductive events related to breast cancer may occur years before a tumor is evident. Moreover, environmental contaminants may alter reproductive development, directly or indirectly, and thereby effect the course of tumorigenesis. Such alterations include change in gender, change in onset of puberty, and inhibition or promotion of tumor formation. Timing of exposure is therefore important with respect to mechanism and susceptibility. Finally, genetic polymorphisms exist in genes that govern capacity to metabolize environmental contaminants. Higher risk may occur among persons whose enzymes either are more active in the production of procarcinogens or fail to detoxify carcinogenic intermediates formed from chemicals in the environment. PMID:9255576

Wolff, M S; Weston, A

1997-01-01

424

Risk factors of developing long-lasting breast pain after breast cancer radiotherapy  

Microsoft Academic Search

PurposePostoperative radiotherapy decreases breast cancer mortality. However, studies have revealed a long-lasting breast pain among some women after radiotherapy. The purpose of this study was to identify risk factors that contribute to breast pain after breast cancer radiotherapy.

Dan Lundstedt; Magnus Gustafsson; Gunnar Steineck; Per Malmström; David Alsadius; Agnetha Sundberg; Ulrica Wilderäng; Erik Holmberg; Karl-Axel Johansson

425

Epidemiology of Inflammatory Breast Cancer (IBC)1  

PubMed Central

Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer with unknown etiology and generally poor outcome. It is characterized by diffuse edema (peau d'orange) and redness (erythema), although either the disease itself or case definitions have varied over time and place, confounding temporal trends and geographic variations. In this review, we discuss case definitions for IBC and its clinical characteristics; describe its geographic variation, age and racial distribution, incidence and survival patterns, and summarize the very limited information on its epidemiologic risk factors. We also incorporate emerging data from the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) Program. PMID:16735783

Anderson, William F.; Schairer, Catherine; Chen, Bingshu E.; Hance, Kenneth W.; Levine, Paul H.

2010-01-01

426

The numb chin in breast cancer 1  

PubMed Central

Numbness of the chin, an uncommon neurological symptom, was observed in 15 patients with cancer. Thirteen had breast cancer. This symptom usually heralded progressive involvement of the cranial nerves or cerebrum and denoted a poor prognosis in patients with a short `tumourfree interval'. The pathogenesis is commonly related to dural involvement of the Vth cranial nerve at the base of the brain, although metastasis to the mandible might sometimes be implicated. The reason for the peculiar predilection for the mandibular branch of the trigeminal nerve to be affected by breast cancer is not known. Images PMID:4708456

Horton, John; Means, Eugene D.; Cunningham, T. J.; Olson, Kenneth B.

1973-01-01

427

Conserving surgery - balance between good cosmetic aspect and local disease control in incipient breast cancer.  

PubMed

New acquisitions in the study of breast cancer, based on several retrospective and prospective studies, have led over the past decades to the possibility of applying conserving methods of treatment for breast cancer (breast conserving therapy -BCT) in incipient stages. Starting with 1996, a single surgical team, among others at the Bucharest Oncology Institute,performed BCT in 497 patients out of the total 2,256 cases of breast cancer treated. Work protocol consisted of tumour excision with safety margins, intraoperative histology exam,samples from all the walls of the remaining cavity, with intraoperative histology exam, axillary lymphadenectomy, followed by mandatory irradiation of the entire breast, associated or not with systemic or hormonal adjuvant treatment. 38 patients developed local disease recurrences, 14 of which in the first 5 years. In this paper we present the results obtained through BCT, as a means of supporting this type of treatment adequate for patients with initial stage breast cancer, with cosmetic results visibly superior to those of mastectomy. PMID:25149608

Gogescu, G; Marinescu, S; Br?tucu, E

2014-01-01

428

Too Few Breast Cancer Patients Getting Radiation After Mastectomy  

MedlinePLUS

... enable JavaScript. Too Few Breast Cancer Patients Getting Radiation After Mastectomy: Study More than a third with ' ... 17, 2015 Related MedlinePlus Pages Breast Cancer Mastectomy Radiation Therapy TUESDAY, Feb. 17, 2015 (HealthDay News) -- Many ...

429

The breast cancer genome - a key for better oncology  

E-print Network

Abstract Molecular classification has added important knowledge to breast cancer biology, but has yet to be implemented as a clinical standard. Full sequencing of breast cancer genomes could potentially refine classification and give a more complete...

Vollan, Hans Kristian Moen; Caldas, Carlos

2011-11-30

430

Breast Cancer Chemo Tied to Small but Significant Leukemia Risk  

MedlinePLUS

... sharing features on this page, please enable JavaScript. Breast Cancer Chemo Tied to Small But Significant Leukemia Risk ... in about a half-percent of early stage breast cancer patients, study finds (*this news item will not ...

431

What's New in Breast Cancer Research and Treatment?  

MedlinePLUS

... Next Topic Additional resources for breast cancer What`s new in breast cancer research and treatment? Research into ... can help some women avoid overly aggressive treatment. New laboratory tests Circulating tumor cells Researchers have found ...

432

Acupuncture, Exercise May Ease Pain for Breast Cancer Patients  

MedlinePLUS

... sharing features on this page, please enable JavaScript. Acupuncture, Exercise May Ease Pain for Breast Cancer Patients ... 2015) Thursday, November 13, 2014 Related MedlinePlus Pages Acupuncture Breast Cancer Exercise and Physical Fitness THURSDAY, Nov. ...

433

Breast Cancer Risk Assessment SAS Macro (Gail Model)  

Cancer.gov

A SAS macro (commonly referred to as the Gail Model) that projects absolute risk of invasive breast cancer according to NCI’s Breast Cancer Risk Assessment Tool (BCRAT) algorithm for specified race/ethnic groups and age intervals.

434

New Treatment Shows Promise in Younger Breast Cancer Patients  

MedlinePLUS

... sharing features on this page, please enable JavaScript. New Treatment Shows Promise in Younger Breast Cancer Patients: ... of breast cancer recurrence in some younger women, new research suggests. This combination approach -- using estrogen-blockers ...

435

BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer  

PubMed Central

The frequency, in women with breast cancer, of mutations and other variants in the susceptibility gene, BRCA1, was investigated using a population-based case–control-family study. Cases were women living in Melbourne or Sydney, Australia, with histologically confirmed, first primary, invasive breast cancer, diagnosed before the age of 40 years, recorded on the state Cancer Registries. Controls were women without breast cancer, frequency-matched for age, randomly selected from electoral rolls. Full manual sequencing of the coding region of BRCA1 was conducted in a randomly stratified sample of 91 cases; 47 with, and 44 without, a family history of breast cancer in a first- or second-degree relative. All detected variants were tested in a random sample of 67 controls. Three cases with a (protein-truncating) mutation were detected. Only one case had a family history; her mother had breast cancer, but did not carry the mutation. The proportion of Australian women with breast cancer before age 40 who carry a germline mutation in BRCA1 was estimated to be 3.8% (95% Cl 0.3–12.6%). Seven rare variants were also detected, but for none was there evidence of a strong effect on breast cancer susceptibility. Therefore, on a population basis, rare variants are likely to contribute little to breast cancer incidence. © 1999 Cancer Research Campaign PMID:10408690

Southey, M C; Tesoriero, A A; Andersen, C R; Jennings, K M; Brown, S M; Dite, G S; Jenkins, M A; Osborne, R H; Maskiell, J A; Porter, L; Giles, G G; McCredie, M R E; Hopper, J L; Venter, D J

1999-01-01

436

Indole compounds against breast cancer: recent developments.  

PubMed

Breast cancer is still the leading cause of cancer deaths among women worldwide and new therapies and drugs are continuously being conceived and explored to better control or even cure this disease. Among the most efficacious low-molecular drugs for the treatment of breast cancer are indole derivatives such as 3,3'-diindolylmethane (DIM), the structurally complex antimitotic vinca alkaloids, and the synthetic receptor tyrosine kinase inhibitor sunitinib. This review is to give an insight into the latest developments in the field of indole based drugs against breast cancers with a focus on those derived from natural products and on their targets and modes of action. Pertinent literature is covered from 2007 up to 2012. PMID:23140282

Biersack, Bernhard; Schobert, Rainer

2012-12-01

437

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer  

ClinicalTrials.gov

Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer

2014-12-09

438

Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery  

ClinicalTrials.gov

Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer

2013-05-07

439

Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus  

ClinicalTrials.gov

Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Oral Complications; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer

2015-01-12

440

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)  

ClinicalTrials.gov

Tubular Breast Cancer Stage II; Tubular Breast Cancer Stage III; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; HER2 Positive Breast Cancer; Inflammatory Breast Cancer

2014-04-25

441

Breast Cancer Basics and You: Detection and Diagnosis | NIH MedlinePlus the Magazine  

MedlinePLUS

... of this page please turn Javascript on. Feature: Breast Cancer Breast Cancer Basics and You: Detection and Diagnosis Past Issues / ... regular clinical breast exams and mammograms to find breast cancer early, when treatment is more likely to work ...

442

3 CFR 9028 - Proclamation 9028 of September 30, 2013. National Breast Cancer Awareness Month, 2013  

Code of Federal Regulations, 2014 CFR

...of September 30, 2013. National Breast Cancer Awareness Month, 2013 9028 Proclamation...2013 Proc. 9028 National Breast Cancer Awareness Month, 2013By the President...in solidarity with those battling breast cancer and those at risk for breast...

2014-01-01

443

Challenges to the Control of Breast Cancer in A Small Developing Country  

PubMed Central

OBJECTIVE The aim of this study is to determine the clinicopathological features of breast cancer in two dedicated cancer treatment centers in north Trinidad. The histological types and stage at presentation were also investigated. DESIGN AND METHODS A retrospective cohort design was used; data were collected from a review of medical records of patients meeting the entry criteria. Clinical and demographic data were extracted. RESULTS A total of 640 patients were selected for the study and were available for the analysis. The annual cumulative incidence rate of breast cancer for the calendar years 2010 and 2011 in north Trinidad was 32.4 per 100,000 and 24.6 per 100,000 of the population. The age group between 51–60 years had the highest proportion of cases of breast cancer. There was a significant ethnic disparity in the occurrence of breast cancer, as it was more common in people of African origin than among South East Asians. Surgery and chemotherapy were the major interventions employed. CONCLUSION Breast cancer prevalence continues to be high in Trinidad; we provide evidence of the extent of and the degree of sophistication required to care for patients with breast cancer in a health care system in a small developing country. PMID:24526837

Mungrue, Kameel; Ramdath, Jeremy; Ali, Siddiq; Cuffie, Winsie-Ann; Dodough, Nicholas; Gangar, Misty; Mohammed, Laura; Mungroo, Vikash; Ramsahai, Justin; Shah, Mariyah

2014-01-01

444

Is triple negative a prognostic factor in breast cancer?  

Microsoft Academic Search

Background  Breast cancer is characterized by hormone dependency, and endocrine therapy is a key treatment in breast cancer. Recently,\\u000a targeted therapies such as Trastuzumab treatment for HER2-positive breast cancer has been important. Triple-negative (TN)\\u000a breast cancer is characterized by lack of expression of estrogen receptor (ER) and progesterone receptor (PgR), and the absence\\u000a of HER2 protein overexpression, and so there is

Reiki Nishimura; Nobuyuki Arima

2008-01-01

445

Breast cancer susceptibility: current knowledge and implications for genetic counselling  

Microsoft Academic Search

Breast cancer is the most common malignancy in women in the Western world. Except for the high breast cancer risk in BRCA1 and BRCA2 mutation carriers as well as the risk for breast cancer in certain rare syndromes caused by mutations in TP53, STK11, PTEN, CDH1, NF1 or NBN, familial clustering of breast cancer remains largely unexplained. Despite significant efforts,

Tim Ripperger; Dorothea Gadzicki; Alfons Meindl; Brigitte Schlegelberger

2009-01-01

446

Breast Cancer awareness among Saudi females in Jeddah.  

PubMed

Breast cancer is the most frequent malignancy of women worldwide. It is the leading cause of female cancer related disability and mortality. In Saudi Arabia breast cancer ranks first among cancerous diseases in females. In the Gulf region, and especially in Saudi Arabia, few studies have been conducted to address breast cancer awareness. The purpose of the current study was therefore to investigate the level of breast cancer awareness among Saudi females in Jeddah, focusing on knowledge of breast cancer warning signs, risk factors, screening programs and breast self-examination (BSE). The design of this study was an exploratory correlational analysis. The sample comprised 200 Saudi females aged 20 and older living in Jeddah. Data were collected using face-to- face interviews. Breast cancer awareness was measured using a modified Arabic version of the Breast Cancer Awareness Measure (Breast CAM) version 2. Descriptive statistical analysis, Pearson's Product Moment correlation coefficients and ANOVA test were used to answer study questions. Out of 200 participants, 50.5% were aware of breast lump as a warning sign of breast cancer, 57.5% claimed that family history was risk factor, 20.5% had undergone breast screening, 79% heard about BSE, and 47.5% knew how to perform BSE. Findings indicated that Saudi females level of awareness of breast cancer is very inadequate. Public awareness interventions are needed in order to overcome an ever-increasing burden of this disease among Saudi females. PMID:23991994

Radi, Sahar Mahmoud

2013-01-01

447

Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells  

PubMed Central

Background The development of immunotherapy has led to significant progress in the treatment of metastatic cancer, including the development of genetic engineering technologies that redirect lymphocytes to recognize and target a wide variety of tumor antigens. Chimeric antigen receptors (CARs) are hybrid proteins combining antibody recognition domains linked to T cell signaling elements. Clinical trials of CAR-transduced peripheral blood lymphocytes (PBL) have induced remission of both solid organ and hematologic malignancies. Chondroitin sulfate proteoglycan 4 (CSPG4) is a promising target antigen that is overexpressed in multiple cancer histologies including melanoma, triple-negative breast cancer, glioblastoma, mesothelioma and sarcoma. Methods CSPG4 expression in cancer cell lines was assayed using flow cytometry (FACS) and reverse-transcription PCR (RT-PCR). Immunohistochemistry was utilized to assay resected melanomas and normal human tissues (n?=?30) for CSPG4 expression and a reverse-phase protein array comprising 94 normal tissue samples was also interrogated for CSPG4 expression. CARs were successfully constructed from multiple murine antibodies (225.28S, TP41.2, 149.53) using second generation (CD28.CD3?) signaling domains. CAR sequences were cloned into a gamma-retroviral vector with subsequent successful production of retroviral supernatant and PBL transduction. CAR efficacy was assayed by cytokine release and cytolysis following coculture with target cell lines. Additionally, glioblastoma stem cells were generated from resected human tumors, and CSPG4 expression was determined by RT-PCR and FACS. Results Immunohistochemistry demonstrated prominent CSPG4 expression in melanoma tumors, but failed to demonstrate expression in any of the 30 normal human tissues studied. Two of 94 normal tissue protein lysates were positive by protein array. CAR constructs demonstrated cytokine secretion and cytolytic function after co-culture with tumor cell lines from multiple different histologies, including melanoma, breast cancer, mesothelioma, glioblastoma and osteosarcoma. Furthermore, we report for the first time that CSPG4 is expressed on glioblastoma cancer stem cells (GSC) and demonstrate that anti-CSPG4 CAR-transduced T cells recognize and kill these GSC. Conclusions The functionality of multiple different CARs, with the widespread expression of CSPG4 on multiple malignancies, suggests that CSPG4 may be an attractive candidate tumor antigen for CAR-based immunotherapies using appropriate technology to limit possible off-tumor toxicity. PMID:25197555

2014-01-01

448

[Chemotherapy of metastatic breast cancer].  

PubMed

The most powerful prognostic factor in the treatment of metastatic breast cancer continues to be the response to induction chemotherapy. The range of drugs which are widely used in the treatment of advanced disease, the anthracyclines, the taxanes and vinorelbine, have all shown interesting activity in terms of their ability to obtain both high response rates and long duration of response. The anthracyclines, doxorubicin (DX) and epiadriamycin (EPI) constitute the established reference agents in the treatment of metastatic disease, and combinations of these drugs with vinorelbine (VRB) and the taxanes, paclitaxel (PTX) and docetaxel (DCT), have produced major increases in objective response rates: PTX-DX (58%), DCT-EPI (69.4%), PTX-EPI (71.1%), VRB-DX (75%), VRB-EPI (77.1%). Suggestions for other combinations of chemotherapeutic agents which do not include anthracyclines available with well tolerated and effective drugs. The way forward after a response has been obtained remains an open question in which the limited efficacy of the available drugs and their cumulative toxicity needs to be balanced against the quality of life of patients during their disease. Defining the optimal strategy for the management of disease after induction treatment is a problem which needs to draw on the results of research, analysis of experience and insight into the needs of patients. PMID:11038414

Brun, B; Pouillart, P

2000-09-01

449

Breast cancer in Singapore: some perspectives  

Microsoft Academic Search

Breast cancer is the commonest malignancy among Singapore women, accounting for 29.7% of all female cancers, with an age-standardized\\u000a rate of 54.9 per 100,000 per year. It has been the most frequent cancer in Singapore women for the last 30 years, with the\\u000a highest rates previously reported in those aged between 45 and 49 years, but with a more recent observation of

Ana Richelia Jara-Lazaro; Shyamala Thilagaratnam; Puay Hoon Tan

2010-01-01

450

Breast cancer prognosis predicted by nuclear receptor-coregulator networks.  

PubMed

Although molecular signatures based on transcript expression in breast cancer samples have provided new insights into breast cancer classification and prognosis, there are acknowledged limitations in current signatures. To provide rational, pathway-based signatures of disrupted physiology in cancer tissues that may be relevant to prognosis, this study has directly quantitated changed gene expression, between normal breast and cancer tissue, as a basis for signature development. The nuclear receptor (NR) family of transcription factors, and their coregulators, are fundamental regulators of every aspect of metazoan life, and were rigorously quantified in normal breast tissues and ER? positive and ER? negative breast cancers. Coregulator expression was highly correlated with that of selected NR in normal breast, particularly from postmenopausal women. These associations were markedly decreased in breast cancer, and the expression of the majority of coregulators was down-regulated in cancer tissues compared with normal. While in cancer the loss of NR-coregulator associations observed in normal breast was common, a small number of NR (Rev-ERB?, GR, NOR1, LRH-1 and PGR) acquired new associations with coregulators in cancer tissues. Elevated expression of these NR in cancers was associated with poorer outcome in large clinical cohorts, as well as suggesting the activation of ER? -related, but ER?-independent, pathways in ER? negative cancers. In addition, the combined expression of small numbers of NR and coregulators in breast cancer was identified as a signature predicting outcome in ER? negative breast cancer patients, not linked to proliferation and with predictive power superior to existing signatures containing many more genes. These findings highlight the power of predictive signatures derived from the quantitative determination of altered gene expression between normal breast and breast cancers. Taken together, the findings of this study identify networks of NR-coregulator associations active in normal breast but disrupted in breast cancer, and moreover provide evidence that signatures based on NR networks disrupted in cancer can provide important prognostic information in breast cancer patients. PMID:24785096

Doan, Tram B; Eriksson, Natalie A; Graham, Dinny; Funder, John W; Simpson, Evan R; Kuczek, Elizabeth S; Clyne, Colin; Leedman, Peter J; Tilley, Wayne D; Fuller, Peter J; Muscat, George E O; Clarke, Christine L

2014-07-01

451

RESEARCH ARTICLE Open Access Molecular apocrine breast cancers are aggressive  

E-print Network

apocrine, estrogen receptor, HER2, GCDFP15, triple negative, basal- like Introduction Breast cancer are estrogen receptor (ER) negative breast cancers characterized by androgen receptor (AR) expression. WeRESEARCH ARTICLE Open Access Molecular apocrine breast cancers are aggressive estrogen receptor

Boyer, Edmond

452

Metabolic disorders and breast cancer risk (United States)  

Microsoft Academic Search

Objective: To clarify the hormonal context of breast cancer etiology we used data from a large, population-based case–control study to investigate the relationship between breast cancer risk and a history of diabetes mellitus, disorders associated with estrogen stimulation (uterine fibroids, endometriosis, gallstones), and disorders associated with androgen stimulation (acne, hirsutism, and polycystic ovaries). Methods: Breast cancer patients between 50 and

John A. Baron; Elisabete Weiderpass; Polly A. Newcomb; Meir Stampfer; Linda Titus-Ernstoff; Kathleen M. Egan; E. Robert Greenberg

2001-01-01

453

Breast cancer risk factors and outcome: a global perspective  

Microsoft Academic Search

The burden of breast cancer had been increasing in Asia. However, little is known regarding the presentation, management and outcome of breast cancer among multi-ethnic Asian women. Asian ethnicities, lifestyles, health beliefs, and even life expectancies are substantially different from those of western women, and each of these may play a distinct role in breast cancer presentation, management and prognosis.

N. Bhoo Pathy

2011-01-01

454

Alcohol: the link between hormone replacement and breast cancer risk  

Microsoft Academic Search

Many women avoid or discontinue hormone replacement therapy due to the fear of breast cancer. They have read studies linking hormone use with increased breast cancer incidence. The link between alcohol use and breast cancer risk, in contrast, is at least as strong as that of hormone replacement therapy (HRT), yet little publicity has reached practicing physicians or patients. A

Susan A Ballagh

1999-01-01

455

A Prospective Study of Cardiorespiratory Fitness and Breast Cancer Mortality  

Microsoft Academic Search

PEEL, J. B., X. SUI, S. A. ADAMS, J. R. HEBERT, J. W. HARDIN, and S. N. BLAIR. A Prospective Study of Cardiorespiratory Fitness and Breast Cancer Mortality. Med. Sci. Sports Exerc., Vol. 41, No. 4, pp. 742-748, 2009. Purpose: Physical activity may protect against breast cancer. Few prospective studies have evaluated breast cancer mortality in relation to cardiorespiratory fitness

J. BRENT PEEL; XUEMEI SUI; SWANN A. ADAMS; JAMES R. HÉBERT; JAMES W. HARDIN; STEVEN N. BLAIR

2009-01-01

456

Health food store recommendations: implications for breast cancer patients  

Microsoft Academic Search

BACKGROUND: Many breast cancer patients use complementary and alternative medicine (CAM). We aimed to determine what advice health food store employees present to individuals seeking treatment options for breast cancer. METHODS: Eight data gatherers asked employees of all retail health food stores in a major Canadian city, what they recommended for a patient with breast cancer. The data gatherers inquired

Edward Mills; Edzard Ernst; Rana Singh; Cory Ross; Kumanan Wilson

2003-01-01

457

Introduction Breast cancer growth is regulated by estrogen, which acts  

E-print Network

R252 Introduction Breast cancer growth is regulated by estrogen, which acts by binding to its-binding protein. Breast Cancer Research Vol 6 No 3 Bièche et al. Research article Relationship between Revisions received: 20 Jan 2004 Accepted: 8 Mar 2004 Published: 26 Mar 2004 Breast Cancer Res 2004, 6:R252-R

Paris-Sud XI, Université de

458

PRECLINICAL STUDY Prediction of lymph node involvement in breast cancer  

E-print Network

PRECLINICAL STUDY Prediction of lymph node involvement in breast cancer from primary tumor tissue- ther lymph node involvement in breast cancer is influenced by gene or miRNA expression of the primary tissue from a group of 96 breast cancer patients balanced for lymph node involvement using Affymetrix

459

Adjustment to breast cancer: The psychobiological effects of psychosocial interventions  

Microsoft Academic Search

This review focuses on the effects of psychosocial interventions on psychological and biological functioning of breast cancer patients. Once in their lifetime, one out of eleven women receive a diagnosis of breast cancer. A diagnosis of breast cancer is a severe stressful life event with profound consequences on all aspects of human life. Whether a woman will regain emotional balance

Gieta van der Pompe; Michael Antoni; Adriaan Visser; Bert Garssen

1996-01-01

460

High Throughput Analysis of Breast Cancer Specimens on the Grid  

E-print Network

as well as improved treatment [1]. Some of the common methods screening of breast cancer include) and hematoxylin are standard staining methods used for breast cancer. There has been increasing interestHigh Throughput Analysis of Breast Cancer Specimens on the Grid Lin Yang1,2 , Wenjin Chen2 , Peter

461

Genetic Susceptibility and Survival: Application to Breast Cancer  

E-print Network

Genetic Susceptibility and Survival: Application to Breast Cancer Edwin S. IVERSEN, JR., Giovanni are known to confer an elevated risk of both breast and ovarian cancers. The effect of carrying such a mutation on survival after developing breast or ovarian cancer is less well understood. We investigate

West, Mike

462

Junctional Adhesion Molecules (JAMs) - New Players in Breast Cancer?  

Microsoft Academic Search

Worldwide, breast cancer remains a leading cause of death amongst women. Annually, it i sestimated that breast cancer is diagnosed in over a million women (Kasler et al., 2009) with over 450,000 deaths worldwide (Tirona et al., 2010). The incidence of the disease is highest in economically-developed countries, with lower rates in developing countries. Despite continual advances in breast cancer

Gozie Offiah; Kieran Brennan; Ann M Hopkins

2011-01-01

463

Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland.  

PubMed

A number of genes other than BRCA1 and BRCA2 have been associated with breast cancer predisposition, and extended genetic testing panels have been proposed. It is of interest to establish the full spectrum of deleterious mutations in women with familial breast cancer.We performed whole-exome sequencing of 144 women with familial breast cancer and negative for 11 Polish founder mutations in BRCA1, CHEK2 and NBS1, and we evaluated the sequences of 12 known breast cancer susceptibility genes. A truncating mutation in a breast cancer gene was detected in 24 of 144 women (17%) with familial breast cancer. A BRCA2 mutation was detected in 12 cases, a (non-founder) BRCA1 mutation was detected in 5 cases, a PALB2 mutation was detected in 4 cases and an ATM mutation was detected in 2 cases. Polish women with familial breast cancer who are negative for founder mutations in BRCA1, CHEK2 and NBS1 should be fully screened for mutations in BRCA1, BRCA2 and PALB2. The PALB2 founder mutation c.509_519delGA should be included in the panel of Polish founder mutations. PMID:25330149

Cybulski, C; Lubi?ski, J; Woko?orczyk, D; Ku?niak, W; Kashyap, A; Sopik, V; Huzarski, T; Gronwald, J; Byrski, T; Szwiec, M; Jakubowska, A; Górski, B; D?bniak, T; Narod, S A; Akbari, M R

2014-10-20

464

Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction  

PubMed Central

Breast cancer comprises a collection of diseases with distinctive clinical, histopathological, and molecular features. Importantly, tumors with similar histological features may display disparate clinical behaviors. Gene expression profiling using microarray technologies has improved our understanding of breast cancer biology and has led to the development of a breast cancer molecular taxonomy and of multigene 'signatures' to predict outcome and response to systemic therapies. The use of these prognostic and predictive signatures in routine clinical decision-making remains controversial. Here, we review the clinical relevance of microarray-based profiling of breast cancer and discuss its impact on patient management. PMID:21787441

2011-01-01

465

Dietery factor obesity microenvironnement and breast cancer  

PubMed Central

Background Breast cancer is a multifactorial disease. Factors most often mentioned risks are those related to the environment, genetics, hormones and individual behaviors. Among these include alcohol, smoking, sedentary lifestyle and eating habits. Identification of eating and the role of nutritional factors may be involved in cancer risk have been studied extensively since nearly 40 years. Purpose We conducted a study of breast cancer type case-control with food frequency questionnaire to assess the causal relationship between dietary factor, obesity and breast cancer risk. Patients and methods: female patients with breast cancer were compared to healthy controls at the National Institute of Oncology of Rabat during 2008-2010 and were interviewed for epidemiological information and for their eating habits. Results A total of 800 women were included in this study (400 cases and 400 controls). Result of univariate analysis showed that significant factors associated with the etiologie of breast cancer: high body mass index (BMI) [odds ratio (OR) =1.30; 95% confidence interval (CI), 1.25-1.37], red meat (OR =1.33; 95% CI, 1.27-1.40), processed meat (OR =1.44; 95% CI, 1.35-1.54), eggs (OR =1.20; 95% CI, 1.14-1.23), poultry (OR =0.70; 95% CI, 0.60-0.80), fish (OR =0.67; 95% CI, 0.61-0.73), fruit (OR =0.67; 95% CI, 0.62-0.72), and vegetable (OR=0.72; 95% CI, 0.67-0.78). Multivariate analysis indicated that a significantly elevated risk of contracting breast cancer was associated with higher BMI (OR =9.61; 95% CI, 6.1-15.15), red meat (OR =4.61; 95% CI, 2.26-9.44) and processed meat (OR =9.78; 95% CI, 4.73-20.24). In contrast consumption of fish (OR =0.07; 95% CI, 0.02-0.24), poultry (OR =0.61; 95% CI, 0.46-0.81), fruit (OR =0.001; 95% CI, 0.00-0.004), and vegetable (OR =0.82; 95% CI, 0.22-3.08) remained as significant beneficial factor associated with breast cancer. Conclusions This study is rather in favour of positive association between obesity, consumption of food rich in fatty matter and breast cancer, which is consistent with data from the literature using the same type of investigation. These results encourage increased cohort studies, case-control and experimentation in order to achieve a genuine code of cancer prevention, to define with precision the positive and negative. PMID:25207209

Laamiri, Fatima Zahra; Bouayad, Abdellatif; Otmani, Azzedine; Ahid, Samir; Mrabet, Mustapha

2014-01-01

466

Metastatic breast cancer presenting as detrusor overactivity.  

PubMed

Breast carcinoma metastatic to the bladder is rare and accounts for approximately 3% of all secondary bladder neoplasms. We examine a case of breast cancer metastatic to the bladder with normal findings at cystoscopy. A 53-year-old woman with a history of breast carcinoma presented with a 6-month history of severe urgency and urgency incontinence. Treatment with multiple antimuscarinic therapies was unsuccessful. Vaginal examination demonstrated a non-mobile uterus with a suggestion of parametrial thickening. Urodynamic studies confirmed detrusor overactivity. CT showed a thickened bladder wall and cystoscopy revealed normal bladder mucosa with reduced bladder capacity. Bladder biopsies identified a poorly differentiated adenocarcinoma with strong oestrogen receptor staining. This was reported as a secondary deposit from a primary breast malignancy. The patient is currently under the care of the breast team and undergoing palliative chemotherapy. PMID:25535238

Balachandran, Aswini Aparna; Duckett, Jonathan

2014-01-01

467

Breast cancer messaging for younger women: gender, femininity, and risk.  

PubMed

Evidence linking both active smoking and secondhand smoke exposure to premenopausal breast cancer makes the development of health messages specific to younger women a pressing priority. To determine how to communicate information about this modifiable breast cancer risk to young women, we analyzed a selection of 32 recent English-language breast cancer messages and campaigns that targeted young women. In addition, we obtained young women's responses to three breast cancer campaign images during focus group discussions. A visual analysis of messages points to an explicitly gendered discourse within contemporary campaigns, one that entails conflicting messages regarding breast cancer, health, feminine beauty, and risk. Although the intent might be to educate and empower young women to "fight" against breast cancer, paradoxically, the messages employ imagery that sexually objectifies young women's breasts and bodies. Recommendations are made for messaging about tobacco and breast cancer risk to avoid reproducing one-dimensional or stereotypical presentations of gender and femininity. PMID:20354237

Haines, Rebecca J; Bottorff, Joan L; Barclay McKeown, Stephanie; Ptolemy, Erin; Carey, Joanne; Sullivan, Kelli

2010-06-01

468

Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection?  

Microsoft Academic Search

In the last few years, several papers have addressed the introduction of contrast-enhanced MR imaging for screening women\\u000a at high risk for breast cancer. Taking in consideration five prospective studies, on 3,571 screened women with hereditary\\u000a predisposition to the disease and 9,652 rounds, we found that 168 patients were diagnosed with breast cancer (155 screen-detected,\\u000a eight interval, and five cancers

Francesco Sardanelli; Franca Podo

2007-01-01

469

Breast Tissue Density and CAD Cancer Detection in Digital Mammography  

Microsoft Academic Search

This study is part of the research of improving early detection of breast cancer in screening mammograms by focusing on computerized analysis and detection of cancers missed by radiologists. It is directed to the analysis of breast density in missed cancer cases and the effect of tissue density on cancer detection. A total of 100 missed cancer cases were collected

Lihua Li; Zuobao Wu; Li Chen; Florence George; Zhao Chen; Angela Salem; Maria Kallergi; Claudia Berman

2005-01-01

470

Cancer Stem Cells in Breast: Current Opinion and Future Challenges  

Microsoft Academic Search

There is increasing evidence for the cancer stem cell hypothesis, which holds that cancers are driven by a cellular subcomponent that has stem cell properties, that is, self-renewal, tumorigenicity and multilineage differentiation capacity. The cancer stem cell hypothesis modifies our conceptual approach of oncogenesis and shall have implications in breast cancer prevention, detection and treatment, especially in metastatic breast cancer

Emmanuelle Charafe-Jauffret; Florence Monville; Christophe Ginestier; Gabriela Dontu; Daniel Birnbaum; Max S. Wicha

2008-01-01

471

pynk : Breast Cancer Program for Young Women  

PubMed Central

Consider this scenario: A 35-year-old recently married woman is referred to a surgeon because of a growing breast lump. After a core biopsy shows cancer, she undergoes mastectomy for a 6-cm invasive lobular cancer that has spread to 8 axillary nodes. By the time she sees the medical oncologist, she is told that it is too late for a fertility consultation, and she receives a course of chemotherapy. At clinic appointments, she seems depressed and admits that her husband has been less supportive than she had hoped. After tamoxifen is started, treatment-related sexuality problems and the probability of infertility contribute to increasing strain on the couple’s relationship. Their marriage ends two years after the woman’s diagnosis. Six years after her diagnosis, this woman has completed all treatment, is disease-free, and is feeling extremely well physically. However, she is upset about being postmenopausal, and she is having difficulty adopting a child as a single woman with a history of breast cancer. Could this woman and her husband have been offered additional personalized interventions that might have helped them better cope with the breast cancer diagnosis and the effects of treatment? Compared with their older counterparts, young women with breast cancer often have greater and more complex supportive care needs. The present article describes the goals, achievements, and future plans of a specialized interdisciplinary program—the first of its kind in Canada—for women 40 years of age and younger newly diagnosed with breast cancer. The program was created to optimize the complex clinical care and support needs of this population, to promote research specifically targeting issues unique to young women, and to educate the public and health care professionals about early detection of breast cancer in young women and about the special needs of those women after their diagnosis. PMID:23443036

Ali, A.; Warner, E.

2013-01-01

472

Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer  

ClinicalTrials.gov

Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer

2014-11-25

473

Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer  

ClinicalTrials.gov

Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer

2015-02-03

474

ICSN Data - Breast Cancer Incidence and Mortality Rates  

Cancer.gov

Skip to Main Content Search International Cancer Screening Network Sponsored by the National Cancer Institute Home | About ICSN | Collaborative Projects | Meetings | Cancer Sites | Publications | Contact Us Breast Cancer: Mortality Rates | Screening

475

Expression of aryl hydrocarbon receptor in relation to p53 status and clinicopathological parameters in breast cancer  

PubMed Central

The aryl hydrocarbon receptor (AhR) is a ligand activated transcription factor implicated in multiple cellular processes and its expression has been shown to play a critical role in tumorigenesis. However, the role of AhR in tumorigenesis of breast cancer remains unclear. In the current study, we investigated the expression levels of AhR in breast lesions and assessing the correlation between AhR expression and clinicopathological variables using